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CD8+ T lymphocytes play a critical role in our protection against pathogens and 
tumours. CD8+ T cell function is shaped by a myriad of environmental cues that 
include TCR-stimulation, co-stimuli, pro- and anti-inflammatory cytokines and 
nutrient availability. Understanding how CD8+ T cells integrate these signals and 
how they influence T cell output is crucial to better comprehend immune 
regulation and to find novel targets for immunotherapy.  
During the last decade, it has become more evident that T cell metabolism tightly 
controls T cell fate. This principle has provided a novel signalling network that 
can be manipulated in order to modulate T cell responses but that still needs to 
be fully explored. In this thesis, I determine the impact of several environmental 
cues on CD8+ T cell activation and metabolism. First, the study of signal 1 (TCR-
triggering), signal 2 (CD28) and signal 3 (IL-12 or IFNa) revealed that these 
cooperate to induce a full T cell activation state, contributing separately to T cell 
functionality and metabolism. Second, the study of the anti-inflammatory cytokine 
TGFb established that its effect on the suppression of CD8+ T cell activation is 
predominantly mediated by the repression of Myc, ultimately impeding TCR-
driven metabolic reprogramming. Finally, the study of asparagine (Asn) 
deprivation showed that CD8+ T cells require the supplementation of this amino 
acid during early stages of T cell activation, but lose this requirement upon 
upregulation of the enzyme asparagine synthetase (ASNS). These findings 
demonstrate that modulation of T cell responses by environmental cues are 
linked to the regulation of metabolic pathways and shed light into new 
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Chapter 1 Introduction 
1.1 An overview of the immune system. 
In the 19th century, Robert Koch described a causative relationship between 
microorganisms and infectious disease. We are constantly surrounded by 
pathogens including bacteria, viruses, fungi and parasites but, despite persistent 
exposure to microorganisms, we rarely become seriously ill. This is a 
consequence of our immune system, a complex network of organs, cells and 
molecules that cooperatively protect us against harmful agents.  
Upon exposure to an infectious organism, epithelial barriers (skin and mucosal 
membranes) build the first line of defence of the body. However, fissures are 
common and further protective mechanisms are needed. Within minutes-hours 
after exposure, granulocytes (neutrophils, eosinophils and basophils), 
macrophages, dendritic cells (DCs), natural killer (NK) cells and the complement 
system get activated. All these components, including the epithelium, comprise 
the first pillar of immunity: the innate system. Innate cells provide responses 
characterised by their rapid speed of action and their lack of specificity as they 
identify, through pattern recognition receptors (PRRs), simple structures that 
have been conserved during evolution and are common to many pathogens. 
These structures are known as pathogen-associated molecular patterns 
(PAMPs) and include lipopolysaccharides (LPS), mannose-rich 
oligosaccharides, peptidoglycans and unmethylated CpG DNA (Akira et al., 2006; 
Kawai and Akira, 2010; Brubaker et al., 2015). The activation of innate cells 
promotes a proinflammatory response that restrains the initial infection and 
induces the stimulation of the second pillar of immunity: the adaptive system. 




by their specificity against antigens and their memory capacity. Their specificity 
relies on the generation of B cell receptors (BCRs) and T cell receptors (TCRs) 
by B and T cells, respectively. While the BCR recognises non-processed 
antigens, the TCR recognises processed peptide antigens presented by major 
histocompatibility (MHC) molecules. Two main types of MHC molecules can be 
distinguished: MHC class I (MHC-I), which are expressed by virtually all cell 
types, and MHC class II (MHC-II), which are only expressed by specialised 
antigen presenting cells (APCs) such as DCs, macrophages and activated B 
cells. T lymphocytes that recognise antigens in association with MHC-I molecules 
are known as CD8+ T cells, whilst those that recognise antigens in association 
with MHC-II molecules are CD4+ T cells (Andersen et al., 2006; Yang, Q. et al., 
2010). 
In this thesis, I focus on the study of T lymphocytes and, therefore, I aim to 
describe in the following sections the development, function and regulation of 
these cells in the mediation of immune responses.  
1.2 T cell development – giving rise to a diverse TCR repertoire. 
Postnatally, all immune cells derive from pluripotent haematopoietic stem cells 
(HSCs) in the bone marrow (BM). HSCs differentiate into common myeloid 
progenitor (CMP) cells or common lymphoid progenitor (CLP) cells which, in turn, 
give rise to the myeloid and lymphoid lineages, respectively. The majority of the 
innate cells, in addition to erythrocytes and platelets, are descended from CMPs. 
On the other hand, innate lymphoid cells (ILCs), such as NK cells, and B and T 
lymphocytes arise from CLPs (Kondo, 2010; Yang, Q. et al., 2010) (Fig. 1.1A). 
Once differentiated, immune cells leave the bone marrow and circulate through 




(SLOs) and tissues. Nonetheless, an additional step is required for T lymphocytes 
in order to become functional. Before commitment to the T cell lineage, CLPs exit 
the BM and traffic to the thymus, where they complete their development after 






Figure 1.1: Development of T lymphocytes.  
(A) HSCs originated in the BM develop into CMPs or CLPs which, in turn, will 
give rise to the myeloid or lymphoid lineages, respectively. (B) CLPs migrate to 
the thymus where they acquire a functional TCR. Specifically,  T cell early 
progenitors undergo three different stages, based on the expression of the co-
receptors CD4 and CD8: DN (includes DN1, DN2, DN3 and DN4), DP and SP. In 
the transit from DN2 to DN3, cells express RAG1 and RAG2, which promote the 
rearrangement of the TCRb chain locus and the formation of a pre-TCR. The 
rearrangement of the TCRa chain locus takes place during the DP stage leading 
to the acquisition of the TCR which functionality is tested through self-pMHC 
presentation by thymic non-lymphoid cells. Failure to bind self-pMHC or high self-
reactivity induces apoptosis, whilst only those T cells that bind to pMHCs with low 
affinity survive and leave the thymus in search of antigens. Adapted from “Stem 
Cell Differentiation from Bone Marrow” and “T-cell Development in Thymus”, by 
Biorender.com (2021). Retrieved from https://app.biorender.com/biorender-
templates. 
 
The development of a diverse TCR repertoire is essential to provide appropriate 
T cell responses against any exogenous antigen. Multipotent immature 
lymphocytes that arrive from the BM localise within the thymic cortex. At this 
stage, T lineage cells are described as double negative (DN) thymocytes as they 
lack expression of CD4 and CD8 co-receptors (Fig. 1.1B). In mice, DN cells are 
divided into 4 subtypes: DN1 (CD44+CD25-), DN2 (CD44+CD25+), DN3 
(CD44lowCD25+), DN4 (CD44-CD25-). Commitment to the ab T cell lineage (95% 
of T lymphocytes in human circulation) starts during DN2 and continues in DN3 
with the rearrangement of the TCRb chain locus. The recombination-activating 
genes (RAGs) RAG1 and RAG2 encode for the key enzymes that orchestrate the 
recombination of antigen receptor variable (V), diversity (D) and joining (J) gene 
segments (Schatz and Ji, 2011). This recombination allows the production of a 
diverse TCR repertoire from a limited number of genes and induces the synthesis 
of a successfully rearranged TCRb chain. Then, the b chain pairs with an invariant 




expression of the pre-TCR triggers signals that lead to a burst of proliferation and 
the repression of RAG1 and RAG2 to ensure allelic exclusion at the b locus.  
During the DN4 stage, proliferation ceases and CD4 and CD8 molecules start to 
be expressed giving rise to the double positive (DP) phenotype (Fig. 1.1B). DP 
cells restore RAG1 and RAG2 expression which induces the rearrangement of 
the TCRa chain locus and the assembly of a functional TCR:CD3 complex. Upon 
migration to the medulla, the TCR functionality of the thymocytes is tested 
through exposure to MHC molecules present in thymic non-lymphoid cells. Here, 
the majority of DP cells die as a result of a failed productive interaction with self-
peptide-MHC (pMHC) complexes in a process known as ‘death by neglect’. On 
the other hand, thymocytes capable of recognising self-pMHC complexes will 
undergo apoptosis if they are bound with high affinity (negative selection) 
whereas those recognised with low-moderate affinity (positive selection) will 
continue the maturation process (Bommhardt et al., 2004). Thus, besides 
generating a high T cell clonality, the thymus is also responsible for central 
tolerance. Finally, thymocytes become mature single positive T lymphocytes, 
CD4+CD8- or CD4-CD8+, depending on the class of MHC molecule that binds the 
TCR during positive selection (Bommhardt et al., 2004; Palmer and Naeher, 
2009; Vicente et al., 2010; Shah and Zúñiga-Pflücker, 2014; Yui and Rothenberg, 
2014).  
The aforementioned description is a brief summary of the complex process of T 
cell lineage commitment and differentiation but it is important to note that 
thymocytes integrate other signals that are also required in this process. For 
example, early precursors that arrive to the thymic cortex interact with Delta-like 




transcription factors that are essential to establish the T cell identity of precursors. 
Another key signal integrated by thymocytes is IL-7, which promotes the survival 
of thymocytes expressing a competent TCR (Hong et al., 2012; Hosokawa and 
Rothenberg, 2018). 
1.3 T cell subpopulations and their role in immune responses. 
T cell responses are developed in an antigen-specific manner. I have already 
introduced the two main T cell populations: CD4+ and CD8+ T lymphocytes; but, 
what is their role in the diverse immune responses to different pathogens? 
Effector CD8+ T cells, also known as cytotoxic T lymphocytes (CTLs), mediate 
responses against intracellular pathogens, such as viruses, or tumour cells. CTLs 
are recruited into the site of infection or within the tumour microenvironment 
(TME) and mediate the lysis of target cells upon TCR-ligation via the exocytosis 
of cytolytic granules at the immunological synapse (IS) (Andersen et al., 2006). 
These granules contain perforins and granzymes. Amongst the several types of 
granzymes (10 in mice and 5 in humans), granzyme A (GrA) and granzyme B 
(GrB) are the most abundant ones. Mechanistically, perforins form pores in the 
plasma membranes of target cells to mediate the entry of granzymes in the cell 
and trigger apoptosis through mitochondrial damage or activation of caspase 3 
(Zhang, N. and Bevan, 2011; Voskoboinik et al., 2015). Recent investigations 
from Bálint et al. (2020) have revealed that perforins and granzymes can also be 
delivered in supramolecular attack particles (SMAPs), multiprotein complexes 
that contain trombospondin-1 (TSP-1) in its shell to mediate cytotoxicity. 
Nonetheless, secretion of cytolytic granules is not the only mechanism by which 
CTLs can eliminate target cells. For instance, CTLs release cytokines including 




activate other immune cells such as macrophages, inhibit viral replication, induce 
MHC-I expression and even kill target cells directly via TNFR-I (Zhang, N. and 
Bevan, 2011). CTLs also express ligands for the death receptor Fas (FasL) 
enabling the recruitment and activation of caspases 8 and 10 and, therefore, 
promoting the extrinsic pathway of apoptosis in target cells (Andersen et al., 
2006; Zhang, N. and Bevan, 2011; Halle et al., 2017) (Fig. 1.2). 
Conversely, CD4+ T cells are known as ‘helper’ T (Th) cells as they produce 
cytokines that recruit, activate and coordinate other effector cell types and 
mechanisms. Depending on the cytokine milieu, CD4+ T cells can be 
differentiated into at least 4 different subtypes: Th1, Th2, Th17 and Th9 (Murphy 
and Reiner, 2002; Zhu, J. et al., 2010; Luckheeram et al., 2012). Each subtype is 
characterized by a distinct cytokine repertoire that mediates pathogen-selective 
responses. Th1 cells are involved in type 1 responses - i.e., cell-mediated 
immunity to intracellular pathogens. Th1 cells secrete IFN-g and express CD40L 
to activate macrophages and induce the inflammatory M1-phenotype. Among 
other mechanisms, they also produce interleukin-2 (IL-2) to support CTL 
expansion and secrete other cytokines such as TNF or LTa to promote 
macrophage recruitment at the site of infection (Zhu, J. et al., 2010). Th2 cells 
mediate type 2 immunity including responses against extracellular parasites. To 
do so, they secrete IL-4, IL-5 and IL-13 to induce epithelial cells repair, muscle 
contraction for helminth expulsion, activation of M2-macrophages, recruitment of 
eosinophils and IgE antibody production (Zhu, J. et al., 2010). Th17 cells 
coordinate responses against extracellular bacteria and fungi. Their function is 
mediated by production of IL-17A and IL-17F which mobilise neutrophil 
responses and promote the generation of antibacterial peptides by epithelial cells 




crucial sources of IL-9. However, due to the pleiotropic functions of IL-9 (mainly 
promotes the survival of CD4+ T cells and other immune cells) it is thought that 
Th9 cells play a broader role amongst the different types of immunity (Kaplan, 
2013). Importantly, Th cells do not always play a protective role and, instead, have 
been associated with pathologies such as allergies (Th2, Th9) or autoimmune 
diseases including type 1 diabetes (Th1), rheumatoid arthritis and multiple 
sclerosis (Th17) (Zhu, J. et al., 2010; Hirahara et al., 2013; Zhu, J., 2018). 
Additional CD4+ T cell subsets are involved in the regulation of immune 
responses. T follicular helper cells (TFH) develop in concert with the other subsets 
and provide help to B cells to promote germinal centre responses and generate 
class-switched immunoglobulins (Ig) of different isotypes (Luckheeram et al., 
2012). Furthermore, naïve CD4+ T cells can also differentiate into peripheral Tregs 
(pTregs), which provide immunosuppressive responses rather than stimulatory. 
pTregs are characterised by the expression of forkhead box P3 (FoxP3) and CD25 
and secrete inhibitory cytokines such as IL-10 and transforming growth factor b 
(TGFb) to restore and limit immune responses. Moreover, they prevent 
autoreactivity against self-peptides providing an important mechanism of 
peripheral tolerance (Murphy and Reiner, 2002; Sakaguchi et al., 2010; 
Luckheeram et al., 2012). The majority of FoxP3-expressing Tregs are generated 
in the thymus; these are referred to as natural Tregs (nTregs) (Dhamne et al., 2013). 
1.4 CD8+ T cell responses – from the thymus to memory 
formation. 
In this thesis, that aims to determine how T cells integrate signals and modulate 




Naïve CD8+ T cells recirculate throughout the bloodstream and lymphatics into 
lymph nodes, spleen and mucosa-associated lymphoid tissues (MALT) in search 
of specific antigen. Until then, naïve T cell peripheral homeostasis is regulated 
via IL-7 and self-peptide TCR signals which promote survival through the 
expression of antiapoptotic factors and maintain cells in quiescence (Surh and 
Sprent, 2008). The accumulation of APCs and T lymphocytes within SLOs 
facilitates T cell priming. Here, initial T cell binding to APCs is mediated by low-
affinity interactions of the cell adhesion molecules lymphocyte function-
associated antigen 1 (LFA-1) with the intracellular adhesion molecule 1 (ICAM-
1) (Walling and Kim, 2018). If the antigen is successfully recognised by the TCR 
while receiving appropriate stimulation from co-receptors and cytokines, the T 
cell will grow, clonally expand and acquire cytotoxic functions differentiating, 
therefore, into an effector CTL (Fig. 1.2). Activated T cells migrate via the action 
of chemokines, integrins and selectins to the site of infection or tumour 
microenvironment (TME), where the CTL recognises target cells and delivers 
cytolytic granules and cytokines to carry out its effector functions, as described in 
Section 1.3 (Zhang, N. and Bevan, 2011) (Fig. 1.2). Finally, upon clearance of 
antigen and cytokine withdrawal most of the lymphocytes will die (contraction 
phase) but some will form a pool of memory cells to provide long-term responses, 
which will survive in the periphery due to the action of the homeostatic cytokines 
IL-7 and IL-15 (Kaech and Cui, 2012; Mueller et al., 2013). When CTLs are not 
able to efficiently clear antigen, such as during chronic infections or cancer, the 
memory T cell population will not form and might instead result in an exhausted 
phenotype (McLane et al., 2019; Franco et al., 2020). 
Thus, the life of a CD8+ T cell can be differentiated into several stages that include 




naïve T cell homeostasis in the periphery, (4) T cell priming in SLOs, (5) T cell 
growth proliferation and differentiation, (6) migration to site of infection or TME, 
(7) delivery of cytotoxic functions and, after pathogen removal, (8) effector cell 
death and survival of a memory population. In the following sections, I explain the 
mechanisms by which T cell priming is regulated. 
 
Figure 1.2: CD8+ T cell activation and cytotoxic functions.  
Naïve CD8+ T cells are primed within SLOs, where APCs present antigen. After 
appropriate pMHC:TCR interaction (signal 1), accompanied by co-stimulation 
(signal 2) and signal 3 cytokines IL-12 and type I IFNs, activation, clonal 
expansion and differentiation is triggered. CTLs migrate to the site of infection or 
the TME, where target cells are detected and killed through the delivery of 
cytotoxic granules, Fas/FasL interactions or the secretion of cytokines such as 






1.5 T cell priming: signal integration and modulation of CD8+ T 
cell responses. 
CD8+ T cell priming is triggered by antigen presentation via pMHC binding to the 
TCR. Activation of TCR signalling alone allows for limited proliferation and 
differentiation of naïve CD8+ T cells (Shahinian et al., 1993; Wang, B. et al., 
2000). However, for the development of optimal T cell responses, the ‘three 
signals model’ has been established in which the signalling provided by the TCR, 
co-stimulatory molecules and cytokines synergise to modulate T cell activation, 
expansion and fate (Mescher et al., 2006; Marchingo et al., 2014) (Fig. 1.2). 
Further detail of each signal and its role in T cell function are provided in Sections 
1.5.1, 1.5.2 and 1.5.3, respectively. 
1.5.1 Signal 1: TCR signalling.  
1.5.1.1 Structure of MHC-I and TCR complexes. 
Antigen recognition by the TCR of CD8+ T lymphocytes is only carried out in the 
context of MHC-I molecules. MHC-I molecules – HLA-A/B/C in humans and H-
2K/D/L in mice - are formed by two polypeptide chains: the a chain and the b2-
microglobulin. The former consists of three domains (a1, a2, a3) and is anchored 
to the membrane through the a3 domain, whereas the a1 and a2 domains fold 
together into a single structure where the peptide binds. This structure is known 
as the peptide-binding cleft and is highly polymorphic. b2-microglobulin does not 
span the membrane and binds noncovalently to the a chain (Garcia and Adams, 
2005; Rudolph et al., 2006). TCRs are formed by the TCRa and TCRb chains 
which are linked by a disulphide bond. Each chain consists of an Ig-like constant 
domain (C), a variable domain (V) and a transmembrane region that chains the 




the MHC-I molecule, constitute the antigen-binding site (Wucherpfennig et al., 
2010).  
The TCR alone recognises peptide antigen but cannot directly trigger signalling 
as it has no intrinsic enzymatic activity. Thus, the TCR associates with the CD3 
complex (CD3g, CD3d and CD3e chains) and the homodimer of z chains 
generating the so-called TCR complex (Dong et al., 2019; Hwang et al., 2020). 
The CD3 complex is composed by two dimers: CD3e:CD3d and CD3e:CD3g. 
Each chain contains an extracellular Ig-like domain, a transmembrane region and 
a cytoplasmic region that contains one immunoreceptor tyrosine-based activation 
motif (ITAM). On the other hand, z chains have a short extracellular region and a 
long intracellular region that contains three ITAMs. Additionally, the CD8 co-
receptor is recruited to the immunological synapse. CD8 is a dimer whose chains 
(a and b) are constituted by an extended polypeptide with an Ig-like domain in its 
extracellular region. CD8 binds to the cytoplasmic SRC family tyrosine kinase 
(SFK) Lck  (Veillette et al., 1988; Mørch et al., 2020). Together, the TCR complex 
in association with the CD8 co-receptor enables TCR-mediated antigen 
recognition to be translated into an intracellular cascade initiated by tyrosine 
phosphorylation of the ITAMs that results in activation of a transcriptional 
programme necessary for T cell activation (Fig. 1.3).  
1.5.1.2 Initiation of TCR signalling: regulation of Lck activity. 
The extent of Lck-mediated phosphorylation of the CD3 and z chain ITAMs 
determines whether or not the signal received is sufficient to surpass the TCR 
affinity threshold and initiate the downstream signalling cascade (Stepanek et al., 
2014). Lck structure consists of a Src homology 3 (SH3) and an SH2 domain 




that binds the CD8 cytoplasmic tail. Lck activity is regulated via phosphorylation 
of critical tyrosine sites: the inhibitory Tyr505, situated in the SH2 domain, and 
the activating Tyr394, located in the kinase domain. Whereas Lck inactivity is 
commonly associated with Tyr505 phosphorylation and a closed conformation, 
activated Lck presents an open conformation and Tyr394 phosphorylation. The 
proteins involved in the phosphorylation/dephosphorylation of those motifs are 
the receptor-type protein tyrosine phosphatase (PTPR) CD45 and the C-terminal 
Src kinase (Csk) whose balancing forces constitute a key regulatory axis of Lck 
activity (Smith-Garvin et al., 2009). Non-stimulated lymphocytes present a basally 
active Lck characterised by Tyr394 phosphorylation (Nika et al., 2010). After 
TCR-stimulation, a series of events including CD45 segregation from the TCR 
complex (Courtney et al., 2019) or diminishment of Csk recruitment (Torgersen 
et al., 2001) modulate Lck-mediated phosphorylation of ITAMs that subsequently 
trigger TCR signalling. Other cytosolic phosphatases, such as the protein tyrosine 
phosphatases non-receptor type 6 (PTPN6; also known as SH2 domain-
containing phosphatase (SHP)1) and PTPN22, are also involved in the negative 
regulation of Lck through direct dephosphorylation of Tyr394 or, in the case of 
PTPN22, also indirectly via interaction with Csk (Bottini and Peterson, 2014; 
Gaud et al., 2018). Thus, intricate regulation of early TCR events set a TCR 
threshold that determines discrimination of exogenous and self-peptides (Acuto 
et al., 2008; Salmond et al., 2014; Manz et al., 2015; Courtney et al., 2019). In 
section 1.5.4, the role of PTPN22 in this process will be further described (Fig. 
1.3). 
1.5.1.3 Proximal TCR signalling. 
Lck-mediated phosphorylation of tyrosine residues within ITAMs facilitates the 




recruited is the Syk family kinase z-chain-associated protein of 70kDa (ZAP70) 
(Chan et al., 1991) which, once bound, is activated via Lck-mediated 
phosphorylation. Activated ZAP70 initiates phosphorylation of the scaffold protein 
linker for activated T cells (LAT) at multiple sites that are utilised as docking points 
for the recruitment of several proteins and the formation of the LAT signalosome 
(Finco et al., 1998; Zhang, W. et al., 1998; Balagopalan et al., 2010). Among the 
proteins that comprise the LAT signalosome are SH2 domain-containing 
leukocyte protein of 76 kDa (SLP-76), phospholipase Cg1 (PLCg1), growth factor 
receptor-bound protein 2 (GRB2), vav guanine nucleotide exchange factor 1 
(VAV1), GRB2-related adaptor protein (GADS), interleukin-2-inducible T cell 
kinase (ITK), adhesion- and degranulation-promoting adaptor protein (ADAP) 
and non-catalytic region of tyrosine kinase adaptor protein 1 (NCK1). The LAT 
signalosome propagates and branches the TCR signalling into at least three 
major signalling modules: Ca2+, nuclear factor-κB (NF-κB) and mitogen-activated 
protein kinase (MAPK) signalling pathways, leading to the activation of 
transcription factors that mediate gene expression for T cell activation (Cantrell, 
D., 1996; Smith-Garvin et al., 2009; Brownlie and Zamoyska, 2013; Navarro and 





Figure 1.3: T cell receptor signalling. 
After TCR-binding, Lck phosphorylates ITAMs within the TCR complex. 
Consequently, ZAP-70 is recruited and activated, which leads to the 
phosphorylation of LAT. LAT phosphorylation results in the recruitment of multiple 
proteins such as PLCg1, Grb2 and SLP-76 that trigger a myriad of signalling 
pathways (e.g. NFkB, MAPK, Ca2+). The engagement of these pathways 
ultimately results in the activation of TFs that induce transcriptional 
reprogramming and T cell activation. The initiation of the TCR signalling is 
regulated by the action of tyrosine phosphatases, such as PTPN22. Adapted from 
“TCR Downstream Signaling”, by Biorender.com (2021). Retrieved from 
https://app.biorender.com/biorender-templates. 
 
1.5.1.4 Branching of TCR signalling: Ca2+, NF-κB and MAPK signalling 
pathways. 
How are these modules engaged and how do they result in the activation of 
transcription factors? In brief, formation of the LAT signalosome induces PLCg1 
recruitment to the inner face of the membrane and its subsequent activation (Sieh 
et al., 1994). Active PLCg1 catalyses the conversion of PIP2 (phosphatidylinositol 
(4,5)-bisphosphate) into the second messengers diacylglycerol (DAG) and 
inositol 1,4,5-triphosphate (IP3) (Brownlie and Zamoyska, 2013; Cantrell, D., 




IP3 binds on the endoplasmic reticulum (ER) to Ca2+ channels which releases 
Ca2+ to the cytosol. Depletion of Ca2+ within the ER causes clustering of the 
transmembrane protein stromal interaction molecule 1 (STIM1). Then, STIM1 
oligomers interact with the calcium-release activated calcium (CRAC) channels 
on the plasma membrane triggering extracellular Ca2+ uptake. Accumulation of 
cytosolic Ca2+ provokes a conformational change of calmodulin which, in turn, 
activates calcineurin. Calcineurin is a serine/threonine phosphatase that 
regulates the localisation of the TF nuclear factor of activated T cells (NFAT) (Oh-
hora and Rao, 2008; Hogan et al., 2010). In resting T cells, NFAT is sequestered 
in the cytosol mainly by the glycogen synthase kinase 3 (GSK3) (Beals et al., 
1997). GSK3-mediated phosphorylation dampens NFAT recognition of nuclear 
transporters thereby preventing entry of NFAT into the nucleus. Upon TCR-
stimulation and calcineurin activation, cytosolic NFAT is dephosphorylated 
allowing transporter recognition, entrance to the nucleus and transcriptional 
activation of crucial genes, such as IL-2 (Feske, 2007; Oh-hora and Rao, 2008; 
Hogan et al., 2010; Cantrell, D., 2015).  
In contrast, DAG production contributes to the other two signalling modules. First, 
DAG recruits and activates Ras guanyl-releasing protein (RasGRP), a guanine-
nucleotide exchange factor (GEF) that specifically activates the small GTPase 
Ras (Ebinu et al., 2000; Dower et al., 2000; Roose et al., 2005). Ras, which can 
also be activated by the Grb-2-recruited GEF Son of sevenless (Sos) (Buday et 
al., 1994), triggers the three-tiered MAPK cascade: Ras activates Raf, which 
activates MAPK/ERK Kinase 1 (MEK1), which activates extracellular signal-
regulated kinases ERK1 and ERK2 (Genot and Cantrell, 2000). ERKs enter the 
nucleus and phosphorylates the transcription factor Elk-1 which, consequently, 




N-terminal kinase (JNK) by protein kinase C q (PKC-q) leads its mobilisation to 
the nucleus where phosphorylates c-Jun. Afterwards, c-Jun/Fos dimerisation 
generates and activates activator-protein 1 (AP-1) transcription factor that turns 
on transcription of important genes for T cell activation (Cantrell, D.A., 2003; 
Brownlie and Zamoyska, 2013; Cantrell, D., 2015; Hwang et al., 2020).  
Moreover, DAG also activates the already mentioned PKC-q which is also 
involved in initiation of NF-κB signalling. NF-κB transcription factors are dimers 
formed by combinations of the NFκB/Rel family proteins p50, p52, RelA/p65, 
RelB and c-Rel. In resting T lymphocytes, the canonical p50:p65 heterodimer is 
kept inactive in the cytosol via interaction with the inhibitory protein IκB. During T 
cell activation, PKC-q phosphorylates the scaffold protein caspase recruitment 
domain-containing membrane-associated guanylate kinase protein-1 (CARMA-
1) (Matsumoto et al., 2005). CARMA1 associates and forms a multisubunit 
complex with BCL10 and MALT1 implicated in the recruitment of the E3 ubiquitin 
ligase TNF receptor associated factor 6 (TRAF-6) (Che et al., 2004; Wang, D. et 
al., 2004). Next, TRAF-6 makes a polyubiquitin scaffold on itself that recruits 
TAB1/2 and activates TAK1 (Sun et al., 2004). TAK1 phosphorylates IKK-b, a 
subunit of the IκB kinase (IKK) complex which is constituted by the serine kinases 
IKK-a, IKK-b and IKK-g (also known as NEMO; NF-κB essential modulator). 
Subsequently, the IKK complex phosphorylates and stimulates IκB ubiquitination 
which is then degraded by the proteasome. The p50:p65 dimer is then released 
from IκB and able to access the nucleus and commence transcription (Spitaler 
and Cantrell, 2004; Matthews and Cantrell, 2009; Brownlie and Zamoyska, 2013; 




Together, TCR signalling results in the activation of a network of transcription 
factors that leads to T cell growth, expansion and differentiation. TCR-stimulation 
results in naïve T cells exiting G0 and entering the cell cycle upon activation and 
expression of cyclins. Furthermore, TCR signalling stimulates T cell activation 
pathways and rapid expression of IL-2 and CD25 (a chain of the IL-2 receptor) 
that promotes T cell growth, proliferation and differentiation (Smith-Garvin et al., 
2009). At the same time, transcription factors such as Eomesodermin (Eomes) 
and T-box expressed in T cells (Tbet) are expressed to mediate CD8+ T cell 
differentiation and effector function (Kaech and Cui, 2012). Importantly, T cell 
activation is also accompanied by upregulation of metabolic transcription factors 
such as Myc that induce a metabolic reprogramming to support energetic and 
biosynthetic demands (Wang, R. et al., 2011; Buck et al., 2017; Chapman et al., 
2019). The metabolism of activated T cells is further described in Section 1.6.  
1.5.2 Signal 2: Co-stimulatory signals 
Not all self-peptides are presented in the thymus and, therefore, central tolerance 
alone cannot fully explain non-responsiveness against all self-antigens in 
peripheral tissues (Bretscher and Cohn, 1970; Lafferty and Cunningham, 1975; 
König, 2010). This idea gave rise to the hypothesis that an additional signal to 
TCR-ligation is required for T cell activation. Today, we know that engagement of 
the TCR alone often induces T cell anergy (Harding et al., 1992; Schwartz, 2003) 
and that co-stimulatory molecules, predominantly CD28, provide a fully activated 







1.5.2.1 CD28 signalling and its role in T cell activation 
CD28 is an Ig-superfamily (Ig-SF) transmembrane homodimer constitutively 
expressed in naïve and activated CD4+ and CD8+ T lymphocytes. CD28 binds to 
CD80 and CD86 (also known as B7.1 and B7.2, respectively) which are 
expressed by activated, but not resting, APCs. Following TCR-stimulation, CD28 
co-localises with the TCR complex within the immunological synapse and 
mediates a myriad of functions resulting in the amplification of the TCR signalling, 
increased IL-2 secretion and the induction of bigger and prolonged T cell 
responses to antigen (Rudd and Schneider, 2003; Miller et al., 2009; Rudd et al., 
2009; Boomer and Green, 2010; Esensten et al., 2016). Specifically, TCR-driven 
phosphorylation of CD28 in its cytoplasmic YMNM and PYAP motifs, mediated 
predominantly by Lck and Fyn, allows interaction with multiple proximal TCR 
proteins (Hutchcroft and Bierer, 1994; Raab et al., 1995). In particular, interaction 
with the p85 subunit of phosphatidylinositol-3 kinase (PI3K) triggers activation of 
the PI3K-Akt pathway (Rudd and Schneider, 2003; Boomer and Green, 2010). 
Mechanistically, PI3K induces the conversion of PIP2 to PIP3 which, in turn, binds 
and retains Akt at the plasma membrane facilitating its activation by 
phosphoinositide-dependent kinase 1 (PDK1). Then, activation of the Akt kinase 
leads to the phosphorylation and subsequent activation of an array of 
downstream signals including GSK3, NFkB, nuclear factor 90 (NF90), 
mechanistic Target of Rapamycin (mTOR) and enhanced expression of pro-
survival Bcl-xL. These pathways synergise with TCR-signalling and promote 
transcription and mRNA stabilisation of IL-2, cell cycle progression, metabolic 
reprogramming and survival (Fraser et al., 1991; Boise et al., 1995; Frauwirth, K. 
A. et al., 2002; Pei et al., 2008; Boomer and Green, 2010). In addition, TCR 




recruitment which induces activation of PLCg1, PKCq and JNK, among others 
(Boomer and Green, 2010). 
1.5.2.2 Co-signalling: beyond CD28 
Our current understanding of ‘signal 2’ has evolved to incorporate a more 
complex regulatory system. Many additional receptors and ligands, both 
stimulatory and inhibitory, are expressed by T cells and APCs that contribute to 
determining T cell fate and survival, as well as the degree of T cell responses and 
their termination (Chen, L. and Flies, 2013). For instance, the co-inhibitory 
receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) has been established as a 
crucial signal for self-tolerance (Perez et al., 1997; Alegre et al., 2001; Greenwald 
et al., 2001). CTLA-4, which is constitutively expressed by Tregs and upregulated 
in conventional T lymphocytes upon TCR-stimulation, binds CD80/CD86 with 
high affinity and thereby outcompetes CD28. The CD28/CTLA-4/CD80/CD86 
regulatory network modulates self-reactivity within the thymus and periphery, 
impairing T cell priming and highlighting the importance of additional co-signals 
in the tight regulation of T cell responses (Rudd et al., 2009; Chen, L. and Flies, 
2013; Verhagen et al., 2013; Paterson et al., 2015). Other co-signals include the 
co-stimulatory CD137 (also known as 4-IBB), inducible T cell co-stimulator 
(ICOS), CD134 (also known as OX40), CD27 and CD244 (also known as 2B4) 
and the co-inhibitory programmed cell death 1 (PD-1), T cell immunoglobulin and 
mucin-domain containing 3 (TIM3) and lymphocyte activation gene 3 protein 
(LAG3), among others (Chen, L. and Flies, 2013). 
1.5.3 Signal 3: Cytokines 
Once T cells have encountered cognate antigen and co-signals, lymphocytes can 




effector functions and promote survival and memory formation (Mescher et al., 
2006). IL-2, a common g-chain (gc) multifunctional cytokine, promotes effector 
responses in both CD4+ and CD8+ T cell subsets (Th1, Th2, CTLs) but suppresses 
the inflammatory Th17 responses and inhibits TFH cells. Furthermore, IL-2 induces 
development and maintenance of Tregs suggesting that IL-2 fine-tunes the 
balance of stimulatory and suppressive signals to provide adequate regulation of 
T cell responses (Fontenot et al., 2005; Ross and Cantrell, 2018). In the context 
of CD8+ T lymphocytes, IL-2 triggers a metabolic and transcriptional program, 
characterised by the upregulation of the STAT5-dependent Blimp1 and the 
engagement of glycolysis, that induces survival, growth and clonal expansion 
following TCR-stimulation. Moreover, IL-2 signalling determines CD8+ T cell fate: 
whereas strong and prolonged IL-2 signals drive differentiation into short-lived 
effector cells (SLECs), shorter IL-2 signals have been associated with the 
generation of memory-precursor effector cells (MPECs) (Kalia and Sarkar, 2018; 
Ross and Cantrell, 2018).  
In addition to the key role of IL-2 differentiation is determined, in CD4+ T 
lymphocytes, by cell exposure to cytokines such as IL-12 (Th1), IL-4 (Th2) or IL-
6, TGFb and IL-23 (Th17) (Zhu, J. et al., 2010; Luckheeram et al., 2012). In CD8+ 
lymphocytes, the major cytokines that support differentiation into CTLs are IL-12 
and type I IFNs (IFNa/b) (Curtsinger and Mescher, 2010). IL-12 is a heterodimeric 
cytokine (p35 and p40 subunits) secreted by macrophages, DCs and B 
lymphocytes upon intracellular pathogen infection. On the other hand, type I IFNs, 
known for their potent antiviral function, are secreted by almost all cell types upon 
infection. Whilst IL-12 signals are sensed by T cells through the IL-12 receptor 




alpha receptor (IFNAR). Both receptors trigger JAK/STAT signalling pathways 
and regulate T cell effector functions mainly in a STAT4 (IL-12) or a STAT1/2 
(IFNa/b) dependent manner (Liu et al., 2005; Decker et al., 2005; Curtsinger et 
al., 2005). Lack of both IL-12 and IFNa/b has been associated with an inability to 
promote cytolytic activity, IFNg production and long-term responses in CD8+ T 
cells while engaging an anergic state (Curtsinger, J. M. et al., 2003; Curtsinger et 
al., 2005; Curtsinger and Mescher, 2010). Mechanistically, IL-12 and IFNa/b 
stimulation regulates expression of effector proteins and differentiation 
transcription factors (such as GrB, IFNg and Eomes) through, at least in part, 
histone acetylation modifications that lead to chromatin remodelling of critical loci 
and, therefore, maintain effector function and support memory formation 
(Agarwal et al., 2009; Xiao et al., 2009; Curtsinger and Mescher, 2010).  
1.5.4 Modulators of TCR signalling: PTPN22 
1.5.4.1 Structure, targets and role of PTPN22 in T lymphocytes 
PTPN22 is a cytoplasmic class I protein tyrosine phosphatase predominantly 
expressed in cells of haematopoietic origin. Human PTPN22 is formed by 807 
AAs and its structure is comprised of three major domains: an N-terminal 
canonical PTP domain, an interdomain and a C-terminal domain containing 4 
proline (P), glutamate (E), serine (S), threonine (T) (PEST)-enriched C-terminal 
motifs, termed P1-P4. The phosphatase activity lies in the PTP domain, in which 
the amino acid sequence is >90% conserved between the human and mouse 
proteins. Catalytic activity is critically dependent on amino acid residues C227 
and D195. The P1 motif mediates interaction with Csk whilst the interdomain 
regulates PTPN22 activity inhibiting the catalytic domain through intramolecular 




In T lymphocytes, PTPN22, also known as lymphoid tyrosine phosphatase (Lyp) 
in humans and PEST-enriched protein tyrosine phosphatase (Pep) in mice, 
targets several TCR downstream signalling proteins. Thus, PTPN22 has been 
reported to dephosphorylate tyrosine residues within ZAP70, Lck (Tyr394), Fyn 
or TCRz limiting proximal TCR signalling (Hasegawa et al., 2004; Wu, J. et al., 
2006; Bottini and Peterson, 2014) (Fig. 1.3). PTPN22 control of proximal TCR 
signalling is tightly linked to Csk as 25-50% of PTPN22 is in complex with Csk in 
resting T lymphocytes (Cloutier and Veillette, 1999; Vang et al., 2012). Some 
studies suggest that PTPN22-Csk interaction enables synergistic inhibition of Lck 
activity (Gjörloff-Wingren et al., 1999; Bottini and Peterson, 2014). However, 
other reports have established that association with Csk is indeed counter-
productive. For example, Fiorillo et al. (2010) described that Lck suppressed 
PTPN22 through phosphorylation of tyrosine residues, a mechanisms that is 
reduced when the binding to Csk decreases, suggesting, therefore, that the 
PTPN22-Csk interaction negatively affects PTPN22 activity. Moreover, Vang et 
al. (2012) showed that the PTPN22-Csk complex disassociates upon TCR-
binding facilitating PTPN22 recruitment into lipid rafts and dephosphorylation of 
its TCR signalling targets. Another study by Wallis et al. (2017) revealed that a 
third component, the adaptor protein TNF receptor associated factor (TRAF) 3, 
is involved in the regulation of PTPN22. Experiments performed using a T cell-
specific Traf3-/- model suggest that TRAF3 promotes T cell activation inducing a 
tri-partite complex that regulates localisation and function of both Csk and 
PTPN22 (Wallis et al., 2017). Thus, the mechanism by which PTPN22 function is 
regulated upon TCR-stimulation are complex and there is still a lack of complete 




The discrimination between high affinity antigens and low affinity self-peptides 
strongly relies on early TCR signalling events. Salmond et al. (2014) described, 
using a Ptpn22-/- OT-I transgenic model, which expresses an MHC-I restricted 
ovalbumin (OVA)-specific TCR, that PTPN22 restricts T cell responses against 
weak affinity peptides while not impeding T cell activation against strong agonists. 
Ptpn22-deficient T lymphocytes display enhanced T cell responses when 
stimulated with low-affinity peptides as shown by increased expression of 
activation markers, IL-2 and effector proteins upon TCR-binding (Salmond et al., 
2014; Brownlie et al., 2017; Bray et al., 2018). Thus,  PTPN22 is important in 
determining TCR-signalling strength and setting an affinity threshold for T cell 
activation in order to avoid hyperreactivity against low affinity self-peptides. 
These data place PTPN22 in a complex network formed by phosphatases and 
kinases such as CD45, Csk and other PTPs that allow accurate antigen 
discrimination and maintain T cell homeostasis through control of proximal TCR 
signalling (Gaud et al., 2018).  
In TCR-transgenic Ptpn22-/- mice, cell number and phenotype of both CD4+ and 
CD8+ T lymphocytes within the thymus and lymph nodes is comparable to its wild-
type counterparts (Salmond et al., 2014; Wu, D.J. et al., 2014), suggesting that 
the lack of PTPN22 does not significantly affect thymic development of 
conventional T cells. Nonetheless, naïve Ptpn22-/- T cells display enhanced basal 
activation state and proliferation under lymphopenic conditions (Salmond et al., 
2014), highlighting the key role of PTPN22 in maintenance of T cell homeostasis. 
Despite having a lower TCR activation threshold, total absence of PTPN22 in 
knockout mice does not result in spontaneous autoimmune defects (Hasegawa 
et al., 2004). Maine et al. (2012) reported that Treg development was affected 




Tregs. Additionally, Ptpn22-/- Tregs are more immunosuppressive as shown by 
increased IL-10 secretion and LFA-1-mediated adhesion properties (Brownlie et 
al., 2012) suggesting that increased Treg numbers and improved function might 
maintain T cell homeostasis in mice lacking PTPN22.  
The lack of PTPN22 also enhances LFA-dependent adhesion resulting in 
increased stabilisation of APC:T cell conjugates (Brownlie et al., 2012; Salmond 
et al., 2014; Sanchez-Blanco et al., 2018). Also, PTPN22 is involved in integrin 
‘outside-in’ signalling regulating activation of Lck, ZAP70 and VAV1 following 
LFA-1:ICAM-1 engagement in migrating T cells (Burn et al., 2016). Furthermore, 
PTPN22 determines effector function of CTL responses. PTPN22-deficient mice 
display expanded effector/memory T cell populations and augmented Lck activity 
in re-stimulated T lymphocytes (Hasegawa et al., 2004). CTLs lacking PTPN22 
are reactive against very low-affinity antigens showing higher secretion of 
inflammatory cytokines (e.g. IFNg and TNF) and enhanced cytolytic effector 
responses both in vitro and in vivo when compared to wild-type CTLs (Salmond 
et al., 2014; Brownlie et al., 2017; Brownlie et al., 2019). 
Additionally, PTPN22 is also significant in the context of other immune cells and 
T cell subsets, such as TFH cells, limiting formation of germinal centres and Ab 
production, or myeloid cells, promoting PRR signalling primarily in Toll-like 
receptor (TLR)-induced IFNa/b responses (Wang, Y. et al., 2013; Maine et al., 
2014; Bottini and Peterson, 2014).  
1.5.4.2 Role of PTPN22 in autoimmune diseases 
PTPN22 function has been strongly linked to autoimmunity. A common single 
nucleotide polymorphism (SNP) in the PTPN22 gene, C1858T, results in an 




and has been associated with an increased risk of developing several 
autoimmune diseases including type I diabetes, rheumatoid arthritis (RA) and 
systemic lupus erythematosus (SLE) (Begovich et al., 2004; Bottini et al., 2004; 
Bottini and Peterson, 2014). PTPN22R620W localises in the Csk-interacting P1 
motif, greatly reducing PTPN22-Csk association (Bottini et al., 2004; Bottini and 
Peterson, 2014). Similarly to the lack of consensus in regards to whether or not 
PTPN22 activity is increased or decreased in association with Csk, discrepancies 
are shown in mouse studies describing the consequences of PTPN22R619W 
(equivalent to R620W) expression. Some investigations imply that the 
polymorphism partially mimics the phenotype of Ptpn22-/- T cells, i.e. enhanced 
activation profiles and effector functions, suggesting a PTPN22 loss-of-function 
upon Csk dissociation (Zhang, J. et al., 2011; Dai et al., 2013; Burn et al., 2016). 
Conversely, studies describing PTPN22R260W significance in human T cells have 
reported a PTPN22 gain-of-function acting as a more potent inhibitor of TCR 
signalling (Vang et al., 2005; Rieck et al., 2007; Vang et al., 2012).  
1.5.4.3 Role of PTPN22 in T cell anti-tumour responses 
T cells in autoimmunity are frequently characterised by increased sensitivity to 
weak TCR agonists and resistance to immune-regulatory mechanisms. By 
contrast, one of the mechanisms by which tumour cells evade immune responses 
is by the expression of low-affinity tumour-associated antigens (TAAs) and the 
manifestation of a harsh TME defined by the presence of immunosuppressive 
signals such as transforming growth factor b (TGFb), among many others 
(Hanahan and Coussens, 2012; Becker et al., 2013; Maueröder et al., 2014). 
Thus, engineering T cells with autoimmunity-associated risk alleles provide a 
rational approach in adoptive cell transfer (ACT) therapies. For instance,    




ovarian carcinoma cells expressing the low-affinity OVA-peptide SIITFEKL (T4) 
when compared to control, whilst no significant differences were shown against 
the high-affinity OVA-peptide SIINFEKL (N4) (Brownlie et al., 2017; Brownlie et 
al., 2019). Importantly, Ptpn22-/- CD8+ memory T cells retain their enhanced 
protective capacity during long-term in vivo responses (Brownlie et al., 2019). 
Furthermore, Brownlie et al. (2017) described that Ptpn22-/- T lymphocytes are 
highly resistant to TGFb-mediated suppression of proliferation as an indirect 
effect of enhanced  TCR signalling and IL-2 secretion. Altogether, these data 
propose PTPN22 as a potential target for cancer immunotherapy to improve TAA-
recognition and anti-tumour responses in ACT therapy (Maueröder et al., 2014; 
Brownlie et al., 2018).  
1.6 Transforming growth factor b (TGFb)  
1.6.1 Classification, activation and signalling 
The TGFb superfamily is a pleiotropic group of cytokines involved in embryonic 
development, immune regulation and tissue regeneration. It is composed of 32 
members divided into the TGFb and bone morphogenetic protein (BMP) 
subfamilies. TGFb1 in particular, as well as TGFb2 and TGFb3, members of the 
TGFb subfamily, are strongly associated with immune regulation (Batlle and 
Massagué, 2019).  
TGFb1 (referred as TGFb from now on) is synthesised as pro-TGFb, an inactive 
form that includes a N-terminal portion known as the latency-associated peptide 
(LAP) forming the so-called small latent complex. LAP encircles the active TGFb 
preventing contact with its cognate receptor.  After secretion, the complex 




or interaction with ab integrins (Travis and Sheppard, 2014; Batlle and 
Massagué, 2019). Then, cells sense TGFb signals through binding and 
subsequent assembly of a hetero-tetrameric receptor complex consisting of two 
type I and two type II receptor components known as TGFbR1 and TGFbR2, 
respectively. These contain a cytoplasmic domain with both serine/threonine and 
tyrosine kinase activity (Shi, Y. and Massagué, 2003; Massagué, 2012; David 
and Massagué, 2018). Following ligand binding, TGFbR2 phosphorylates and 
activates TGFbR1 which, in turn, phosphorylates the transcription factors small 
mothers against decapentaplegic homolog 2 (SMAD2) and SMAD3, referred as 
receptor regulated SMADs, or R-SMADs. SMAD2/3 phosphorylation leads to the 
formation of heterotrimeric complexes with SMAD4 which then translocate to the 
nucleus (Massagué, 2012; David and Massagué, 2018). In the nucleus, SMAD 
complexes interact with cell- and context-dependent co-activators and co-
repressors that determine transcriptional outcomes (David and Massagué, 2018). 
Termination of TGFb signalling is driven by induction of the inhibitory SMAD6 and 
SMAD7 that promote degradation of the TGFb receptor. Additionally, CDK8 and 
CDK9 induce recognition of SMAD complexes by GSK3b, which marks SMADs 
for SMAD ubiquitination regulatory factor 1 (SMURF1)-mediated 
polyubiquitination and subsequent degradation. Importantly, TGFb also signals 
via SMAD-independent pathways, including MAPK and PI3K pathways (Batlle 





Figure 1.4: TGFb signalling.  
The interaction of the small latent complex with the extracellular matrix (ECM) 
and integrins releases the active form of TGFb. TGFb is then recognised by the 
TGFbR, which leads to the phosphorylation of TGFbRI by TGFbRII. 
Consequently, TGFbRI phosphorylates the TFs SMAD2/3, which consequently 
interact with SMAD4. The SMAD complex translocates to the nucleus and 
regulates transcription through association with other cofactors. SMAD6 and 
SMAD7 mediate the termination of TGFb signalling through SMURF-mediated 
ubiquitination of SMADs and the TGFbR. Termination of TGFb signalling can also 
be mediated by CDK8/9. Adapted from “TGF-Beta Signaling Pathway”, by 







1.6.2 TGFb in immune regulation 
TGFb has a pivotal role in immune regulation modulating both adaptive and 
innate lineages. TGFb is particularly relevant in the development of several T cell 
lineages within the thymus as well as maintaining peripheral tolerance against 
self and benign antigens (Sanjabi et al., 2017). For instance, TGFb induces 
development of Tregs antagonising negative selection and promoting survival of 
its precursors. Also, TGFb induces expression of the IL-7 receptor a chain (IL-
7Ra) in thymocytes, key for the differentiation of conventional CD8+ T cells 
(Sanjabi et al., 2017). High IL-7R levels contribute to IL-7 sensing by low-affinity 
T lymphocytes promoting survival and homeostasis of the peripheral naïve T cell 
pool (Johnson and Jameson, 2012). The importance of TGFb as a regulator of 
peripheral tolerance is shown in transgenic mouse models with abrogated TGFb 
signalling that display aberrant lymphoproliferative phenotypes (Gorelik and 
Flavell, 2000; Lucas et al., 2000; Marie et al., 2006). Furthermore, TGFb 
dampens T cell activation by inhibiting IL-2 transcription and specifically 
suppresses CTL, Th1 and Th2 differentiation while promoting development of 
pTreg, Th17, Th9 and TFH cells (Sanjabi et al., 2017). In the context of CTLs, TGFb 
represses cytotoxic function by directly inhibiting transcription of key effector 
proteins and cytokines upon association of SMADs with the co-activator 
activating transcription factor 1 (ATF1) (Thomas and Massagué, 2005).  
1.6.3 TGFb within the tumour microenvironment 
Immune responses are suppressed within the TME through multiple mechanisms 
including the recruitment and expansion of immunosuppressive cells such as 
Tregs and myeloid-derived suppressor cells (MDSCs), the lack of nutrients and 




phenotype or the accumulation of inhibitory cytokines such as IL-10 and TGFb 
(Anderson et al., 2017; Zhang, Z. et al., 2020).  
TGFb within the TME affects several cell types and displays context-dependent 
effects. TGFb acts as a tumour suppressor at early stages of cancer progression 
via cytostatic and proapoptotic mechanisms and as shown by favoured 
development of premalignant cells into tumours in mice containing genetic 
ablation of TGFBRII or SMAD4 (Takaku et al., 1998; Muñoz et al., 2006; 
Bardeesy et al., 2006; Massagué, 2008). However, malignant cells switch off 
TGFb-derived suppressive mechanisms and convert TGFb into a pro-tumorigenic 
signal. Malignant cells are able to develop resistance to TGFb as a consequence 
of mutations in core TGFb signalling components and its downstream signals 
promoting survival and proliferation in TGFb-rich environments. Additionally, 
tumour cells are also able to use TGFb to their own advantage and rewire TGFb 
programs to instruct metastasis and produce autocrine mitogens (Massagué, 
2008).  
Besides modulating tumour growth and invasion, TGFb is key to drive immune 
evasion as it promotes the differentiation and recruitment of pro-tumour immune 
cells while suppressing the activity of anti-tumour cells (Flavell et al., 2010; 
Gigante et al., 2012; Tu et al., 2014). TGFb impairs activation of immature tumour 
infiltrating DCs downregulating expression of MHC molecules and co-stimulatory 
receptors as well as becoming tolerogenic TGFb-secreting cells that promote 
differentiation of tumour-specific Tregs (Li, M.O. et al., 2006; Flavell et al., 2010). 
Furthermore, TGFb induces differentiation of the pro-tumorigenic M2 
macrophages (Allavena et al., 2008) and N2 neutrophils (Fridlender et al., 2009). 




IFNg secretion and downregulation of activation receptors such as NKG2D 
(Castriconi et al., 2003; Laouar et al., 2005). TGFb also disrupts CD8+ T 
lymphocytes killing capacity through inhibition of the effector proteins GrB, GrA, 
Fas-L, and IFNg (Thomas and Massagué, 2005). In the context of CD4+ T cells, 
TGFb induces FoxP3 and receptor-related orphan receptor-gt (RORgt) 
expression promoting Treg and Th17 differentiation, respectively (Li, M.O. and 
Flavell, 2008).   
1.7 Immunometabolism 
All cellular processes are sustained by metabolism, an interconnected network of 
catabolic or anabolic chemical reactions. Catabolism facilitates the breakdown of 
molecules, ultimately resulting in energy production via adenosine triphosphate 
(ATP) synthesis. Key energy-producing catabolic pathways include glycolysis, 
the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS). In 
the presence of oxygen, a molecule of glucose undergoes glycolysis and is 
oxidised into two pyruvate molecules that translocate to the mitochondria. Here, 
pyruvate is converted by pyruvate dehydrogenase (PDH) into acetyl-CoA which, 
in turn, fuels the TCA cycle. The engagement of the TCA cycle yields free 
electrons carried by nicotinamide adenine dinucleotide (NAD/NADH) and flavin 
adenine dinucleotide (FAD/FADH2) and transferred to the electron transport chain 
(ETC) in order to pump protons (H+) into the mitochondrial intermembrane space. 
The membrane potential generated by the H+ gradient is used by the ATP 
synthase to generate energy. Furthermore, substrates apart from glucose can be 
utilised to support ATP production. For instance, fatty acid b-oxidation (FAO) 
generates acetyl-CoA whilst several amino acids (AAs), such as glutamine, can 




participates in the generation of the membrane potential through the synthesis of 
NADH, which is then translocated to the mitochondria via the aspartate-malate 
shuttle. Finally, the generated ATP pool is used to fuel anabolic pathways, e.g. 
synthesis of fatty acids (FAS), proteins and nucleic acids (O'Neill et al., 2016).  
During the last decade, it has become evident that metabolism shapes immunity. 
T lymphocytes in particular require metabolic modifications to match the energetic 
and biosynthetic demands needed for activation, growth, clonal expansion, 
differentiation and effector functions. Moreover, T cell metabolism has also been 
associated with other non-bioenergetic functions including epigenetic, post-
transcriptional and post-translational modifications as well as the utilisation of 
metabolites as signalling molecules (Gerriets and Rathmell, 2012; Pearce et al., 
2013; Pearce and Pearce, 2013; MacIver et al., 2013; Maciolek et al., 2014; Buck 
et al., 2015; Geltink et al., 2018; Chapman et al., 2019; Shyer et al., 2020). This 
new understanding has provided a novel and valuable tool to manipulate T cell 
function in immunotherapy and, therefore, emphasises the importance to further 
comprehend how T cell metabolism is regulated (O'Sullivan and Pearce, 2015; 
Chang and Pearce, 2016; Patel and Powell, 2017; Bettencourt and Powell, 2017; 
Li, X. et al., 2019; Hope and Salmond, 2019; Pålsson-McDermott and O’Neill, 
2020). Below, I describe the crosstalk between metabolism and function during 
the development of T cell responses followed by some examples on how this 
knowledge can been exploited to manipulate immunity in disease.  
1.7.1 Metabolic reprogramming in activated T lymphocytes 
Quiescent naive T cells take up low levels of nutrients and display a basal 
metabolic activity characterised by the engagement of catabolic pathways such 




recognition, T lymphocytes undergo a metabolic shift that drives the cell into an 
anabolic programme that supports growth and rapid clonal proliferation. 
Specifically, activated T cells upregulate the expression of nutrient transporters 
and, subsequently, significantly increase nutrient uptake in order to provide 
sufficient building blocks for the synthesis of new macromolecules. Furthermore, 
activated T cells mainly rely on aerobic glycolysis, glutaminolysis, FAS and serine 
glycine one-carbon (SGOC) metabolism (MacIver et al., 2013; Buck et al., 2015; 
Geltink et al., 2018; Chapman et al., 2019; Shyer et al., 2020).  
 
Figure 1.5: Metabolism of activated T lymphocytes.  
Naïve T cells display a low metabolic activity, characterised by low nutrient uptake 
and the engagement of OXPHOS and FAO. Upon TCR-stimulation, the activation 
of mTOR and the expression of metabolic TFs (e.g. Myc, HIF1a, SREBPs) leads 
to a metabolic reprogramming that benefits the synthesis of new macromolecules 





How does antigen recognition by the TCR lead to the metabolic reprogramming 
of activated T cells? Transcription factors such as Myc, hypoxia-inducible factor 
1 alpha (HIF1a) and sterol regulatory element binding-proteins (SREBPs) family 
members have been strongly associated with the upregulation of nutrient 
transporters and metabolic-related genes (Hough et al., 2015). Additionally, the 
mTOR/AMPK axis modulates T cell metabolism while sensing energy status and 
nutrient availability triggering a context-dependent response and, therefore, 
providing metabolic plasticity during T cell function (Ma et al., 2017b; Myers et 
al., 2019; Saravia et al., 2020; Shyer et al., 2020). 
1.7.1.1 Transcriptional regulation of the T cell metabolic reprogramming 
The proto-oncogenic transcription factor c-Myc (referred as Myc from now on) is 
involved in a wide range of human cancers and contributes to the regulation of 
cell cycle and metabolism. In T lymphocytes, Myc expression is rapidly 
upregulated in response to TCR-stimulation and sustained by the action of 
costimulatory receptors, IL-2 and nutrient availability (Preston et al., 2015; 
Swamy et al., 2016). Wang, R. et al. (2011) identified Myc as a key transcription 
factor for the metabolic reprogramming of activated T cells and, particularly, for 
the induction of glycolysis and glutaminolysis. A more recent study by Marchingo 
et al. (2020) described that Myc null T cells show no disruption in the upregulation 
of glucose transporter GLUT1 and little impact in the expression of glycolytic 
enzymes. Instead, Myc null T cells display strong inhibition of the lactate 
transporter Slc16a1 and several amino acid transporters including Slc1a5, 
Slc7a1 and, particularly, Slc7a5. In the same study, Slc7a5-deficient T cells 
largely mimicked the phenotype of Myc null T cells suggesting that, 
mechanistically, Myc might trigger T cell metabolic reprogramming via the 




AP4, a transcription factor that sustains the Myc-regulated metabolic program 
after Myc downregulation during TCR signalling withdrawal. (Chou et al., 2014). 
Nonetheless, TCR-induced Myc expression alone is not sufficient to trigger T cell 
activation and sustain T cell function and differentiation. HIF1a is usually 
stabilised under hypoxic conditions and induces gene expression of all glycolytic 
enzymes, including lactate dehydrogenase (LDH) and GLUT1, to minimise 
oxygen consumption. However, HIF1a can also be induced by the TCR and 
despite being dispensable for early T cell activation and proliferation is, similarly 
to AP4, required to sustain glycolysis and glutaminolysis throughout 
differentiation and expansion of CD8+ T cells (Wang, R. et al., 2011; Finlay et al., 
2012).  
In the context of lipid metabolism, activated T cells induce the mTOR-dependent 
SREBP1 and SREBP2 which bind to promoter regions of genes encoding key 
enzymes for fatty acid and cholesterol synthesis, such as fatty acid synthase 
(FASN), acetyl-CoA carboxylase (ACC1) and hydroxymethylglutaryl-CoA 
reductase (HMGCR). CD8+ T lymphocytes lacking SREBP signalling strikingly 
display an altered lipid anabolic program in response to mitogen resulting in an 
impaired capacity to blast, proliferate and survive whilst indirectly affecting 
glycolysis and glutaminolysis due to a compromised bioenergetic status (Kidani 
et al., 2013; Lochner et al., 2015).  
The transcription factors estrogen-related receptor a (ERRa) and mitochondrial 
transcription factor A (MTFA) are also required for T cell activation and have been 
particularly associated with the regulation of mitochondrial function (Michalek et 
al., 2011b; Baixauli et al., 2015). The TCR-induced increase of mitochondrial 




Harel et al., 2016; Fischer et al., 2018; Rambold and Pearce, 2018). How and 
when mitochondrial biogenesis is regulated is largely unknown but it has been 
strongly linked with the peroxisome proliferator-activated receptor g (PPARg) co-
activator 1-a (PGC1a) (Scharping et al., 2016; Dumauthioz et al., 2020).  
1.7.1.2 mTOR/AMPK 
mTOR is a constitutively expressed serine/threonine kinase that performs as a 
central node integrating environmental immune and metabolic cues in order to 
regulate T cell function.  mTOR signals through two main complexes, the 
rapamycin-sensitive mTOR complex 1 (mTORC1) and rapamycin-insensitive 
mTOR complex 2 (mTORC2). mTORC1 is a key metabolic regulator during T cell 
activation and differentiation. mTORC1 is rapidly activated in T cells upon TCR-
stimulation by a PI3K-Akt-independent mechanism involving PDK1 (Finlay et al., 
2012). Furthermore, mTORC1 activity is modulated by intracellular levels of 
nutrients: amino acids can be directly sensed via Rag GTPases whilst low 
glucose availability reduces the ATP:AMP ratio promoting AMPK activation and, 
subsequently, mTORC1 suppression. mTORC1 downstream targets include the 
translational regulators 4E-binding proteins (4E-BPs) and ribosomal protein S6 
kinases (S6Ks), thereby promoting protein synthesis (Chapman and Chi, 2015; 
Saxton and Sabatini, 2017; Zeng and Chi, 2017; Myers et al., 2019). However, a 
recent proteomic analysis by Hukelmann et al. (2016) established that, in T cells, 
mTOR selectively influences specific subsets of proteins rather than having a 
global effect on protein abundance. For instance, rapamycin-treated CTLs 
significantly downregulate the expression of glucose transporters and enzymes 
involved in glycolysis and cholesterol metabolism but not those involved in 
glutaminolysis and OXPHOS (Hukelmann et al., 2016; Howden et al., 2019). 




unable to undergo T cell metabolic reprogramming and enter an anergic state 
(Araki et al., 2010; Shi, L.Z. et al., 2011). The mechanisms underlying the control 
of T cell metabolism by mTORC1 are suggested to be dependent on activation 
of transcription factors such as HIF1a (Finlay et al., 2012) and SREBPs (Kidani 
et al., 2013), but not Myc (Finlay et al., 2012; Howden et al., 2019; Marchingo et 
al., 2020). 
By contrast, AMPK counterbalances mTOR activity in the regulation of T cell 
metabolism. AMPK, formed by 3 subunits (a, b, g), senses AMP/ADP 
accumulation and maintains the ATP/ADP ratio promoting energy-producing 
processes while suppressing anabolic pathways. Furthermore, AMPKa1 can be 
activated directly by liver kinase B1 (LKB1) and calmodulin-dependent protein 
kinase kinase-2 (CamKK2) in response to energetic stress and Ca2+ release after 
TCR-ligation, respectively. One of the best characterised AMPK targets is ACC1, 
an enzyme involved in the generation of malonyl-CoA which serves as a 
substrate for FAS while blocking FAO through allosteric inhibition of CPT1 (Ma et 
al., 2017b; Saravia et al., 2020). Furthermore, as mentioned above, AMPK is 
known to directly inhibit mTOR via activation of the TSC1-TSC2 complex or 
phosphorylation of the mTOR binding partner Raptor. In CTLs, AMPK selectively 
senses glucose deprivation initiating a metabolic adaptive response based on a 
glycolysis-to-glutaminolysis switch derived from mTORC1 inactivation (Blagih et 
al., 2015). AMPKa1-deficient T lymphocytes, despite being able to proliferate and 
differentiate into effector T cells, provide deficient primary responses due to an 
impaired accumulation of both CD4+ and CD8+ T cells in infection sites (Rolf et 
al., 2013). Is speculated that T lymphocytes lacking AMPKa1 fail to adapt and 




might explain their poor capacity in the generation of memory T cells (Rolf et al., 
2013).  
1.7.1.3 Aerobic glycolysis in activated T lymphocytes 
Conversion of pyruvate, the final glycolytic product, into lactate via lactate 
dehydrogenase (LDH) is a transition seen in hypoxic environments to minimise 
oxygen consumption. However, it is likely that all proliferating cells use aerobic 
glycolysis as a central metabolic pathway – i.e. lactate production regardless of 
oxygen levels, a phenomenon known as ‘the Warburg effect’. Within minutes after 
TCR-stimulation, T lymphocytes impair mitochondrial pyruvate import and 
facilitate breakdown into lactate (Menk et al., 2018). Furthermore, rapid mTOR 
activation as well as Myc and HIF1a upregulation promote expression of 
glycolytic enzymes and glucose transporters that sustain glucose metabolism 
during T cell activation and differentiation (Wang, R. et al., 2011; Salmond, 2018). 
As shown by analysis of the impact of glucose deprivation or treatment with 2-
deoxyglucose (2-DG), an inhibitor of hexokinase (HK), or studies of transgenic 
mice lacking GLUT1, glycolytic inhibition abolishes activation-induced expansion 
of effector T cells while significantly affecting survival (Macintyre et al., 2014). In 
effector T cells, limiting glucose availability is sensed by AMPK which, in turns, 
inhibits mTOR activation resulting in slowed proliferation and reduced IFNg 
secretion (Blagih et al., 2015).  
Aerobic glycolysis is a relatively inefficient bioenergetic pathway as only 2 ATPs 
are generated per glucose molecule. However, glycolytic flux provides 
accumulation of intermediaries required for additional functions. For instance, 
glucose-6-phosphate (G6P) is diverted into the pentose phosphate pathway 




NADPH/NADP+ ratio. G6P also fuels the hexosamine pathway driving the 
generation of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), a 
substrate used for O-GlcNAcylation of key T cell signalling molecules such as 
Myc, NFAT or c-Rel. 3-phosphoglycerate (3PG) is used as a substrate for serine 
generation contributing to SGOC metabolism, whilst dihydroxyacetone-
phosphate (DHAP) produces glycerol for the synthesis of complex lipids (Seki 
and Gaultier, 2017; Dimeloe et al., 2017; Shyer et al., 2020). Moreover, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) act as a 
posttranscriptional regulator by directly binding to AU-rich elements within the 3’ 
untranslated region (UTR) of IFNg mRNA and preventing translation (Chang et 
al., 2013). After TCR-stimulation, GAPDH is diverted into the glycolytic pathway, 
disengaging from the 3’-UTR and initiating IFNg translation. Importantly, the 
enolase-derived product phosphoenolpyruvate (PEP) performs as a metabolic 
checkpoint modulating cytosolic Ca2+ concentrations and NFAT activation (Ho et 
al., 2015). Therefore, aerobic glycolysis is essential during T cell activation not 
only to support ATP and biomass production, but also contributing to the 
generation of signalling metabolites that directly implicate glycolysis on T cell 
effector function. 
1.7.1.4 Mitochondrial metabolism in activated T lymphocytes 
The Warburg effect, first identified in tumour cells, was initially described as the 
engagement of aerobic glycolysis in parallel to the inhibition of OXPHOS 
(Warburg, 1956; Liberti and Locasale, 2016). Nonetheless, T lymphocytes also 
require mitochondrial metabolism to support activation (Sena et al., 2013; Tan et 
al., 2017). Despite the shift of pyruvate metabolism towards lactate, pyruvate 




the TCA cycle is predominantly replenished by glutamine (Gln)-derived a-
ketoglutarate in a process known as glutaminolysis. Fatty acids are also utilised 
as an additional source of TCA intermediaries as FAO-derived acyl-CoA enters 
the mitochondria via carnitine palmitoyltransferase 1 (CPT1) and induces acetyl-
CoA synthesis (Lochner et al., 2015). Importantly, the relevance of mitochondrial 
metabolism goes beyond coupling the TCA cycle and the ETC to produce ATP. 
ETC-derived ROS has been described as regulator of mTOR and NFAT 
activation and has been described as an additional ‘signal 3’ during T cell 
activation (Sena et al., 2013; Mak et al., 2017; Chamoto et al., 2017). Moreover, 
Krebs intermediaries mediate alternative T cell functions including its utilisation 
as posttranslational regulators or as substrates for biosynthesis. For example, 
citrate can be used to produce lipids via ATP citrate lyase (ACL) and oxalacetate 
to produce nucleotides, whilst malate and succinate can be used to modify 
proteins (Mehta et al., 2017). Besides supporting the Krebs cycle and OXPHOS, 
mitochondria sustain SGOC metabolism, a complex network that comprises the 
folate and methionine cycle and that contributes to glutathione synthesis, redox 
balance and epigenetic remodelling via accumulation of the methyl donor S-
adenosylmethionine (SAM) (Ron-Harel et al., 2016; Ma et al., 2017a).  
1.7.1.5 Amino acid uptake in activated T lymphocytes 
Amino acids represent, in addition to glucose and lipids, the third pillar that 
sustain T cell metabolism. The expression of AA transporters, such as Slc7a5 
(large neutral AA transporter 1; LAT1), Slc3a2 (CD98) and Slc1a5 (alanine serine 
cysteine transporter 2; ASCT2), is highly upregulated upon TCR-stimulation in a 
Myc-dependent manner (Marchingo et al., 2020; Wang, W. and Zou, 2020). As 
shown by Sinclair et al. (2013), Slc7a5-deficient T lymphocytes are unable to 




mediated AA transport is essential to undergo T cell metabolic reprogramming 
after antigen recognition. On the other hand, ASCT2, a major glutamine 
transporter, despite being dispensable for T cell proliferation and IL-2 production, 
is associated with optimal mTORC1 activation resulting in defective Myc 
expression and effector differentiation in activated T cells lacking ASCT2 (Nakaya 
et al., 2014). Importantly, activated T lymphocytes require extracellular uptake of 
both essential and several non-essential AAs emphasising the high demand on 
AAs and its importance in the modulation of T cell responses (Kelly and Pearce, 
2020). 
The mechanisms underlying T cell suppression in the absence of AAs are mainly 
associated with impaired protein synthesis and/or mTORC1 inactivation (Kelly 
and Pearce, 2020). However, T cells are able to induce an adaptive response in 
this scenario. Mechanistically, T cells can sense AA deprivation upon interaction 
of uncharged tRNAs with general control nonderepressible 2 (GCN2). GCN2 
activates ATF4, an stress-induced transcription factor that upregulates the 
expression of genes involved in metabolic reprogramming that leads to the 
synthesis of AA (Yang et al., 2018). In addition to protein synthesis and the 
regulation of mTORC1 activity, recent investigations have linked several AAs to 
other T cell functions. For example, (1) glutamine is used as a substrate for 
anaplerosis, glutathione generation (Mak et al., 2017), O-GlcNAcylation (Swamy 
et al., 2016) and asparagine (Asn) synthesis via asparagine synthetase (ASNS) 
(Hope et al., 2020); (2) serine incorporates into SGOC metabolism, as mentioned 
in section 1.7.1.3; (3) methionine uptake is a rate limiting step for SAM generation 
in activated T cells, as shown by impaired RNA and histone methylation upon 
deprivation of external methionine supply (Sinclair et al., 2019; Klein Geltink and 




survival while promoting a transition from glycolysis to OXPHOS (Geiger et al., 
2016). Therefore, AAs are essential pleiotropic metabolites for T cell function 
involved in protein synthesis, mTORC1 activation, signalling and regulation of 
gene expression.  
1.7.2 Metabolism determines T cell fate 
Changes in metabolism remarkably determine T cell differentiation into an 
effector vs memory phenotype. Resting memory T lymphocytes, as they do not 
proliferate and produce little or no cytokines, mainly rely on catabolic pathways 
such as FAO or OXPHOS. Unlike naïve T cells, memory T cells are characterised 
by an increased spare respiratory capacity (SRC) that promotes longevity and 
rapid recall responses (van der Windt et al., 2012). Enhanced mitochondrial 
capacity, driven by the common g chain cytokines IL-7 and IL-15 as well as CD28 
co-stimulation (Cui et al., 2015; Klein Geltink et al., 2017), has been associated 
with increased FAO since CPT1 overexpression increases SRC and generation 
of memory T cell populations in vivo (Pearce et al., 2009). Interestingly, FAO is 
preferentially fuelled by de novo FAS as shown by impaired memory formation in 
T cells lacking aquaporin 9 (AQP9), a mediator of glycerol import (O'Sullivan et 
al., 2014). Furthermore, memory T cells present increased mitochondrial mass 
driven by high expression of PGC1a (Scharping et al., 2016; Chamoto et al., 
2017). In contrast, the metabolism of short-lived effector T cells is characterised 
by high glycolytic and mTORC1 activity. Attenuation of the glycolytic flux, either 
by 2-DG or rapamycin supply in low doses, has been associated with the 
acquisition of memory-like phenotypes and long-term responses in vivo (Araki et 
al., 2009; Sukumar et al., 2013). Similarly, enforcement of mitochondrial function 




persistent and durable responses (Chamoto et al., 2017; Li, W. and Zhang, 2020; 
Dumauthioz et al., 2020).  
In the context of CD4+ T lymphocytes, each subset also has a unique metabolic 
profile. In general terms, effector CD4 Th cells (Th1, Th2 and Th17) preferentially 
rely on glycolysis whilst Tregs depend on FAO and OXPHOS (Michalek et al., 
2011a; Gerriets and Rathmell, 2012; MacIver et al., 2013; Buck et al., 2015). 
Thus, the glycolytic/mitochondrial dichotomy comprises a key regulatory axis that 
determines T cell fate and, as discussed below, provides a therapeutic tool to 
manipulate T cell immunity. 
1.7.3 Immunometabolism as an emerging target in immunotherapy  
The understanding of immunometabolism and its regulation has provisioned a 
new mechanism to attenuate or boost T cell responses in autoimmune diseases 
and cancer, respectively. Particular interest is arising in the field of anti-tumour 
responses as the TME imposes metabolic barriers, either by nutrient and oxygen-
depletion or the secretion of immunomodulatory metabolites, that dampen 
effective T cell responses (Ho and Kaech, 2017; Sugiura and Rathmell, 2018; 
Hope and Salmond, 2019; Lim et al., 2020).  
Investigations revealing the direct implications of glycolysis in T cell effector 
function have been used to improve cytotoxicity of T lymphocytes in ACT 
therapies by enforcing accumulation of glycolytic intermediaries, such as PEP 
(Ho et al., 2015). Nonetheless, constitutive glycolytic flux is associated with 
terminal differentiation of CTLs (Kishton et al., 2017). Instead, new studies have 
been focused on the modulation of mitochondrial metabolism to reinforce 




(Geiger et al., 2016; Klein Geltink et al., 2017; Chamoto et al., 2017; Li, W. and 
Zhang, 2020).  
Unravelling how pro-tumour cells such as Tregs, MDSCs or M2 macrophages are 
favoured within the TME has also been of interest in cancer therapy. For instance, 
recent research by Wang, H. et al. (2020) revealed that intratumoral Tregs adapt 
to lactate-rich environments switching to a lipid metabolism mediated by the 
upregulation of CD36, a fatty acid translocase, that sustains mitochondrial fitness 
and suppressive function selectively within the TME. Consequently, tumour 
rejection substantially improves in Treg-specific CD36-ablated mice models while 
not affecting to peripheral homeostasis proposing CD36 as a potential target for 
cancer therapy. Co-inhibitory molecules also influence T cell metabolism per se 
(Patsoukis et al., 2015). Therapies combining immune checkpoint blockade (ICB) 
and metabolism-directed strategies have provided enhanced therapeutic 
efficiency suggesting that targeting metabolism is also promising in this context 
(Hope and Salmond, 2019; Li, X. et al., 2019). Another attractive strategy is to 
metabolically compromise tumour cells. Tumour cells are strongly dependent on 
nutrient availability to sustain aberrant proliferation and, therefore, nutrient 
deprivation limits tumour progression. A good example of this is the utilisation of 
asparaginases, which deprives tumour cells from the AA Asn, as a conventional 
chemotherapeutic adjuvant in acute lymphoblastic leukaemia (ALL) (Chiu et al., 
2020).  
On the other hand, immune cell metabolism is also aberrant in autoimmunity and, 
therefore, the manipulation of autoreactive T cell metabolism is increasingly 
becoming a field of interest (Teng et al., 2019). Particularly, limiting glucose 
metabolism successfully reduces Th1, Th17 and TFH hyperreactivity resulting in 




Kornberg et al., 2018).  For example, a recent study by Angiari et al. (2020) 
showed that the utilisation of TEPP-46, a small molecule that acts on pyruvate 
kinase isozyme M2 (PKM2), the enzyme that converts PEP into pyruvate, 
inhibited the development of experimental autoimmune encephalomyelitis (EAE). 
PKM2 is mostly present as a monomer/dimer in activated T cells, which has been 
associated with moonlighting activities beyond canonical glycolytic control (Luo 
et al., 2011). Instead, monomer/dimer PKM2 translocates to the nucleus and 
regulates gene expression of HIF1a which, in turn, promotes expression of 
glycolytic enzymes. Mechanistically, TEPP-46 enforces PKM2 tetramerization 
and exit from the nucleus resulting in glycolysis attenuation, decreased Th1 and 
Th17 polarization and inhibited EAE development.  
Altogether, these studies indicate that the role of metabolism in immunity goes 
beyond sustaining immune function bioenergetically and, rather than being only 
a consequence of T cell signalling, metabolism per se belongs to the complex 
signalling machinery that regulates T cell responses. This finding has provisioned 
researchers with a whole new spectrum of possibilities to manipulate immune 
responses and has positioned the study of immunometabolism as a state-of-the-
art field.  
1.8 Thesis aims 
As described above, emerging investigations have provided evidence that 
metabolic modulation of T lymphocytes is a strategy that can be successfully 
exploited for immunotherapy. The outcome of T cell responses is defined by the 
integration of a wide array of environmental signals that include TCR signalling, 
co-stimulation, cytokines or nutrient availability (Ramsay and Cantrell, 2015) (Fig. 




its deregulation is associated with the development of autoimmunity and cancer 
progression (Bantug et al., 2018). Further understanding how metabolism is 
shaped by these signals during the development of CD8+ T cell responses will 
shed light into novel strategies to precisely manipulate T cell function in disease 
and acquire better clinical outcomes.  
 
Figure 1.6: Environmental cues are integrated to dictate CD8+ T cell fate. 
CD8+ T cell function is influenced by the presence of environmental signals that 
modify their gene expression and metabolic profile. Amongst the main signals 
that shape CD8+ T cells we find: (1) ‘Signals 1, 2 and 3’, which include TCR 
signalling, co-stimulation (e.g. CD28) and inflammatory cytokines (e.g. IL-12 and 
type I IFNs); (2) anti-inflammatory cytokines and (3) the availability of nutrients.  
 
Here, in order to gain further understanding of the fundamental mechanisms that 
regulate CD8+ T cell responses with the long-term goal of identifying new targets 
for immunotherapy, I aim to investigate how some of these environmental cues 
are integrated by CD8+ T cells and how these differentially influence their function 




1.  Define how signals 1, 2 and 3 are integrated to mediate with CD8+ T cell 
activation and the TCR-induced metabolic reprogramming. The study of 
‘Signals 1, 2 and 3’ and its influence on T cell function and metabolism is 
included in Chapter 3.  
2. Determine the effect of TGFb during CD8+ T cell priming and subsequent 
metabolic reprogramming. The study of TGFb and its influence on T cell 
function and metabolism is included in Chapter 4 and Chapter 5. 
3. Interrogate the requirements for the amino acid asparagine to sustain 
CD8+ T cell function and metabolism. The study of asparagine availability 

















Chapter 2 Materials and methods 
2.1 Transgenic mice 
All mice were maintained at the St. James Biomedical Services (SBS) animal 
facility (University of Leeds, UK). Experiments were performed in accordance with 
UK Home Office project licence PDAD2D507. Age-matched (7-12 weeks) mice 
were used in the majority of the experiments. However, some repeated 
experiments were performed using older mice (28-32 weeks) due to the 
difficulties caused by the COVID-19 situation between March and August 2020.  
2.1.1 Rag1-/- CD45.1+ OT-I mice 
The OT-I mouse strain expresses a transgenic TCR that specifically recognises 
an H-2Kb-restricted ovalbumin peptide (OVA257-264). Single amino acid 
substitutions in this peptide alter the affinity for the OT-I TCR (Hogquist et al., 
1994). Additionally, this OT-I strain lacks mature B cells and T cells expressing 
non-transgenic TCRs (Rag1-/- genotype). 
2.1.2 Ptpn22-/- Rag1-/- CD45.2+ OT-I mice 
OT-I mice with global deletion of Ptpn22 were generated as described previously 
(Salmond et al., 2014). This mouse strain is also RAG1-deficient. Furthermore, 
Ptpn22-/- T cells express a CD45.2 allele, whilst Ptpn22+/+ T cells (Section 2.1.1) 
express CD45.1. This is used to distinguish both cell types in in vitro and in vivo 
experiments where these cells are co-cultured or co-transferred, respectively. 
2.1.3 AsnsTm1a(EUCOMM)/Wtsi mice 
The genetically-modified mouse strain AsnsTm1a(EUCOMM)/Wtsi, referred from now on 
as AsnsTm1a, was generated by the International Mouse Phenotyping Consortium 




mice, originally on a C57BL/6N background, were back-crossed with C57BL/6J 
mice. AsnsTm1a mice contain a gene-trap insertion in intron 2 of the Asns locus 
that results in an hypomorphic Asns allele (Ruzzo et al., 2013) which, when 
expressed homozygously, reduces ASNS protein to <10% of control levels (Hope 
et al., 2020). Polymerase chain reaction (PCR), as described in Section 2.2, was 
performed to determine the genotype of AsnsTm1a mice. When performing 
experiments with AsnsTm1a mice, WT littermates or in-house C57BL/6 mice were 
used as controls.  
2.2 AsnsTm1a  genotyping 
2.2.1 DNA extraction 
First, DNA from ear samples was extracted adding lysis buffer [100mM Tris 
(pH8.5), 5mM EDTA, 0.2% SDS, 200mM NaCl] and proteinase K (100µg/ml; 
Roche) overnight at 56°C. The following day, samples were centrifuged 
(13000rpm, 10min) and supernatants were transferred to 1.5mL tubes containing 
isopropanol. Samples were centrifuged (13000rpm, 10min), the supernatant was 
discarded and pellets were washed carefully in 70% EtOH and dried for at least 
30 min. TE buffer (10mM Tris, 1mM EDTA) was added and samples were kept 
overnight at 56°C.  
2.2.2 Polymerase chain reaction (PCR) 
PCR master mix containing deoxynucleotides (dNTPs; 10mM, Invitrogen), MgCl2 
(50mM, Thermo Scientific), KAPA2G Fast HotStart DNA Polymerase (Kapa 
Biosystems) and dH20 was mixed in PCR tubes with the forward (ASNS-5arm-
WTF: 5’ GCATTTAAGTGCACAGGAGGA 3’; 20µM, Sigma) and reverse primers 
(ASNS-Crit-WTR: 5’ ACAAGGGTCAGGCATCAGAG 3’; 5mut-R1: 




PCR was performed using a 96-well thermocycler (Applied Biosystems) following 
the next protocol:  
- Stage 1: 95°C, 1 minute. 
- Stage 2 (x29 cycles): 95°C, 10 seconds à 60°C, 10 seconds à 72°C, 1 
second.  
- Stage 3: 72°C, 30 seconds. Then, samples were kept at 16°C until further 
analysis. 
2.2.3 Electrophoresis 
PCR products, mixed with BlueJuiceÔ gel loading buffer (Invitrogen), were 
analysed through electrophoresis (Bio-Rad) in a 2% agarose gel containing 
ethidium bromide (Alfa Aesar). The amplified Asns-WT (223pb) or Asns-Tm1a 
(123pb) fragments were detected using ChemiDoc imagers (Bio-Rad). Asns-WT 
and Asns-Tm1a bands were distinguished according to a 100bp DNA ladder 
(Invitrogen). 
2.3 Cell culture 
2.3.1 Reagents 
For all experiments included in Results Chapters 3, 4 and 5 T cells were cultured 
in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with penicillin-
streptomycin, 50µM b-mercaptoethanol and 5% heat-inactivated Fetal Bovine 
Serum (FBS) (Table 2.1). All experiments included in Chapter 6, unless otherwise 
stated, were performed using Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with penicillin-streptomycin, 50µM b-mercaptoethanol, 5% 





Reagent Final concentration Manufacturer 
b-mercaptoethanol 50µM Gibco #21985-023 
Dialysed FBS NA Gibco #1050064 
DMEM NA Gibco #11880-036 
FBS NA Gibco #26140087 
IMDM NA Gibco #12440-053 
PBS NA Gibco #10010-015 
L-Asparagine 300µM Sigma #A4159 
L-Glutamine 2mM Gibco #25030-081  
Penicillin/Streptomycin 100IU/mL penicillin 100µg/mL streptomycin Gibco #15140-122 
anti-CD25 (cl 3C7) 5µg/ml BioLegend #101906 
anti-CD28 (cl 37.51) 1µg/mL BioLegend #102116 
hIL-2 1ng/mL or 20ng/mL PeproTech #200-02 
TGFb 5ng/mL PeproTech #100-21 
IFNa 20ng/ml BioLegend  #752802 
IL-12 2ng/ml PeproTech #210-12 
IL-7 10ng/mL PeproTech #217-17 
SIINFEKL (N4) 10-6M-10-8M Cambridge Peptides 
SIITFEKL (T4) 10-6M-10-8M Cambridge Peptides 
SIIGFEKL (G4) 10-6M-10-8M Cambridge Peptides 
Table 2.1: List of reagents for cell culture.  
NA – Not applicable; IU – international units.  
 
2.3.2 T lymphocyte stimulation 
Naïve T lymphocytes were obtained from lymph nodes and/or spleens of OT-I 
(Ptpn22+/+ or Ptpn22-/-). Single cell suspensions were obtained by filtering the 
cells through a 70 µm strainer (Sigma Aldrich). No additional cell purification was 
needed for lymph nodes from OT-I mice (>90% CD8+ T cells, of which >80% are 
naïve CD8+ T cells). Spleen samples were treated with Ammonium-Chloride-
Potassium (ACK) lysing buffer to remove red blood cells and utilised without any 
further purification. In all experiments, viable T cell concentration was determined 
by trypan exclusion, counted with a haemocytometer and adjusted to a final 




For activation of OT-I T lymphocytes, cells were stimulated with the ovalbumin-
derived peptides SIINFEKL, SIITFEKL or SIIGFEKL (hereafter referred as OVA-
N4,  OVA-T4 or OVA-G4 respectively) (Table 2.1). OVA-N4, OVA-T4 and OVA-
G4 differ in their fourth amino acid (asparagine in OVA-N4, threonine in OVA-T4, 
glycine in OVA-G4), which results in a modification in their TCR affinity [OVA-N4 
Kd = 54µM; OVA-T4 Kd = 444µM; OVA-G4 Kd = >1000µM] (Stepanek et al., 2014). 
Where indicated, T lymphocytes were also stimulated with combinations of 
recombinant human IL-2 (hIL-2), recombinant human TGFb, murine IL-12, 
murine IFNa and/or soluble anti-CD28. Moreover, T cells were cultured with IL-7 
as a control for non-TCR activated cells (Table 2.1). Cells were incubated at 37°C 
and 5% CO2 for the indicated time at figure legends.  
After appropriate incubation, the density separation medium Lympholyte®-M 
(Cedarlane) was occasionally utilised to remove dead cells prior to assay 
initiation. 
2.3.3 Expansion of CTLs 
OT-I T cells from lymph nodes (2x106 cells/ml) or spleens (2.5x106 cells/ml) were 
stimulated with N4 peptide (10-9M) for 48h. Then, cells were washed twice in T 
cell medium to remove excess N4. Cell density was adjusted to 2.5x105 cells/ml 
and maintained with hIL-2 (20ng/ml) for 4 days further.  
2.3.4 Cell culture – ID8 cell line 
ID8 is a mouse ovarian carcinoma cell line (Roby et al., 2000). Three OVA-
expressing variants have been used: ID8-N4, ID8-T4 and ID8-V4 (originally a gift 
from D. Zehn, Technical University Munich). In addition, these cell lines stably 




reached a 70% confluence. Cells were washed in PBS to remove excess media 
and FBS, then were treated with trypsin for 2 minutes to allow detachment.  
2.3.5 Killing assays 
Target cells (ID8-N4, ID8-T4, ID8-V4) were cultured for 5h in 48-well plates at a 
density of 2x104 cells/well. After cells adhered, wild-type and Ptpn22-/- OT-I CTLs 
were added to the wells at effector:target (E:T) ratios of 2:1, 10:1 and 20:1. ID8 
cells with no CTLs was used as a negative control. Cells were incubated 
overnight at 37°C, 5% CO2. Then, supernatant was discarded and each well was 
washed in PBS (37°C) to remove cell debris before fresh medium was added to 
the wells. Finally, target cell viability was quantified by measuring luciferase 
activity, following addition of luciferin (Regis Technologies), with bioluminescence 
imaging using IVIS Spectrum and Living Image software (Perkin Elmer) or 
Cytation 5 Imaging Plate Reader (BioTek). 
2.3.6 ID8 and OT-I co-culture experiments 
Target cells (ID8-N4, ID8-T4, ID8-V4) were cultured for 5h in 48-well plates at a 
density of 2x104 cells/well. After cells adhered, OT-I naïve T cells were added to 
the wells at a density of 2x105 cells/well. Where indicated, the TGFbRI selective 
inhibitor SB431542 (5µM, Sigma Aldrich) was added to the wells. Cells were 
incubated for 48h at 37°C, 5% CO2. Then, cells were trypsinised and analysed 
by flow cytometry.   
2.4 Flow cytometry 
All Fluorescence-Activated Cell Sorting (FACS)-based experiments were 
performed using LSRII (BD Biosciences) or LX Cytoflex (Beckman Coulter) flow 




experiments were performed with unstained and single colour staining samples 
used as negative and positive controls for each fluorophore. Compensation was 
manually adjusted in the flow cytometer prior to acquisition of experimental 
samples.  
A minimum of 20000 events were collected per sample and stored ungated. 
Before measurement of the indicated marker, all T lymphocytes were gated using 
the following procedure (Fig. 2.1): 
• Lymphocyte gate using FSC-A/SSC-A. 
• Removal of doublets using FSC-A/FSC-H. 
• Removal of dead cells using live-dead Aqua dye (1:700, Molecular 
Probes) or zombie NIRTM (1:1000, BioLegend), as indicated. 
• In some experiments, CD8b+ gating was performed to optimise population 
purification. 
• In some experiments, mixed Ptpn22+/+ and Ptpn22-/- T cells were 
distinguished by CD45.1/CD45.2 expression, respectively.  
 
Figure 2.1: Gating strategy in flow cytometry experiments. 
Dot plots are representative of the strategy used to assess activated T cells 
gated as shown above (Lymphocytes > Single cells > Live cells). FSC-A – 


























To be noted, in all histograms shown in this thesis, the Y axis is normalised and 
represents the percentage of events relative to the maximum value.  
2.4.1 Surface staining 
After appropriate stimulation, cells were transferred to FACS tubes, washed in 
PBS and stained with the indicated conjugated antibodies and cell viability dye at 
4°C in the dark in PBS (Table 2.2). After 15 minutes, cells were washed and re-
suspended in PBS prior to analysis with the flow cytometer. Occasionally, cell 
fixation was performed using 2% formaldehyde in PBS.  
2.4.2 Intracellular staining 
Typically, cells were fixed and permeabilized using FoxP3 fix/permeabilisation 
buffer (eBioscience) followed by staining with the indicated conjugated antibodies 
in the dark for 20 minutes at 4°C in permeabilisation buffer (eBioscience) (Table 
2.2). Afterwards, cells were washed in permeabilisation buffer, re-suspended in 
PBS and analysed with the flow cytometer. For TNF and IFNg staining, cells were 
previously treated in culture with 2.5µg/ml Brefeldin A (Sigma Aldrich), an inhibitor 
of protein transport from the ER to the Golgi, to retain cytokines intracellularly.  
For phospho-rpS6 (pS6) Ser240/244 and phospho-SMAD2 Ser465/467 
detection, cells were fixed in 4% formaldehyde followed by permeabilization in 
ice-cold 90% methanol. Cells were stained for 1h at RT with the indicated 
antibody diluted in 0.5% bovine serum albumin (BSA, Tocris) in PBS (Table 2.2). 
As the utilised pS6 (Ser240/244) antibody was unconjugated, an additional 
staining, performed with the PB conjugated secondary goat Anti-Rabbit IgG 





Table 2.2: List of antibodies utilised for FACS analysis. 
AF488 – Alexa Fluor 488; AF647 – Alexa Fluor 647; APC – Allophycocyanin; 
BV421 – Brilliant Violet 421; Cy – Cyanine; FITC – Fluorescein isothiocyanate; 
PE – Phycoerythrin; PercP – Peridinin-Chlorophyll-protein; PB – Pacific Blue. 
 
2.4.3 Proliferation assays 
Prior to stimulation, naïve T lymphocytes were stained in PBS with CellTraceTM 
Violet Cell Proliferation Dye (5µM; Invitrogen) for 20 minutes at 37°C in the dark. 
Cells were stimulated as indicated in Figure legends and then analysed by flow 
cytometry (~405/450 nm). To calculate the division index, FlowJo® v10.3 was 



















CD25 PE 101904 3C7 
CD36 PE 102606 HM36 
CD44 APC-Cy7 101916 IM7 
CD45.1 AF647 103028 A20 
CD69 PercP-Cy5.5 110720 H1.2F3 
CD71 FITC 113806 RI7217 



















IFNg AF488 505813 XMG1.2 
GrB BV421 515408 GB11 
TNF PercP-Cy5.5 506322 MP6-XT22 
c-Myc APC 1:50 Cell Signalling Technologies 13871S 
D84C12 
GLUT1 AF488 1:400 Abcam ab195359 EPR3915 
ASCT2 Unconjugated 1:50 Cell Signalling Technologies 5345S 
V501 
pS6 Unconjugated 1:200 Cell Signalling Technologies 5363S 
D68F8 





utilised. This software automatically counted the number of cells included in each 
generation and calculated the average of divisions.  
2.4.4 Protein synthesis assays  
For protein synthesis assays, cells were treated with 20µM O-propargyl- 
puromycin (OPP; Jena Bioscience), an alkyne puromycin analogue that 
incorporates into newly synthesised proteins, for 10min. As negative control, 
100µg/ml cyclohexamide (CHX; Sigma Aldrich) was added 15min prior to OPP 
labelling to stop protein synthesis. OPP incorporation was analysed using Click-
iTTM Plus Alexa FluorTM 488 Picolyl Azide Toolkit (Invitrogen) followed by flow 
cytometry detection. 
2.4.5 Nutrient uptake assays 
2.4.5.1 Glucose uptake assays 
To measure glucose uptake, the fluorescent glucose analogue 2-(N-(7-Nitrobenz-
2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG; Abcam) was added to 
the cultures at a concentration of 50µM for 1h. Then, cells were washed in PBS 
twice and stained with cell viability dye for 5 minutes. Cells were analysed by flow 
cytometry (~465/540 nm).  
2.4.5.2 Fatty acid uptake assays 
To measure lipid uptake, the fluorescent fatty acid analogue 4,4-Difluoro-5,7-
Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-Hexadecanoic Acid (BODIPYTM FL 
C16; Thermo Fisher) was added to the cultures at a concentration of 2µM for 30 
min. Then, cells were washed in PBS twice and stained with cell viability dye for 





2.4.5.3 Amino acid uptake assays 
To measure AA uptake, kynurenine (Kyn), a tryptophan metabolite with self-
fluorescent properties that utilises the system-L AA transporters to enter the cell, 
was used (Sinclair et al., 2018). T cells were cultured with Kyn in Hank’s Balanced 
Salt Solution (HBSS, Sigma-Aldrich) and fixed with 2% paraformaldehyde after 
4min. Then, cells were washed in PBS, stained with cell viability dye for 5min and 
analysed by flow cytometry (~380/480 nm). 
2.5 Metabolic assays 
2.5.1 Seahorse XFe96 Analyser 
Extracellular consumption rate (ECAR) and O2 consumption rate (OCR) values, 
indicators of glycolysis and OXPHOS, respectively, were acquired using a 
Seahorse XFe96 Analyzer.  The Seahorse XFe96 Analyser utilises a specialised 
96-well plate with two compartments: the Seahorse XFe96 cell culture microplate 
(bottom) and a sensor cartridge (top) that, when ensembled together, form a 
microchamber that allows real-time ECAR and OCR detection. Furthermore, the 
sensor cartridge contains four ports per well to enable injection of compounds 
during the assay. 
2.5.1.1 General Seahorse XFe96 Analyser protocol 
First, the sensor cartridge was hydrated overnight at 37°C in a non-CO2 incubator 
using XF calibrant solution. On the day of the assay, the 96-well microplate was 
coated with 25µL/well of a 22.4µg/ml Cell-Tak (Corning), 1M NaOH, 1M NaHCO3 
solution. After 20min incubation at room temperature (RT), the microplate was 
washed twice with sterile H20 and air dried for 30min. Then, T lymphocytes (105 
cells/well) were transferred to the microplate in XF base media supplemented 




and pyruvate (1mM). The plate was centrifuged (300rpm for 1min), left 30min to 
allow cells to adhere and immediately analysed following system calibration. 
Where indicated, MitoStress Test or Glycolytic Test were performed by adding 
specific compounds diluted in the supplemented XF media into the cartridge 
ports. The compounds were sequentially added in the same order as shown in 
Table 2.3. Three measurements were taken of baseline ECAR/OCR levels and 
after each compound injection. Each measurement took 3min followed by 3min 
of mixing and 2min of waiting. At least five replicates per sample were analysed. 
Data was acquired using Wave software.  
  Compound(s) Final concentration 
MitoStress Test 
1 Oligomycin 1µM 
2 FCCP 1.5µM 
3 Rotenone / antimycin A 0.5µM 
Glycolytic Test 1 Glucose 10mM 
Table 2.3: List of compounds utilised for metabolic assessment with 
Seahorse XFe96.  
FCCP - 2-[2-[4-(trifluoromethoxy)phenyl]hydrazinylidene]-propanedinitrile 
 
To calculate basal ECAR/OCR, all values acquired prior to injection of the first 
compound, including the three measurements of all technical replicates, were 
used. When performing a MitoStress Test, maximal OCR was calculated with all 
values acquired after FCCP injection and prior to rotenone / antimycin A injection, 
including the three measurements of all technical replicates. Spare respiratory 
capacity (SRC) was calculated as the difference between maximal and basal 




calculated using all values acquired after glucose injection, including the three 
measurements of all technical replicates. 
 
Figure 2.2: Schematic representation of MitoStress Test data. 
 
2.5.2 ATP assay 
Levels of ATP were determined using Luminescent ATP Detection Assay Kit 
(Abcam, ab113849). Briefly, T cells (1 x 105 cells/well with at least three replicates 
per sample) were lysed adding a detergent solution for 5min. Then, substrate 
solution, which contains luciferase enzyme and luciferin, was added to the wells 
and the plate was stored in the dark for 10min. As the luciferase reaction requires 
ATP, the emitted light correlates with ATP levels. Luminescence was measured 
using a Cytation 5 Imaging Plate Reader (BioTek). ATP levels were quantified 









2.6 Enzyme-Linked ImmunoSorbent Assay (ELISA) 
2.6.1 Reagents 
Item Manufacturer 
Mouse IL-2 DuoSet ELISA R&D Systems #DY402-05 
Mouse IFNg DuoSet ELISA R&D Systems #DY485-05 
DuoSet Ancilliary Reagent Kit 2 R&D Systems #DY008 
ELISA MAXTM Standard Set Mouse IL-2 BioLegend #431001 
ELISA MAXTM Standard Set Mouse IFNg BioLegend #430801 
Biotin Rat Anti-Mouse IgM BD BioSciences #553406 
Biotin Rat Anti-Mouse IgG1 BD BioSciences #550331 
eBioscienceÔ Avidin-HRP Invitrogen #18-4100-94 
TMB substrate solution LifeTechnologes #7335 
Table 2.4: List of reagents utilised for ELISA. 
 
For IL-2 and IFNg detection, capture and detection antibodies, as well as 
horseradish-peroxidase (HRP)-conjugated streptavidin were provided in Mouse 
IL-2 DuoSet ELISA, Mouse IFNg DuoSet ELISA, ELISA MAXTM Standard Set 
Mouse IL-2 or ELISA MAXTM Standard Set Mouse IFNg.  
The utilised solutions and buffers were included in DuoSet Ancilliary Reagent Kit 
2 or prepared as followed: 
• Wash buffer: 0.05% Tween 20 in PBS, pH 7.2 - 7.4 
• Block buffer: 1% BSA in PBS, pH 7.2 – 7.4, 0.2 µm filtered 
• Reagent diluent: 0.1% BSA, 0.05% Tween 20 in Tris-buffered Saline 
(20mM Trizma base, 150mM NaCl), pH 7.2 – 7.4, 0.2 µm filtered 
• Substrate solution: 1:1 mixture of Color Reagent A (H202) and Color 
Reagent 2 (Tetramethylmenzidine; TMB) 




For IgG and IgM detection, biotinylated anti-mouse IgM and IgG antibodies 
and other standard reagents were purchased individually, as shown in Table 
2.4. Buffers and solutions were prepared, unless otherwise specified in 
Section 2.6.3, as shown above. 
2.6.2 General ELISA protocol for IL-2 and IFNg 
To measure IL-2 and IFNg levels, 1 x 105 T lymphocytes per well were cultured 
in 96-well plates. When measuring IL-2 levels, T cells were cultured in the 
presence of anti-CD25 blocking antibody to prevent IL-2 consumption. At least 
three replicates per sample were analysed. After incubation under appropriate 
stimulation, supernatants were collected and stored at -20°C until further 
analysis. Cytokine levels in supernatants were quantified following 
manufacturer’s instructions (see section 2.5.1). Briefly, the following assay 
procedure was performed: (1) 96-well plates were coated overnight at RT with 
plate-bound anti-mouse capture antibody. (2) The plate was blocked with block 
buffer for at least 1h at RT. (3) Diluted samples or standards were added to the 
wells for 2h at RT. (4) Detection antibody was added to the wells for 2h at RT. (5) 
Working dilution of streptavidin-HRP was added to each well for 20min at RT in 
the dark. (6) Substrate solution was added to each well at RT in the dark until 
colour reaction was completed and stopped with stop buffer. (7) Optical density 
was determined using a microplate reader (Thermo Fisher) set to 450nm. Data 
analysis was performed in Microsoft Excel by generating a standard curve. 
Between each step, reagents were aspirated and wells were washed at least 
three times with wash buffer. During incubation times, the plate was sealed and 





2.6.3 General ELISA protocol for IgG and IgM 
4-Hydroxy-3-nitrophenylaacetyl (NP)-specific IgG and IgM levels in serum were 
acquired using the following procedure: (1) 96-well plates were coated with NP-
BSA (Ratio > 20; 10µg/mL; Biosearch Technologies) in carbonate buffer (0.05M, 
pH9.5) overnight at 4°C. (2) Plate was blocked for 1h at RT. (3) Samples diluted 
in 0.1% BSA in PBS were added with five 4-fold serial dilutions (1:200, 1:800, 
1:3200, 1:12800, 1:51200) and incubated overnight at 4°C. (4) Detection antibody 
(biotinylated anti-mouse IgM or anti-mouse IgG1; 1:1500 in 0.1% BSA in PBS) 
was added to the wells for 1h at RT. (5) Avidin-HRP (1:1000 in PBS) was added 
to each well for 1h at RT in the dark. (6) TMB was added to each well at RT in 
the dark until colour reaction was completed and stopped with stop buffer. (7) 
Optical density was determined using a microplate reader (Thermo Fisher) set to 
450nm. Between each step, reagents were aspirated and wells were washed at 
least three times with wash buffer. During incubation times, the plate was sealed 
and covered with an adhesive strip.  
2.7 RNA-seq 
2.7.1 Sample preparation 
OT-I T lymphocytes (5 x 106 cells per condition) were stimulated in vitro with OVA-
T4 (10-8M) ± TGFb (5ng/ml). After 24h, cells were centrifuged (15000 x g for 1min) 
at RT and resuspended in TRI Reagent® (Zymo Research, R2050-1-50), a 
solution that lyses and deproteinises the sample.  
2.7.2 RNA extraction 
RNA was isolated using Direct-zolä RNA Miniprep Plus (Zymo Research, 
R2070), a spin-column based kit that purifies total RNA directly from TRI 




into a Zymo-Spinä IIICG Column in a collection tube. Columns were centrifuged 
and transferred into new collection tubes. After DNase I treatment, columns were 
washed twice in Direct-zolä RNA PreWash solution and once in RNA Wash 
Buffer for 1min. Finally, columns were transferred into RNase-free tubes and RNA 
was eluted by adding 100µL of RNase-free water. Upon centrifugation, flow-
through was collected and RNA purity was checked using NanoDropä 
spectrophotometer (A260/A280 and A260/A230 > 1.8). All steps were performed at 
RT and centrifugation was set at 15000 x g for 30sec, unless specified. Samples 
were stored at -70°C until further analysis.  
2.7.3 RNA-seq data analysis 
RNA sequencing (RNA-seq) procedure and data analysis was performed by 
Novogene Bioinformatic Technology Co. (Hong Kong). Briefly, upon arrival, 
samples were quantified and quality tested: (1) RNA degradation and 
contamination was monitored on 1% agarose gels, (2) RNA purity was assessed 
by the NanoPhotometer® spectrophotometer (IMPLEN, CA, USA) and (3) RNA 
integrity and quantitation was determined using the RNA Nao 6000 Assay Kit of 
the Bioanalyser 2100 system (Agilent Technologies, CA, USA). After validation, 
mRNA was purified from total RNA. Fragmentation was carried out and cDNA 
was synthesised. Then, PCR was performed according to a sequencing library 
generated using NEBNext® Ultra RNA Library Prep Kit for Illumina. PCR products 
were purified and library quality was assessed. Finally, after cluster generation, 
the library preparations were sequenced on an Illumina platform.  
For data analysis, raw data was first processed and low quality reads were 
removed. Paired-end clean reads were mapped to the reference genome 




Per Kilobase of exon model per Million (RPKM) was calculated based on the 
length of the gene. Differentially expressed genes (DEGs) were identified after 
statistical analysis, as indicated in Section 1.8. 
For Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis or 
chromatin immunoprecipitation (ChIP) Enrichment Analysis (ChEA), RNA-seq 
data was processed using Enrichr. Only DEGs with a fold-change (FC) > 1.5 or 
FC > 2, as determined in Figure legends, were analysed. FC was calculated as 
the ratio of the two compared conditions [i.e. “condition 1” (C1)/ “condition 2”(C2)] 
using the average RPKM values of the biological replicates. 
For the generation of heatmaps, the RPKM ratio of the two compared conditions 
in each biological replicate, both C1/C2 and C2/C1, was performed. Values in 
heatmaps represent the logarithm with base 2 of the ratios.  
2.8 Statistical analysis 
All data was processed using GraphPad Prism v7.0d software. Statistical 
analysis was performed applying paired or unpaired two-tailed Student’s t-test, 
Mann-Whitney test and one- or two- way ANOVA with Tukey’s or Sidak’s multiple 
comparison tests, as appropriate. Differences were considered significant for p-
value<0.05. Number of experiments and technical replicates are indicated in 
Figure legends.  
For RNA-seq data, differential expression analysis was determined using 
DESeq2 R package and p-values were adjusted with the Benjamini and 
Hochberg’s approach, as assessed by Novogene Co. Differences were 





2.9 Generation of figures 





















Chapter 3 The integration of signals 1, 2 and 3 
and its impact on CD8+ T cell activation and 
metabolism 
3.1 Introduction 
The signals required to induce a CD8+ T cell response include: (1) TCR triggering, 
(2) co-stimuli and (3) inflammatory cytokines. Whilst TCR-triggering promotes T 
cell activation, co-stimulatory receptors, mainly CD28, support population 
expansion and survival while inflammatory cytokines drive differentiation. 
Nonetheless, it is unlikely that these processes are uniquely regulated by one of 
these signals, but rather, that they synergise with the ultimate outcome of 
promoting an optimal T cell response. Furthermore, it is well-established that the 
quantitative and qualitative balance of signals 1, 2 and 3 received during TCR-
priming imprints T cell fate (Kaech and Cui, 2012). Thus, investigating how these 
signals are integrated, their predominant roles and how they cooperate is key to 
understand the regulation CD8+ T cell responses and, therefore, find new 
mechanisms for its manipulation (Etxeberria et al., 2020).  
Although the effect of these signals on T cell function has been extensively 
studied (Mescher et al., 2006; Tian et al., 2007; Zehn, D. et al., 2009; Corse et 
al., 2011; Esensten et al., 2016; Richard et al., 2018), it is less known how they 
influence T cell activity through metabolic modulation. The purpose of this chapter 
is to define how signals 1, 2 and 3 distinctively shape CD8+ T lymphocytes, both 
functionally and metabolically. Specifically, here I aim to: 
1. Define how TCR signal strength controls early events of CD8+ T cell 
activation and metabolic reprogramming. 




3. Establish how signals 2 and 3 regulate CD8+ T cell activation and 
metabolism. 
4. Unravel how distinct signal 3 cytokines, either IL-12 or IFNa, modulate 























3.2.1 TCR signalling strength determines early CD8+ T cell activation 
The first keystone of CD8+ T cell activation is TCR signalling, which can be 
influenced by the quantity or quality of pMHC:TCR interactions. In order to study 
how TCR signal strength affects CD8+ T cell activation, I used T lymphocytes 
from a Rag1-/- OT-I mouse strain. OT-I T cells express a transgenic TCR that 
specifically recognises an ovalbumin (OVA)-peptide in the context of MHC-I 
molecules (Hogquist et al., 1994). Furthermore, modifying the sequence of the 
OVA-peptide (SIINFEKL or OVA-N4) generates peptides with different affinities 
for the OT-I TCR. Here, the following peptides, from high to low affinity, were 
used: OVA-N4 (Kd = 54µM), OVA-T4 (SIITFEKL, Kd = 444µM) and OVA-G4 
(SIIGFEKL, Kd = >1000µM) (Stepanek et al., 2014). As an additional tool to 
assess TCR signal strength, I also used lymphocytes from Ptpn22-/- OT-I mice. 
As described in Section 1.5.4, PTPN22 is a protein tyrosine phosphatase that 
inhibits early TCR signalling and, therefore, its deficiency increases TCR signal 
strength, particularly in response to low affinity peptides. Thus, in the following 
experiments, TCR signal strength was evaluated by modulating cell-extrinsic 
(antigen affinity) and cell-intrinsic (lack of PTPN22) mechanisms. 
First, Ptpn22+/+ or Ptpn22-/- OT-I naïve T cells were stimulated in vitro with either 
OVA-N4, OVA-T4 or OVA-G4 peptides (10-8M). Moreover, T cells were cultured 
with IL-7 (10ng/ml), a homeostatic cytokine that prevents cell death in the 
absence of TCR-binding, as an unstimulated or negative control (indicated as ‘No 
TCR’ in figures). One key indicator of TCR-induced activation is an increase in 
cell size or blastogenesis. After 48h of incubation and as assessed by FSC-




and OVA-T4. However, OVA-N4 stimulation resulted in a small, but consistent, 
increase in T cell size when compared to OVA-T4 stimulated cells. By contrast, 
T cells stimulated with the very low affinity peptide OVA-G4 were only able to 
engage a moderate growth (Fig. 3.1A).  
Furthermore, T cell viability was determined by exclusion of Live/Dead Aqua dyes 
and FACS analysis. As expected, OVA-G4 stimulated T cells displayed very high 
rates of cell death, with <5% of the cells surviving after 48h in the absence of 
homeostatic signals (Fig. 3.1B). On the other hand, ~80% of the OT-I cells were 
alive in the presence of the high affinity peptide OVA-N4, whilst the proportion 
decreased to ~50% in the presence of OVA-T4. The absence of PTPN22 did not 
impact on levels of cell death (Fig. 3.1B).  
Figure 3.1: TCR-signalling strength determines CD8+ T cell growth and 
survival. 
Ptpn22+/+ and Ptpn22-/- OT-I T lymphocytes were stimulated in vitro with OVA-
N4, OVA-T4 or OVA-G4 (10-8M) for 48h. T cells cultured in the presence of IL-7 
(10ng/ml) were utilised as unstimulated/negative controls. (A) T cell growth was 
determined by FACS analysis. Representative FSC-A/SSC-A dot plots of wild-
type OT-I T cells after exclusion of dead cells and doublets is shown. Values 
indicate FSC MFI. (B) Cell death was assessed by FACS analysis using the 
viability dye LD Aqua. Data is from one of at least three experiments. Data in 
graphs represents mean and SD of technical triplicates. NS – Not significant, as 
assessed by two-way ANOVA with Sidak’s multiple comparisons test. Differences 
in the effect of OVA-N4 vs OVA-T4 vs OVA-G4 were shown statistically significant 












































Next, in order to further assess the activation state of the cells, I measured the 
levels of the cell surface molecule CD44 and the effector protein granzyme B 
(GrB), known to be upregulated in activated CD8+ T cells. Almost all T cells 
(~90%) were CD44+ after stimulation with OVA-N4 or OVA-T4 whereas only 
~60% of the cells were CD44+ when primed with OVA-G4 (Fig. 3.2). Although 
Ptpn22-/- T cells did not show any increase in the proportion of cells expressing 
CD44 in any condition, the amounts of CD44, determined by mean fluorescence 
intensity (MFI) in CD44+ cells, were higher in both OVA-N4- and OVA-T4-
stimulated T cells, but not in OVA-G4-stimulated T cells (Fig. 3.2). T cells 
stimulated with OVA-G4 did not upregulate GrB whilst almost all T cells primed 
with the high affinity OVA-N4 had high levels of GrB expression. By contrast, the 
stimulation mediated by OVA-T4 induced an intermediary phenotype where not 
only the proportion of GrB+ cells was diminished by ~20%, but also the levels that 
they expressed were significantly reduced (Fig. 3.2). The loss of PTPN22 resulted 
in elevated GrB expression in OVA-T4 stimulated T cells, increasing both the 






Figure 3.2: TCR-signalling strength determines upregulation of activation 
markers after antigen recognition. 
Ptpn22+/+ and Ptpn22-/- OT-I T lymphocytes were stimulated in vitro with OVA-
N4, OVA-T4 or OVA-G4 (10-8M) for 48h. T cells cultured in the presence of IL-7 
(10ng/ml) were utilised as unstimulated/negative controls. Upon incubation, 
CD44 and GrB expression was analysed after staining with conjugated antibodies 
followed by FACS analysis. Data is from one of at least three experiments. Data 
in graphs represents mean and SD of technical triplicates. NS – Not significant; * 
- P<0.05; ** - P<0.005; *** - P<0.0005, as assessed by two-way ANOVA with 
Sidak’s multiple comparisons test. Differences in the effect of OVA-N4 vs OVA-
T4 vs OVA-G4 were shown statistically significant as determined by row factor 
variation with p < 0.0001.   
 
Then, I assessed the impact of the strength of TCR signaling on IL-2 production 
and proliferation. In this experiment and the followings, I decided to exclude the 
OVA-G4 stimulated T cells due to their poor responsiveness and the low levels 
of T cell survival experienced during the previous assays. Thus, from now on, 
only the comparison between OVA-N4 and OVA-T4 stimulated T cells is shown. 
After 24h of TCR-stimulation in vitro, IL-2 levels in culture supernatants were 
analysed by ELISA. In Ptpn22+/+ T cells, stimulation with the high affinity peptide 
OVA-N4 induced a 3-fold increase in IL-2 levels when compared to OVA-T4 
stimulated cells (Fig. 3.3A). Moreover, Ptpn22-/- T cells showed enhanced IL-2 







































































































secretion relative to control cells in both conditions (Fig. 3.3A). To examine the 
proliferative capacity of T cells, naïve OT-I T cells were stained with Cell Trace 
Violet (CTV) prior to TCR-stimulation. CTV is used as a label to trace cell 
generations based on dye dilution. After 72h of TCR activation, consistent with 
my previous data, OVA-N4 stimulated T cells displayed enhanced proliferative 
capacity, as shown by an increase proportion of proliferating cells (~100% vs 
~60% with OVA-T4) and division index (~3 vs ~1 with OVA-T4) (Fig. 3.3B). 
PTPN22-deficiency served to boost T cell proliferation, but only against the low 
affinity peptide OVA-T4 (Fig. 3.3B).  
 
Figure 3.3: IL-2 secretion and proliferative capacity of CD8+ T cells is 
defined by the strength of TCR signal.  
Ptpn22+/+ and Ptpn22-/- OT-I T lymphocytes were stimulated in vitro with OVA-N4 
or OVA-T4 (10-8M). T cells cultured in the presence of IL-7 (10ng/ml) were utilised 
as unstimulated/negative controls. (A) Levels of secreted IL-2 in supernatants 
were measured by ELISA after 24h of TCR-stimulation in the presence of 
blocking CD25 Ab. (B) T cell proliferative capacity was assessed after 72h of 
stimulation by Cell Trace Violet (CTV)-labelling and FACS analysis. On the right, 
a representative histogram of OVA-T4-stimulated T cells is shown. Data is from 
one of three experiments. Data in graphs represents mean and SD of technical 
triplicates. NS – Not significant; *** - P<0.0005; **** - P<0.0001, as assessed by 
two-way ANOVA with Sidak’s multiple comparisons test.  Differences in the effect 
of OVA-N4 vs OVA-T4 vs OVA-G4 were shown statistically significant as 
determined by row factor variation with p < 0.0001. 
 
Taken together, these results indicate, in accordance with previous reports 





































































al., 2018), that TCR signal strength determines T cell growth, survival, activation 
and proliferation upon TCR-priming. 
3.2.2 TCR signalling strength determines CTL function 
After differentiation, CTLs migrate to the site of infection or TME, where they 
recognise antigens to deliver effector functions. So, what is the role of antigen 
affinity in this scenario? In order to answer this question, I differentiated both 
Ptpn22+/+ and Ptpn22-/- naïve OT-I T cells into CTLs in vitro during 6d (for protocol 
see Section 2.3.3). CTLs were restimulated with either OVA-N4 or OVA-T4       
(10-8M) in the presence of brefeldin A, a repressor of the ER to Golgi protein 
transport that provokes the intracellular accumulation of cytokines synthesised 
within the re-stimulation time frame. After 4h of re-stimulation, the levels of IFNg 
and TNF were assessed by intracellular FACS analysis. CTLs re-stimulated with 
the high affinity peptide OVA-N4 displayed a higher proportion of IFNg+ and TNF+ 
cells when compared to OVA-T4 re-stimulated CTLs (80% vs 60%, respectively) 
(Fig. 3.4A). No differences were detected between Ptpn22+/+ and Ptpn22-/- CTLs 
(Fig. 3.4A). Moreover, I tested whether TCR signal strength was also affecting IL-
2 secretion of CTLs. After 24h of re-stimulation, I measured the levels of IL-2 in 
supernatants and saw that, consistently, re-challenging CTLs with OVA-N4 
doubled the amounts of IL-2 when comparing with OVA-T4 re-stimulated CTLs. 
Here, the lack of PTPN22 resulted in increased IL-2 levels in both conditions, but 
the effect was more accentuated when re-stimulating with OVA-T4 (Fig. 3.4B). 
Thus, these results further validate that TCR signal strength plays an important 






Figure 3.4: Cytokine secretion in CTLs is regulated by TCR affinity. 
Ptpn22+/+ and Ptpn22-/- CTLs were re-stimulated in vitro with OVA-N4 or OVA-T4 
(10-8M). T cells cultured in the presence of IL-7 (10ng/ml) were utilised as 
unstimulated/negative controls. (A) IFNg and TNF levels were determined by 
FACS analysis after 4h of re-stimulation in the presence of Brefeldin A. (B) Levels 
of secreted IL-2 in supernatants were measured by ELISA after 24h of TCR-
stimulation in the presence of aCD25. Data is from one of at least three 
experiments. Data in graphs represents mean and SD of technical triplicates. NS 
– Not significant; **** - P<0.0001, as assessed by two-way ANOVA with Sidak’s 
multiple comparisons test.  Differences in the effect of OVA-N4 vs OVA-T4 vs 
OVA-G4 were shown statistically significant as determined by row factor variation 
with p < 0.0001. 
 
3.2.3 Antigen affinity regulates the TCR-induced metabolic 
reprogramming 
T cell activation is accompanied by a metabolic reprogramming that is 
predominantly mediated by Myc (Wang, R. et al., 2011). After confirming that 
higher affinity peptides provide stronger T cell responses (Fig. 3.1-4), I assessed 









































































First, the impact of antigen affinity on TCR-induced Myc expression was 
assessed. Naïve OT-I T cells were stimulated in vitro with OVA-N4 or OVA-T4 for 
48h and results showed that, in accordance with my data and consistently with 
previous reports (Preston et al., 2015), Myc expression increased with ligand 
potency, with OVA-N4 stimulated T cells expressing approximately twice as much 
Myc as compared with OVA-T4 stimulated T cells (Fig. 3.5).  
Figure 3.5: Antigen affinity determines Myc expression upon TCR-priming. 
OT-I T lymphocytes were stimulated in vitro with OVA-N4 or OVA-T4 (10-8M). T 
cells cultured in the presence of IL-7 (10ng/ml) were utilised as 
unstimulated/negative controls. After 48h of incubation, Myc expression was 
assessed by FACS analysis. Data is from one of at least three experiments. Data 
in graphs represents mean and SD. Dots represent technical triplicates. **** - 
P<0.0001, as assessed by one-way ANOVA with Tukey’s multiple comparisons 



























One of the main roles of Myc during T cell activation is the upregulation of AA 
transporters, such as Slc7a5 or Slc1a5 (Marchingo et al., 2020), that allow the 
uptake of AAs to support the synthesis of new proteins required for growth, 
proliferation and differentiation.  Therefore, I hypothesised that the attenuated 
growth and proliferation presented by OVA-T4 stimulated T cells (Fig. 3.1-3) 
could be associated with a diminished protein synthesis ability caused by a lower 
Myc expression. To test this, I utilised O-propargyl puromycin (OPP), a puromycin 
analogue, that incorporates into newly translated proteins and can be detected 
by flow cytometry. As a negative control, T cells were treated with cycloheximide 
(CHX), a blocker of translation, 15min prior to OPP labelling. As expected, T cells 
primed with the low affinity peptide OVA-T4 had lower levels of protein synthesis 
as compared with OVA-N4 stimulated cells (Fig. 3.6).  
Figure 3.6: Antigen affinity determines protein synthesis upon TCR-
priming. 
OT-I T lymphocytes were stimulated in vitro with OVA-N4 or OVA-T4 (10-8M). 
After 48h of incubation, Myc expression was assessed by FACS analysis. Data 
is from one of three experiments. Data in graphs represents mean and SD. Dots 
represent technical triplicates. *** - P<0.0005, as assessed by one-way ANOVA 




























Another feature of TCR-induced metabolic reprogramming is the upregulation of 
nutrient transporters and subsequent nutrient uptake. Following the previous 
rationale, I speculated that lower affinity peptides would induce a reduced nutrient 
uptake. OVA-T4 stimulated T cells displayed a trend for diminished uptake of a 
fluorescent glucose analogue, 2NBDG, when compared to OVA-N4 stimulated T 
cells, although it did not reach statistical significance (Fig. 3.7A). Similarly, the 
uptake of BODIPY-C16, a fluorescent fatty acid analogue, was also reduced (Fig. 
3.7B).  
 
Figure 3.7: Low antigen affinity restricts nutrient uptake upon TCR-
stimulation. 
OT-I T lymphocytes were stimulated in vitro with OVA-N4 or OVA-T4 (10-8M). 
After 48h of incubation, 2NBDG (A) or Bodipy C16 (B) uptake was determined by 
FACS analysis. Data is from four (A) or three (B) experiments. Data in graphs 
represents mean and SD. Dots represent biological replicates. NS – Not 
























































To further define how TCR signalling strength affected the metabolic activity of T 
cells I used the Seahorse XFe96, an analyser that measures in real-time the 
extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) of 
cells cultured in vitro, serving as readouts for aerobic glycolysis and OXPHOS, 
respectively. The analysis in real-time allows several metabolic parameters to be 
determined through the injection of drugs at different timepoints of the assay. 
Specifically, I performed the ‘MitoStress Test’. This assay first measures the 
basal cell respiration, then, the addition of oligomycin into culture wells inhibits 
the ATP synthase and shuts down the OCR linked to cellular ATP production. 
The second injection, FCCP, collapses the proton gradient and increases OCR 
to its maximum capacity. The difference between the maximal respiration and the 
basal respiration permits the calculation of the spare respiratory capacity (SRC), 
known as the ability of the cells to produce extra ATP under situations of sudden 
high energy demand. Finally, rotenone and antimycin A, inhibitors of complex I 
and III of the ETC, respectively, are added completely blocking mitochondrial 
respiration (Fig. 3.8A).  
OT-I T cells were stimulated for 24h with either OVA-N4 or OVA-T4.  Results of 
the Mitostress test indicated that antigen affinity impacted upon mitochondrial 
activity, as shown by diminished basal respiratory capacity and SRC in low affinity 
OVA-T4 stimulated T cells (Fig. 3.8B and C). Furthermore, although this is a 
mitochondrial test, the Seahorse XFe96 simultaneously measures ECAR values. 
Consistently, I found that the basal ECAR, i.e, prior to oligomycin injection, was 
also decreased in OVA-T4 stimulated cells as compared to OVA-N4 stimulated 
cells (Fig. 3.7C). As indicated by the ECAR/OCR ratio, OVA-N4 stimulation 
provokes a general enhancement of metabolic activity, increasing both OXPHOS 




Figure 3.8: The metabolic activity of activated CD8+ T cells is shaped by 
TCR affinity. 
OT-I T lymphocytes were stimulated in vitro with OVA-N4 or OVA-T4  (10-8M) for 
24h. After incubation, a MitoStress Test using the Seahorse XFe96 analyser was 
performed. (A) Schematic representation of MitoStress Test data, showing the 
key parameters of mitochondrial function. (B) Representative MitoStress Test 
profile of OVA-N4 vs OVA-T4 stimulated T cells. (C) Summarised data from four 
biological replicates. From left to right: basal OCR, SRC, basal ECAR and basal 
ECAR:OCR ratio. Data in graphs represents mean and SEM (B) or SD (C). Dots 
(C) represent biological replicates. NS – Not significant; * - P<0.05, ** - P<0.005, 
as assessed by two-tailed paired Student’s t-test. 
 
3.2.4 Signals 1, 2 and 3 cooperate to induce optimal CD8+ T cell 
responses 
Above, I focused on describing how signal 1 (i.e., TCR signalling) influences 
CD8+ T cell activation and metabolic reprogramming. However, as mentioned in 
previous sections, T cells require additional inputs to acquire a fully activated 
phenotype (Mescher et al., 2006). In order to investigate how signals 2 (co-




























































































































were stimulated with ‘Signal 1’ only,  ‘Signal 1 + Signal 2’  or ‘Signal 1 + Signal 2 
+ Signal 3’. OVA-T4 was utilised as a provider of signal 1, as I reasoned that the 
effects of signals 2 and 3 were more likely to be observed under suboptimal TCR-
stimulations. The predominant co-stimulatory receptor CD28 was used as a 
provider of signal 2. Finally, either IL-12 or IFNa (type I IFN), key inflammatory 
cytokines that drive the differentiation of CD8+ T cells (Curtsinger, Julie M. et al., 
2003; Curtsinger et al., 2005), were used as providers of signal 3.  
After stimulating naïve OT-I T cells as described, I observed that the effects 
provisioned by the addition of signals 2 and 3 varied depending on the readout, 
suggesting that they contributed to different aspects of T cell function rather than 
being simply ‘amplifiers’ of CD8+ T cell activation. First, results demonstrated that, 
upon 48h of stimulation, T cells were able to fully blast in the presence of signal 
1 alone, whilst the addition of signals 2 and 3 did not further change cell size (Fig. 
3.9A). By contrast, and as expected, CD28 supplementation significantly boosted 
IL-2 production when compared to T cells stimulated with only OVA-T4 (Fig. 
3.9B). The addition of IL-12 or IFNa did not further increase IL-2 production (Fig. 
3.9B). However, IL-12 and IFNa stimulation did impact upon other parameters of 
T cell activation. For example, both cytokines, but not CD28, strongly enhanced 
GrB upregulation (Fig. 3.9C). Despite comparable effects on GrB expression, IL-
12 and IFNa differed in their regulation of the transcription factors Tbet and 
Eomes: whereas IL-12 enhanced Tbet expression, IFNa signalling led to 
upregulated Eomes upregulation (Fig. 3.9C). Here, the addition of CD28 alone 
moderately enhanced Tbet expression, but no differences were observed with 






Figure 3.9: Signals 1, 2 and 3 differently regulate CD8+ T cell activation. 
OT- I naïve T cells were stimulated with OVA-T4 (10-8M) ± CD28 (1µg/ml) ± IL-
12 (2ng/ml) or IFNa (20ng/ml) for 24h (B) or 48h (A, C). (A) Cell size was 
assessed by FACS analysis determining MFI of FSC-A. (B) Levels of IL-2 in 
supernatants were measured by ELISA. (C) GrB, Tbet and Eomes expression 
were determined by IC staining with conjugated antibodies followed by FACS 
analysis. Data is from one of at least four independent experiments. Dots 
represent technical replicates. Data represents mean and SD. NS – Not 
significant; ** - P<0.005, *** - 0.0005; **** - P<0.0001, as assessed by one-way 
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3.2.5 Signals 1, 2 and 3 distinctively shape CD8+ T cell metabolism 
Above, I have strengthened the idea that signals 1, 2 and 3 distinctively regulate 
CD8+ T cell function to cooperatively induce full activation. So, how is that 
mirrored in the metabolism of CD8+ T cells? Several studies have reported that 
CD28 signalling regulates both glycolytic and mitochondrial metabolism 
(Frauwirth, Kenneth A. et al., 2002; Klein Geltink et al., 2017), but little is known 
about the impact of IL-12 and IFNa in this context.  
Before describing the results obtained in regards to the study of signals 1, 2 and 
3 and its impact on T cell metabolism, it is important to mention that the following 
data presented a few inconsistencies amongst its repeated experiments. Due to 
the limitations and lack of time caused by the COVID-19 situation during 2020, 
these experiments could not be further repeated. However, my findings show a 
strong trend towards the data described below, but these are not definitive 
statements and additional assays are required for confirmation. 
As described in Section 1.7.1.2, the key integrator of environmental cues is 
mTOR which, in turn, regulates T cell metabolism accordingly (Chapman and Chi, 
2015). Hence, in order to examine how signals 1, 2 and 3 were involved in its 
regulation upon priming, OT-I T cells were stimulated with OVA-T4 ± CD28 ± IL-
12 or IFNa for 48h. After incubation, I quantified mTOR activation based on the 
phosphorylation of its downstream target the ribosomal protein S6. My results 
showed that stimulation with OVA-T4 alone upregulated mTOR activity. 
Nevertheless, stimulation with CD28 seemed to potently enhance S6 
phosphorylation, whilst the addition of signal 3 cytokines did not further impact on 





Figure 3.10: Signal 2 boosts mTOR activation upon TCR-priming. 
OT- I naïve T cells were stimulated with OVA-T4 (10-8M) ± CD28 (1µg/ml) ± IL-
12 (2ng/ml) or IFNa (20ng/ml) for 48h. After incubation, S6 phosphorylation was 
quantified by IC staining and FACS analysis. Data is from one of two independent 
experiments. Dots represent technical replicates. Data represents mean and SD. 
NS – Not significant; **** - P<0.0001, as assessed by one-way ANOVA with 
Tukey’s multiple comparisons test.   
 
Next, I evaluated how signals 1, 2 and 3 affected the upregulation of nutrient 
uptake during T cell activation. As assessed using 2-NBDG, stimulation with only 
OVA-T4 promoted high levels of glucose uptake that were not further increased 
by the addition of signals 2 and 3 (Fig. 3.11A). By contrast, as determined using 
Bodipy-C16, both IL-12 and IFNa, but not CD28, significantly increased lipid 
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Figure 3.11: Signal 3 enhances lipid uptake upon TCR-stimulation. 
Naïve OT- I T cells were stimulated with OVA-T4 (10-8M) ± CD28 (1µg/ml) ± IL-
12 (2ng/ml) or IFNa (20ng/ml) for 48h. After incubation, uptake of 2NBDG (A) or 
Bodipy-C16 (B) was assessed by FACS analysis. Data is from one of at least four 
independent experiments. Dots represent technical replicates. Data represents 
mean and SD. NS – Not significant; ** - P<0.005; *** - P<0.0005, as assessed by 
one-way ANOVA with Tukey’s multiple comparisons test.   
 
As lipids are an important fuel for mitochondrial metabolism, it was possible that 
the signals provided by IL-12 and IFNa shaped mitochondrial activity. To test this 
hypothesis, a MitoStress Test was performed using the Seahorse XFe96 
analyser, as described in Section 1.2.3. First, results suggested that, after 48h of 
stimulation, CD28 signalling enhanced both OCR and ECAR basal values when 
compared to T cells stimulated with OVA-T4 alone (Fig. 3.12A-C). However, 
CD28 did not promote variations in the ECAR:OCR ratio suggesting that Signal 
2 amplifies T cell metabolic activity rather than promoting a certain pathway (Fig. 
3.12D). By contrast, the addition of IL-12 or IFNa seemed to lead to a change on 
the type of metabolism that T cells were engaging. On the one hand, IL-12 
boosted basal ECAR while preventing the CD28-induced augment in OCR (Fig. 
3.12A-C). Consequently, the ECAR:OCR ratio significantly increased in this 
















































































glycolysis (Fig. 3.12D). On the other hand, T cells stimulated with OVA-T4 + 
CD28 + IFNa presented an increase in both OCR and ECAR basal levels (Fig. 
3.12A-C).  Nevertheless, the ECAR:OCR ratio was <1 suggesting that these T 
cells favored mitochondrial metabolism rather than glycolysis (Fig. 3.12D). 
Furthermore,  T cells stimulated with IFNa displayed a heightened maximal 
respiration leading to an improved SRC, also observed in the presence of CD28 
alone (Fig. 3.12E). Taken together, these findings suggest that, whilst IL-12 
promoted the engagement of glycolysis, IFNa-treated T cells shifted their 









Figure 3.12: CD28, IL-12 and IFNa shape the metabolic activity of activated 
CD8+ T cells. 
OT-I T lymphocytes were stimulated in vitro with OVA-T4 (10-8M) ± CD28 
(1µg/ml) ± IL-12 (2ng/ml) or IFNa (20ng/ml) for 48h. After incubation, a MitoStress 
Test using the Seahorse XFe96 analyser was performed. (A) Representative 
MitoStress Test profile (left) and ECAR trace (right) of T cells stimulated under 
the indicated conditions. (B) Basal OCR values. (C) Basal ECAR values. (D) 
Basal ECAR:OCR ratio. (E) SRC, i.e., difference between maximal and basal 
OCR. In (A), data is representative of one of three independent experiments. Data 
represents mean with SEM. In (B, C, D, E), graphs collect data from three 
independent experiments. Data is normalised to control (OVA-T4) and represents 
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The principle that CD8+ T cells require the integration of at least 3 types of signals 
(TCR signalling, co-stimulation and cytokines) to become fully activated has been 
extensively studied and well-established in previous studies. However, how these 
signals cooperated in a metabolic level was less understood. Here, I have 
reinforced the hypothesis that signals 1, 2 and 3 add together, both functionally 
and metabolically, to promote optimal CD8+ T cell activation.  
Regarding to the influence of TCR signalling strength (signal 1), the experiments 
described here involving antigens with different affinities concluded that TCR 
signalling strength is key to determine the extent of CD8+ T cell responses: 
whereas T cells stimulated with the high-affinity peptide OVA-N4 displayed high 
rates of T cell growth, activation, proliferation and cytokine secretion upon TCR-
binding, these were decreased in T cells stimulated with the low affinity peptide 
OVA-T4. Consistently, previous investigations have described a correlative 
strength-response relationship, indicating that T cells stimulated with strong 
peptides show enhanced outputs (Zehn, D. et al., 2009; King et al., 2012). 
However, strong TCR signals are not only achieved by strong antigen affinities 
but also by high antigen doses. Here, for practical reasons, I have only chosen 
one antigen dose but it is important to highlight that both parameters define the 
magnitude of T cell responses. In fact, it is well-established that an increased 
antigen density partially compensates weak pMHC:TCR interactions suggesting, 
therefore, that increasing OVA-T4 abundance T cells could achieve the same 
activation state of OVA-N4 activated T cells (Rosette et al., 2001; Salmond et al., 
2014; Allison et al., 2016; Mayya and Dustin, 2016).  
The results presented here have further demonstrated that the manipulation of 




T cell responses. Specifically, PTPN22-deficiency, in accordance with other 
studies, benefited T cell activation and expansion after TCR-priming (Bottini and 
Peterson, 2014; Salmond et al., 2014; Brownlie et al., 2017; Bray et al., 2018). 
Salmond et al. (2014) described that PTPN22 is crucial to discriminate weak self-
peptides from exogenous antigens, with PTPN22 acting as a ‘brake’ of early TCR 
signalling and unwanted T cell responses upon recognition of self-peptides. 
These findings suggest, therefore, that the presence or absence of PTPN22 in T 
cells entails a significant difference particularly in the context of stimulations with 
low-affinity peptides. This phenomenon has also been observed here with, for 
example, the T cells’ proliferative rates or GrB expression: whilst PTPN22-
deficiency induced an improvement of both parameters when recognising the 
low-affinity OVA-T4, no changes were shown after stimulation with OVA-N4 (Fig. 
3.2 and 3.3). In spite of the general accordance of my PTPN22 data with previous 
findings, some discrepancies can be found when analysing TNF and IFNg 
production in CTLs (Fig. 3.4A). In these experiments, by contrast with other 
studies (Salmond et al., 2014; Brownlie et al., 2019), the lack of PTPN22 did not 
enhance its expression. However, we should note that CTLs are more responsive 
than naïve T cells to low affinity antigens (Stone et al., 2009). As mentioned 
above, in order to see a significant difference in Ptpn22-/- T cells, these should be 
stimulated under sub-optimal conditions, achieved by reducing the affinity and/or 
amount of antigen. It is therefore plausible that the in vitro stimulations performed 
here have been sufficient to show differences in naïve T cells but not in all 
parameters of CTLs. 
Altogether, it all seems to indicate that an increased TCR signal strength is 
associated with an improved T cell response, but what does exactly mean that a 




Richard et al. (2018) recently demonstrated that whilst low affinity peptides 
provide weaker responses, the observed effects are rather a consequence of a 
delayed response caused by a limited or slower TCR-binding. However, naïve T 
cells are ultimately capable of differentiating into CTLs of the same ‘quality’ 
irrespective of the strength of the initial stimulation (Richard et al., 2018). Hence, 
these findings suggest that antigen affinity regulates the speed of action and the 
magnitude of a T cell response inducing an improvement only on a population 
level, but not on a single-cell level. Furthermore, antigen affinity not only plays an 
important role during TCR-priming but also upon re-challenge of CTLs on sites of 
infection or the TME, dictating the amount of secreted cytokines and also their 
killing capacity (Fig. 3.4) (Salmond et al., 2014; Brownlie et al., 2019).  
Zehn, D. et al. (2009) studied the progression of monoclonal CD8+ T cells in vivo 
in response to a panel of six TCR ligands with different affinities. They concluded 
that, although lower-affinity peptides can provide a complete response and 
generate T cell memory, T cells exit lymphoid organs earlier leading to a shorter 
expansion phase. In terms of efficiency of T cell responses, Zhong et al. (2013) 
described that TCRs with a higher affinity for a variant of gp100 (gp206), a 
melanocyte protein, displayed delayed tumour growth and more severe ocular 
autoimmunity (destruction of melanocytes in the eye) when compared to lower 
TCR affinities. These findings suggest, therefore, that manipulating TCR or 
antigen affinity is a promising strategy to enhance T cell responses. On the other 
hand, another report by Corse et al. (2010) demonstrated that pMHC:TCR 
interactions sustained for too long impaired T cell proliferation and memory 
formation. More recently, Zahm et al. (2017) proved that higher affinity epitopes 
induce higher levels of inhibitory receptors, which ultimately resulted 




increase in ligand potency does not always lead to an improved CTL response 
and that is crucial to find appropriate pMHC:TCR interactions in order to maximise 
the efficacy of CD8+ T cell responses. 
OVA-T4 stimulated T cells displayed lower levels of Myc when compared to T 
cells stimulated with high affinity OVA-N4 (Fig. 3.5). Preston et al. (2015) 
established, also using the OT-I model, that antigen affinity proportionally 
correlates with the number of T cells that trigger Myc expression within the first 
hours upon TCR-priming. However, at later stages, the levels of Myc are 
maintained through the action of IL-2. The experiments described here were 
performed at later timepoints, after 48h of stimulation, suggesting that the 
observed differences are likely to be a consequence of IL-2 diminishment. As 
described in Section 1.7.1.1, the role of Myc has been strongly associated with 
its capacity to induce the upregulation of AA transporters, such as Slc7a5, in 
order to sustain protein synthesis, which was accordingly enhanced in OVA-N4 
stimulated T cells (Fig. 3.6). I have also observed that antigen affinity controls 
nutrient uptake as well as glycolytic and mitochondrial activity (Fig. 3.7-8). King 
et al. (2012) showed that CD8+ T cells stimulated with high affinity peptides 
displayed increased differentiation into SLECs when compared to those 
stimulated with low affinity peptides. As mentioned in Section 1.7.2, the balance 
between glycolytic and mitochondrial activity is key to determine terminal vs 
memory differentiation and it has been proposed as a potential modulatory axis 
to dictate T cell fate.  Thus, it is expected that high T cell affinity, glycolysis and 
SLEC differentiation are associated. Further exploring how pMHC:TCR 
interactions modulate T cell metabolism will provide new insight into the 




In regards to the role of CD28 stimulation (signal 2) during T cell activation, it has 
been well established that CD28 promotes T cell expansion due to IL-2 secretion, 
as also described in Fig. 3.9B (Fraser et al., 1991; Appleman et al., 2000; 
Sanchez-Lockhart et al., 2004). Considering that the induction of IL-2 secretion 
by CD28 is thought to be mediated by PI3K activation, it was unsurprising that, 
following the classic PI3K/Akt/mTOR pathway, pS6 phosphorylation was also 
particularly boosted upon CD28 stimulation (Zheng et al., 2007). In the context of 
metabolism,  early studies confirmed that CD28 stimulation leads to an enhanced 
glucose uptake and aerobic glycolysis (Frauwirth, Kenneth A. et al., 2002; Jacobs 
et al., 2008). More recently, Klein Geltink et al. (2017) also proved that T cells 
primed with CD28 not only provoked an increase in 2NBDG uptake and 
glycolysis, but also promoted mitochondrial priming, crucial for memory 
development. Consistently, my data strongly suggested that addition of CD28 
favored both glycolytic and mitochondrial metabolism, as shown by increased 
ECAR and OCR values and SRC (Fig. 3.12). On the other hand, the 2NBDG 
experiments did not completely corroborate previous findings. However, it is 
essential to mention again that the experiments performed to investigate the role 
of signals 1, 2 and 3 on T cell metabolism (Fig. 3.10-12) showed a degree of 
variability (e.g., few repeats showed a moderate but not consistent upregulation 
of 2NBDG uptake) and those require to be repeated.  
Finally, in regards to the role of IL-12 and IFNa (signal 3), it has been determined 
that these are essential to allow productive T cell responses and differentiation of 
CD8+ T cells (Curtsinger, J. M. et al., 2003; Curtsinger et al., 2005; Mescher et 
al., 2006; Curtsinger and Mescher, 2010). My findings showed, in accordance 
with these statements, that an added signal 3 during TCR-stimulation boosted 




whereas IL-12 and IFNa are not required for T cell priming and expansion, these 
play a relevant role in T cell differentiation (Fig. 3.9C). Both IL-12 and IFNa have 
been associated not only with the acquisition of an effector phenotype, but also 
with a subsequent development of a memory population. However, the 
underlying mechanisms of this regulation are less understood and whether each 
cytokine favours a distinct developmental programme or whether IL-12 and 
IFNa have redundant roles is still under debate (Agarwal et al., 2009; Curtsinger 
and Mescher, 2010). Differentiation into terminally-differentiated effector T cells 
is generally associated with a higher Tbet/Eomes ratio and the engagement of 
glycolysis. By contrast, memory formation is favoured by the maintenance of 
Eomes expression and an enhanced mitochondrial metabolism (Araki et al., 
2009; Kaech and Cui, 2012; Klein Geltink et al., 2017).  The findings of this 
chapter indicate that IL-12 increases Tbet levels at the expenses of Eomes 
upregulation, whilst IFNa has the opposite effect (Fig. 3.9C) (Takemoto et al., 
2006; Rao et al., 2010; Martinet et al., 2015). Furthermore, my results suggest 
that IL-12 pushes towards a glycolytic phenotype while repressing the 
mitochondrial priming derived by CD28 stimulation (Fig. 3.12). These results 
might imply that IL-12 and IFNa regulate T cell development in a different 
manner, promoting either an effector or a memory phenotype, respectively. 
Similarly, this hypothesis has been previously proposed in human CD8+ T cells 
in the context of memory formation, with IL-12 inducing the development of an 
effector memory T cell population and IFNa/b driving the differentiation of central 
memory T cells (Ramos et al., 2009; Chowdhury et al., 2011). Thus, albeit having 
overlapping functions, it is likely that the responsiveness to IL-12 and type I IFNs 
dictates CD8+ T cell fate. Here, my findings suggest that the modulation of T cell 




Recent investigations have been focused on the search of different mechanisms 
that modulate the glycolytic/mitochondrial axis in order to manipulate T cell fates 
(see Section 1.7.2). How IL-12 and IFNa regulate T cell metabolism and whether 
these cytokines could be used with this objective will be of interest in future 
investigations. 
Taken together, this chapter has served as a basis to show that the final output 
of fully activated CD8+ T cells depends on a myriad of signals that differently 
shape its function and metabolism. In the following chapters, I investigate how 
















Chapter 4 The influence of TGFb during CD8+ T 
cell activation 
4.1 Introduction 
In the previous chapter, I explored how CD8+ T lymphocytes integrate signals 1, 
2 and 3 to induce T cell activation and metabolic reprogramming. However, T cell 
responses are not only shaped by these key signals, but also, by the balance of 
pro-inflammatory and anti-inflammatory cytokines present in the tissue 
microenvironment.   
TGFb is an essential immunoregulatory cytokine that controls T cell responses 
both in the thymus and the periphery, playing an essential role in the maintenance 
of homeostasis and tolerance (Sanjabi et al., 2017). Moreover, TGFb is 
recognised as one of the most influential cytokines in cancer and its neutralisation 
is in the spotlight as a promising cancer therapy (Teixeira et al., 2020; 
Groeneveldt et al., 2020). Although anti-TGFb therapies frequently aim to restrict 
tumour invasion and metastasis, it has been reported that targeting TGFb also 
benefits anti-tumour immune responses (Yang, L. et al., 2010; Groeneveldt et al., 
2020). In fact, specific blockade of TGFb signalling in T lymphocytes reinforces 
rejection of transplanted B16 and EL4 tumours in mice, indicating that TGFb plays 
a crucial role in the depletion of T cell responses against tumours (Gorelik and 
Flavell, 2001). Similarly, the lack of TGFb signalling in T cells prevents the 
development of tumours in a mouse model of spontaneous prostate cancer 
(Donkor et al., 2011). In these studies, TGFb decreased the number and activity 
of tumour-specific CTLs, which has been generally associated with a deleterious 




these investigations utilised transgenic mice expressing a dominant-negative 
TGFbRII, a model that blocks TGFb signalling in both CD4+ and CD8+ T 
lymphocytes. Due to the pleiotropic effects that TGFb exerts (Li, M.O. and Flavell, 
2008; Batlle and Massagué, 2019), whether other T cell lineages and to what 
extent these influenced the TGFb-mediated suppression of CD8+ T cell 
responses is unclear. A few studies have explored the direct effects of TGFb 
during CD8+ T cell priming in vitro but there is still a lack of in-depth understanding 
in this field and its underlying mechanisms (Thomas and Massagué, 2005; 
Brownlie et al., 2017). Another gap in our current knowledge of the mechanism 
of action of TGFb in the suppression of anti-tumour T cell responses is whether 
TGFb exclusively inhibits the activity of CD8+ T cells during early stages of 
activation or whether this also occurs to the fully differentiated CTLs that migrate 
to the TME.  
In this chapter, I aim to: 
1. Define in detail the impact of TGFb treatment during the priming of CD8+ 
T cells  
2. Assess the mechanisms by which TGFb modulates T cell activation by 
analysis of the TCR-induced T cell transcriptome using RNA-seq 











4.2.1 Tumour-derived TGFb suppresses activation of CD8+ T cells 
To assess the effects of TGFb during early CD8+ T cell activation I used OT-I 
TCR transgenic T cells stimulated in vitro with OVA-peptide ± exogenous TGFb 
(5ng/ml). It has been proposed that the effects of TGFb are dependent on the 
strength of the TCR-stimulation (Arumugam et al., 2015; Brownlie et al., 2017; 
Gunderson et al., 2020) and, therefore, I used both the high affinity peptide OVA-
N4 and the lower affinity OVA-T4 to stimulate OT-I T cells. T cells cultured in the 
presence of the homeostatic cytokine IL-7 (10ng/ml) were utilised as a negative 
control (no TCR stimulation). After 48h of TCR-stimulation, the levels of the 
activation markers CD25, CD44 and CD71, as well as granzyme B, a well-
established target of the SMAD2/3 transcription factors (Thomas and Massagué, 
2005), were determined. CD25 is the	 a	 subunit of the IL-2 receptor, further 
constituted by the g and b subunits (also known as gc and CD122, respectively). 
Whilst gc and CD122 are present in naïve T cells, CD25, which is the high-affinity 
receptor of IL-2, is only upregulated in activated T cells.  By contrast, CD71 is the 
transferrin receptor, which mediates the uptake of iron. In T cells, the levels of 
CD71 have been directly associated with Myc expression implying, therefore, that 
the measurement of CD71 not only serves as an activation marker but also as a 
readout of the metabolic status of the cell (Preston et al., 2015). As measured by 
staining with conjugated antibodies and following FACS analysis, I observed that 
TGFb did not affect the upregulation of CD25 and CD71 in T cells stimulated with 
OVA-N4. However, the expression of granzyme B was reduced by >80% in the 
same conditions (Fig. 4.1A). On the other hand, OT-I T cells stimulated with the 




and granzyme B when treated with TGFb indicating, therefore, that TGFb is 
particularly suppressive against CD8+ T cells primed with weak agonists (Fig. 
4.1A). Interestingly, the expression of CD44, an adhesion receptor usually 
upregulated in activated T cells to promote migration, was not diminished but 
instead strongly induced in the presence of TGFb (Fig. 4.1A), an observation that 






Figure 4.1: TGFb suppresses CD8+ T cell activation and growth in vitro. 
OT-I T lymphocytes were stimulated in vitro for 48h with OVA-p (10-6M/10-8M) ± 
TGFb (5ng/ml). (A) After incubation, levels of the activation markers CD25, CD44, 
CD71 and granzyme B were assessed by FACS analysis. (B) Cell size was 
determined by FACS analysis. On the left, FSC-A/SSC-A dot plots of 
lymphocytes after exclusion of doublets and dead cells. On the right, FSC-A MFI 
values are shown. In (A), figures collect data from three independent 
experiments. In (B), data is from one of at least three experiments and dots in 
graph represent technical replicates. Data represents mean with SD. NS – Not 
significant; * - P<0.05; ** - P<0.005; **** - P<0.0001, as determined by one-way 
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Another key indication of T cell activation is an increase in cell size. As expected, 
I observed in FSC-A/SSC-A plots that T lymphocytes stimulated with only OVA-
peptide, irrespective of the strength of the stimulation, at least doubled their size 
within the first 48h (Fig. 4.1B). The addition of TGFb, consistently with the 
previous data, prevented the optimal growth of T cells upon TCR-stimulation, an 
effect that was found more severe in OVA-T4-stimulated cells (Fig. 4.1B). 
To validate these results in the context of anti-tumour responses, I designed an 
in vitro approach that directly tested the effects of cancer cell-derived TGFb on 
the activation of CD8+ T cells responding to tumour associated antigens (TAAs).  
To do so, I utilised OVA-expressing ID8 cells, an ovarian carcinoma cell line that 
secretes TGFb (Chen, S. et al., 2019). I co-cultured naïve OT-I T cells with OVA-
N4, OVA-T4 or OVA-V4-expressing ID8 cells and determined T cell activation 
state. To determine the impact of tumour cell-derived TGFb, cells were also 
treated with SB431542 (5µM), a selective TGFbRI kinase inhibitor. After 48h, 
approximately >95% of the OT-I T cells co-cultured with ID8-N4 cells expressed 
both GrB and IFNg (Fig. 4.2A). In these co-cultures, the addition of SB431542 did 
not affect GrB and IFNg levels indicating no effects of ID8-derived TGFb against 
CD8+ T cells primed with high affinity peptides (Fig. 4.2A). On the other hand, 
whilst ID8 cells expressing the very weak agonist OVA-V4 did not induce a T cell 
response, ID8 cells expressing the low affinity peptide OVA-T4 promoted T cell 
activation more efficiently in the presence of the TGFbRI inhibitor (Fig. 4.2A). In 
this condition, ~65% of the cells were GrB+IFNg+ whereas only ~35% of the cells 
could upregulate these activation markers when the TGFb signalling was not 
blocked (Fig. 4.2A). Similarly, the activation markers CD25 and CD71 were only 




differences were observed when cultured with high affinity ID8-N4 or very low 
affinity ID8-V4 cells (Fig. 4.2B). Altogether, this data suggests that tumour cell-
derived TGFb dampens initial CD8+ T cell activation only against low affinity 
antigens.  
Figure 4.2: Tumour cell-derived TGFb inhibits CD8+ T cell activation against 
weak agonists. 
OT-I T lymphocytes were co-cultured with ID8-N4, ID8-T4 or ID8-V4 cells for 48h 
in the presence or absence of the TGFbRI blocker SB321542. Brefeldin A 
(2.5µg/ml) was added the last 4h of incubation and levels of GrB, IFNg, CD25 and 
CD71 were assessed by FACS analysis. Data is representative from three 
independent experiments. In (B), summarised data from the three experiments 
are shown. Fold change ([ID8-OVA + OT-I + SB431542] / [ID8-OVA + OT-I]) is 
calculated based on MFI.  
































































































4.2.2 TGFb inhibits growth and proliferation upon TCR-stimulation 
Other investigations have described the restriction of IL-2 secretion as an 
important mechanisms by which TGFb limits CD8+ T cell responses (Thomas and 
Massagué, 2005; Brownlie et al., 2017). In order to validate these findings in the 
OT-I model, I stimulated OT-I cells with OVA-p ± TGFb for 24h in the presence 
of anti-CD25 blocking antibody. Then, I evaluated IL-2 secretion as assessed by 
ELISA quantification of IL-2 levels in supernatants. Consistently, I observed that 
(1) OVA-N4 stimulation augments early IL-2 secretion when compared to OVA-
T4 stimulated T cells and (2) that TGFb hampers IL-2 secretion. Importantly, 
TGFb-mediated inhibition of IL-2 secretion was performed irrespective of the 






Figure 4.3: TGFb restricts IL-2 production and proliferation upon TCR-
priming. 
OT-I T lymphocytes were stimulated in vitro for 24h (A) or 72h (B, C, D) with OVA-
p (10-8M) ± TGFb (5ng/ml). In (A), secreted IL-2 levels in supernatants were 
assessed by ELISA. In (B, C, D), proliferative capacity was determined by dilution 
of CTV dye. The histogram shown in (D) represents CTV staining of OVA-T4 
stimulated T cells ± TGFb. Data is representative from one of three independent 
experiments. Data represents mean of technical triplicates and SD. * - P<0.05; 
*** - P<0.005; **** - P<0.0001, as determined by one-way or two-way ANOVA 
with Tukey’s or Sidak’s multiple comparisons test, as appropriate. 
 
Previous studies have also well-stablished that TGFb significantly dampens T cell 
proliferation, an effect that has been associated with inhibition of IL-2 secretion 
(Brownlie et al., 2017). To also validate these findings, I determined the 
proliferative capacity of  T lymphocytes treated ± TGFb using CTV dye. As 
expected, the strength of the TCR-stimulation determined the magnitude of the 
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when primed with OVA-N4 whilst only 65% did when primed with OVA-T4. Under 
TGFb treatment, fewer T cells did undergo cell division, particularly in OVA-T4 
stimulated lymphocytes (45% vs 65% in control conditions) (Fig. 4.3B and D). 
Moreover, as shown by a diminished division index (i.e. the average number of 
cell divisions that a cell undergoes), T cells stimulated in the presence of TGFb 
were unable to go through as many divisions as compared to those stimulated 
with only OVA-p, indicating that TGFb attenuated T cell expansion (Fig. 4.3C and 
D). This effect was observed in both OVA-N4 and OVA-T4 stimulated T cells (Fig. 
4.3C and D). 
Next, due to the essential role of IL-2 in promoting early T cell growth, activation 
and proliferation I questioned whether the inhibitory effects of TGFb seen during 
early T cell activation (Fig. 4.1-3) were caused indirectly by the loss of IL-2. Thus, 
I stimulated OT-I T cells with OVA-T4 ± TGFb and added hIL-2 (1ng/ml) from 
timepoint 0h to test if IL-2 replenishment would protect from TGFb mediated 
suppression. After 48h, I measured the levels of CD25 and granzyme B and 
observed that whilst the presence of IL-2 alone seemed to improve the activation 
state of the cells (increased granzyme B expression), IL-2 replenishment did not 
prevent the downregulation of both markers when added together with TGFb (Fig. 
4.4A). Furthermore, to firmly demonstrate that the TGFb-mediated inhibition of T 
cell activation was performed independently of IL-2 levels I treated the T cells 
with TGFb only after 24h of TCR-stimulation. The rationale behind this 
experiment relies on the fact that the peak of IL-2 secretion takes place within the 
first 24h upon TCR-binding and, therefore, the cell culture media at this timepoint 
is enriched with plenty IL-2. My data indicates that, upon 48h of TCR-stimulation, 




addition of TGFb is delayed for 24h (Fig. 4.4B). However, suppression was more 
pronounced when TGFb is present from timepoint 0h (Fig. 4.4B).  Altogether, 
these findings demonstrate that although the loss of IL-2 contributes to the 
suppressive effects, TGFb also acts through IL-2 independent mechanisms to 
limit T cell activation.  
Figure 4.4: IL-2 replenishment does not prevent TGFb-mediated 
suppression. 
OT-I T lymphocytes were stimulated in vitro for 48h with OVA-p (10-8M) ± TGFb 
(5ng/ml). Where indicated, hIL-2 (1ng/ml) was added to the cells from timepoint 
0h (A, B) or at 24h (B). After incubation, levels of CD25 and GrB were assessed 
by FACS analysis. Data is from one of three (A) or two (B) experiments with 
technical triplicates. Error bars represent SD. NS – Not significant; * - P<0.05; ** 
- P<0.005; *** - P<0.0005; **** - P<0.0001, as determined by one-way ANOVA 
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4.2.3 TGFb dampens cytokine secretion, but not immediate killing 
capacity, of CTLs 
So far, I have described in detail the implications of TGFb treatment during the 
priming of CD8+ T cells, but how does the presence of TGFb affect fully 
differentiated CTLs? Investigations by Tu et al. (2018) showed that CD4+ T 
lymphocytes activated with strong agonists downregulate the expression of 
Tgfbr1 and Tgfbr2 upon TCR-binding to facilitate Th1 lineage commitment. I 
hypothesised that a similar scenario could occur in CD8+ T cells making effector 
CTLs less responsive to TGFb, as compared to naïve cells. To test this, I 
compared levels of TGFb-induced SMAD phosphorylation in CTLs, generated by 
initial priming with OVA-N4 for 2 days and expanded for 4 days further in the 
presence of hIL-2, and naïve OT-I cells. The TGFbRI inhibitor SB431542 was 
utilised as a negative control. I found that both naïve OT-I T cells and CTLs were 
able to trigger SMAD2/3 phosphorylation in response to TGFb (Fig. 4.5). In fact, 
the abundance of pSMAD2/3 upon TGFb stimulation was higher in CTLs than in 
naïve T cells (Fig. 4.5). Thus, my data indicates that, in contrast to results 





Figure 4.5: TGFb triggers SMAD2/3 phosphorylation in both naïve and 
effector CD8+ T cells. 
Naïve OT-I T lymphocytes or CTLs were stimulated in vitro for 1h with TGFb 
(5ng/ml). The TGFbRI inhibitor SB431542 was utilised as a negative control. After 
incubation, levels of pSMAD2/3 (Ser465/467) were assessed by IC staining 
followed by FACS analysis. (A) Representative histogram of pSMAD2/3 levels in 
naïve T cells and CTLs. Values represent pSMAD2/3 MFI. Summarised data of 
pSMAD2/3 levels in naïve T cells (B) or CTLs (C) are indicated. Data is from one 
of three experiments with technical triplicates. Error bars represent SD.  
 
Other groups (Thomas and Massagué, 2005), in accordance with the findings 
described previously, have clearly established that TGFb is a strong inhibitor of 
granzyme B upregulation upon antigen detection and this has been linked to the 
increased tumour rejection observed in mouse models following TGFb 
neutralisation (Gorelik and Flavell, 2001; Thomas and Massagué, 2005). 
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cytotoxicity of fully differentiated CTLs. Hence, I performed a killing assay by co-
culturing luciferase-expressing ID8-T4 or ID8-V4 cells with OT-I CTLs overnight 
in the presence or absence of TGFb. First, as expected, my data showed that the 
killing capacity of the CTLs correlated with the affinity of the OVA-peptide (Fig. 
4.6). However, the proportion of targeted tumour cells (either ID8-T4 or ID8-V4) 
was equal irrespective of the presence of TGFb (Fig. 4.6) suggesting, therefore,  
that TGFb does not directly affect the cytotoxicity of CTLs.  
Figure 4.6: TGFb does not impair CTL killing capacity. 
CTLs generated in vitro during 6d were co-cultured with luciferase-expressing 
ID8-T4 or ID8-V4 in the presence or absence of TGFb. After an overnight 
incubation, cell cultures were washed in PBS and ID8 confluence was determined 
by bioluminescence imaging. % killing was determined based on negative control 
(no added CTLs). Data is from one of two repeated experiments with technical 
triplicates. Error bars represent SD. NS – Not significant, as determined by two-
way ANOVA with Sidak’s multiple comparisons test. 
 
Next, I tested whether TGFb affected cytokine production of CTLs. I re-stimulated 
CTLs with OVA-p ± TGFb for 24h and quantified IFNg levels in supernatants by 
ELISA. I observed that TCR-induced IFNg levels were substantially diminished 








































conditions (Fig. 4.7). These data indicate that TGFb inhibits CTL IFNg production 
irrespective of the strength of TCR stimulation.  
 
Figure 4.7: TGFb limits IFNg secretion of CTLs. 
CTLs generated in vitro during 6d were re-challenged with OVA-p (10-8M) ± TGFb 
(5ng/ml). After 24h, Levels of IFNg in SN were determined by ELISA. Data is from 
one of three experiments with technical replicates. Error bars represent SD. ** - 
P<0.005; **** - P<0.0001, as determined by two-way ANOVA with Sidak’s 
multiple comparisons test. 
 
4.2.4 TGFb reshapes the transcriptome of activated CD8+ T 
lymphocytes  
In order to gain a broad understanding on the mechanisms that sustain the 
suppression of CD8+ T cell priming by TGFb, I decided to explore the 
transcriptomic profile of activated T cells ± TGFb. Thus, I stimulated OT-I T cells 
from 4 biological replicates with OVA-T4 ± TGFb for 24h. Then, cells were lysed, 
mRNA was isolated and mRNA-seq performed (all details are specified in  
Section 2.7). The number of differentially expressed transcripts (adjusted p-value 
< 0.05, determined as described in Section 2.8) between TGFb treated and non-
























genes in the presence of TGFb (Fig. 4.8A). However, the number decreased from 
3248 to 1224 and from 2552 to 333, respectively, when limiting the analysis to 
those transcripts differentially expressed with a fold-change (FC) > 2 (Fig. 4.8B).  
As indicated in the volcano plot (Fig. 4.8C), Gzmb and Eomes, which encode for 
granzyme B and the differentiation transcription factor Eomesodermin, were 
remarkably repressed by TGFb . On the other hand, genes encoding for the 
chemokine receptor C-C Motif Chemokine Receptor 8 (Ccr8), the nucleotidase 
CD73 (Nt5e), the  Acyl-CoA synthase ACBG1 (Acsbg1) or the TGFb signalling 
associated Ski and Tgbr1 are some of the highlighted transcripts when analysing 
the upregulated genes (Fig. 4.8B). In Table 4.1, the top 20 most upregulated and 












Figure 4.8: TGFb modulates the transcriptome of CD8+ T lymphocytes upon 
TCR-priming. 
OT-I T lymphocytes were stimulated in vitro for 24h with OVA-T4 (10-8M) ± TGFb 
(5ng/ml). After incubation, mRNA was isolated and mRNA-seq was performed. 
Only differentially expressed genes (adjusted p-value < 0.05) are displayed 
(n=5800). In (A), values represent log2(FC). In (C), dashed lines determine cut-
offs – i.e. adjusted p-value < 0.05 (horizontal) and FC > 2 (vertical).  Data from 4 
biological replicates is included.  
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Table 4.1: Most upregulated and downregulated transcripts by TGFb. 
Left: top 20 upregulated transcripts, FC = (OVA-T4 + TGFb) / (OVA-T4). Right: 













4.2.5 TGFb profoundly modifies the metabolic transcriptome of 
activated CD8+ T cells 
To better understand how TGFb inhibits CD8+ T cell activation I performed Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway analysis on the 5800 
differentially expressed genes (adjusted p < 0.05, no FC cut-off). Genes 
associated with metabolic pathways were the most affected by TGFb treatment, 
with a total of 464 genes (Fig. 4.9). Specifically, carbon metabolism (n=71), 
glycolysis (n=52) or the biosynthesis of amino acids (n=56) were the major 
metabolic pathways altered by TGFb. Other pathways included genes involved 
in the regulation of RNA transport (n=99), the spliceosome (n=82) or ribosome 
biogenesis (n=62) (Fig. 4.9).  
Figure 4.9: Metabolic pathways are the most affected by TGFb. 
List of the most influenced pathways by TGFb, as assessed by KEGG analysis 
of the 5800 differentially expressed genes (adjusted p-value < 0.05), including 
upregulated and downregulated genes. On the right, n indicates number of genes 
identified in each pathway. 
 
Then, I further explored which pathways were particularly repressed or induced 
by TGFb performing KEGG analysis only of the differentially expressed genes 
with a FC > 2 (1224 upregulated and 333 downregulated genes, as specified in 

































Section 4.2.4). This analysis identified that genes involved in the regulation of 
inflammatory bowel disease, leishmaniasis, Th17 cell differentiation, 
hematopoietic cell lineage and cytokine-cytokine receptor interaction were the 
most upregulated pathways by TGFb (Fig. 4.10A). Within the 1224 upregulated 
transcripts, the most recurrent amongst the top 10 pathways included genes that 
encoded for MHC-II complex proteins (e.g. H2-DMb2, H2-DMb1, H2-DMa), 
cytokine receptors such as IFNGR2, TGFbRI, TGFbRII, IL7R and IL6RA or the 
integrins CD49d (Itga4) and CD11b (Itgam) (Fig. 4.10B). Considering that CD8+ 
T lymphocytes do not express MHC-II, the upregulation of genes encoding for 
this molecule is surprising. However, it is important to note that, in spite of 
showing a high FC, these are expressed at very low levels (FPKM < 5). By 
contrast, genes associated with T cell cytotoxicity (Fasl, Prf1, Gzmb) or the 
metabolism of cysteine and methionine, as well as glycine, serine and threonine 
(Cth, Cbs), were some of the most highlighted transcripts when analysing 






Figure 4.10: Pathway analysis of upregulated and downregulated genes by 
TGFb. 
(A) List of the most influenced pathways by TGFb, as assessed by KEGG 
analysis (FC > 2, p-value < 0.05). (B) Clustergrams include most recurrent genes 
identified amongst the top 10 pathways. Genes associated with the specified 
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4.2.6 TGFb transcriptionally regulates CD8+ T cell activation, 
differentiation and acquisition of effector functions 
As mentioned, the fate of T lymphocytes upon TCR-stimulation is dictated 
depending on the exposure to environmental signals. This fate is manifested 
through the expression of specific markers, such as surface proteins, TFs or 
cytokines. To better comprehend how TGFb was defining the outcome of TCR-
primed CD8+ T cells I performed an in-depth analysis of the expression of the 
activation/differentiation markers.  
First, I analysed expression levels of transcripts that encode for some of the most 
well established early activation markers including CD25, CD44, CD69 and 
CD71, usually induced upon TCR-ligation, or CD62L and the IL-7R, which are 
usually downregulated. Data indicated that TGFb limited the upregulation of 
CD25, CD69 and CD71 transcripts whilst maintained the expression of CD62L 
and IL7R, indicating the suppression of T cell activation (Fig. 4.11). Consistent 
with my previous findings, CD44 expression was induced by TGFb (Fig. 4.11). 
Regarding the expression of inhibitory receptors, the mRNA encoding for PD-1 
(Pdcd1) and TIM3 (Havcr2) was induced in the presence of TGFb. However, this 
was not observed for Ctla4, Lag3 or Tigit, which were either repressed or 
unchanged. Furthermore, the effector molecules perforin, FasL, granzyme C and, 
particularly, granzyme B (with a striking 26-fold change), were strongly repressed 
upon TGFb treatment. Other effector molecules such as granzyme A and M or 





Figure 4.11: TGFb alters the transcription of activation markers and effector 
molecules in CD8+ T cells upon TCR-priming.  
mRNA expression of the indicated markers is displayed, as assessed by RNA-
seq (n=4). Values in heatmaps represent log2(FC). Non-differentially expressed 
genes are indicated with (*). Indicated values for FC are calculated as FC = (OVA-









































































Next, I focused on a myriad of TFs associated with T cell differentiation and 
metabolism. I observed that Eomes was the most downregulated TF-encoding 
gene by TGFb, with a FC > 18 (Fig. 4.12). Moreover, genes encoding for other 
TFs involved in the acquisition of an effector phenotype, e.g. Tbet, IRF4 or 
STAT4, were also repressed in the presence of TGFb. Nonetheless, this trend 
was not uniformly followed when analysing TFs associated with early TCR-
signalling pathways, some of which were upregulated (e.g. Jun, Nfkb1, Nfat2), 
downregulated (Nfatc1) or unchanged (Fos, Rela) (Fig. 4.12). Interestingly, the 
expression of genes encoding for Forkhead box protein O1 (FOXO1) or 
transcription factor 1 (Tcf1; encoded by Tcf7), both downregulated during effector 
differentiation (Danilo et al., 2018), was higher in TGFb-treated T lymphocytes 
(Fig. 4.12). Rorc expression, known to be induced by TGFb in Th17 cells (Zhu, J. 
et al., 2010), was also upregulated. As for the expression of metabolic TFs, Myc 
and Hif1a, associated with glycolysis, glutaminolysis and AA metabolism, were 
significantly reduced but no differences were observed in Esrra, Srepf1 and 






Figure 4.12: TGFb treatment modifies the gene expression of key TFs. 
Gene expression (FPKM) of the indicated TFs is displayed, as assessed by RNA-
seq (n=4). Error bars indicate SD. On the table, blue indicates downregulated 
transcripts; red indicates upregulated transcripts; black indicates non-
differentially expressed transcripts. Indicated values for FC are calculated as FC 
= (OVA-T4) / (OVA-T4 + TGFb). Differences in gene expression are considered 





Then, I looked into how TGFb modulated cytokine transcription of activated T 
cells. I saw that, even in the presence of TGFb, T cells induce the expression of 
Ifng and Tnf, typically represented in effector T cells. Expression of Ifng was 
slightly diminished but, surprisingly, did not reach statistical significance (Fig. 
4.13A). Other cytokines were very low or not expressed and only a significant 
increase was seen in Il17f upon TGFb-treatment (Fig. 4.13A). In regards to 
cytokine receptors, those involved with effector or memory differentiation, such 
as Il2ra, Il12rb1, Il12rb2 and Il15ra were downregulated by TGFb. On the other 
hand, Il6ra, Ifngr2 and, particularly, Tgfbr1, were some of the receptor-encoding 
genes that were expressed at higher levels upon TGFb-stimulation (Fig. 4.13B).  
 
Figure 4.13: TGFb remodels the mRNA expression of cytokines and 
cytokine receptors in CD8+ T cells. 
(A) Gene expression (FPKM) of the indicated cytokines is displayed, as assessed 
by RNA-seq (n=4). Error bars indicate SD. (B) Gene expression of the indicated 
cytokine receptors is displayed. Values represent log2(FC).  
 
















































The effects of TGFb on expression of chemokine receptor genes were variable. 
Canonically, naïve T lymphocytes express CCR7, which is downregulated upon 
TCR-stimulation while CCR5 and CXCR3, among others, are induced (Nolz et 
al., 2011). TGFb impeded the downregulation of Ccr7 upon TCR-stimulation while 
inhibiting the induction of Ccr5. However, Cxcr3 expression was not repressed, 
but instead promoted, in the presence of TGFb. Amongst other potentially 
interesting results, I observed a striking effect on Ccr8 expression being, as 




Figure 4.14: TGFb changes the mRNA expression of chemokine receptors 
in CD8+ T cells. 
mRNA expression of the indicated chemokine receptors is displayed, as 
assessed by RNA-seq (n=4). Values in heatmaps represent log2(FC). Indicated 


































The mechanisms by which TGFb dampens CD8+ T cell responses remains to be 
fully understood. Specifically, as mentioned in Section 4.1, it still is uncertain 
whether TGFb predominantly inhibits CD8+ T cells in vivo through direct action or 
indirectly through effects on other cell types. In the present chapter, I have 
characterised in depth how TGFb is able to directly shape the phenotype of CD8+ 
T lymphocytes in vitro. Furthermore, I examined the transcriptomic changes 
induced by TGFb, acquiring valuable new comprehension on its mechanisms of 
action.  
First, the study of naïve CD8+ T cells stimulated in the presence or absence of 
TGFb confirmed that TGFb negatively affects early events upon TCR-priming as 
shown by reduced growth, proliferation and expression of key activation markers 
and effector molecules (e.g. CD25, CD71, GrB), particularly in response to weak 
agonists (Fig. 4.1). This data supports previous studies that confirm that TGFb 
strongly represses CD8+ T cell expansion and cytotoxicity both in vivo and in vitro 
(Gorelik and Flavell, 2001; Thomas and Massagué, 2005; Arumugam et al., 2015; 
Brownlie et al., 2017). However, my findings differ from those observed by 
Thomas and Massagué (2005) who concluded that TGFb provides a selective 
inhibition of the cytotoxic program rather than a general inhibition of T cell 
activation, as shown by comparable levels of CD44, CD69 and CD62L expression 
but increased GrB and IFNg in tumour reactive CD8+ T lymphocytes upon TGFb 
neutralisation in vivo. However, it is important to note that they utilised tumour 
cell lines that expressed the high affinity peptide OVA-N4 to induce T cell anti-
tumour responses. As shown in this chapter, and in accordance to other 




TCR-stimulation is key to determine the suppressive capacity of TGFb. My 
experiments exploring the direct effects of tumour-derived TGFb during CD8+ T 
cell priming confirmed that TGFb produced by tumour cells was sufficient to limit 
early GrB or IFNg expression in T cells recognising OVA-T4 but not OVA-N4. 
Thus, my data supports a model where the TCR-signalling strength is crucial to 
determine the severity of TGFb immunosuppression: whereas high levels of 
TGFb selectively targets the cytotoxic and proliferative programs in those T cells 
stimulated by strong peptides in vitro, TGFb induces a general inhibition in 
response to weak agonists that results in an unsuccessful exit of quiescence and 
an almost complete loss of T cell activity. Furthermore, these results suggest that 
not only the peptide affinity determines the response to TGFb but that other 
variables, such as its concentration or its source, should be taken into 
consideration when investigating the role of TGFb in the context of anti-tumour T 
cell responses.  
As mentioned, I have shown that whilst mostly all the analysed markers, except 
CD44, are repressed by TGFb upon OVA-T4-stimulation, only some specific 
markers (e.g. GrB, IL-2, IFNg; Fig. 4.1, 4.3 and 4.7) are inhibited irrespective of 
the strength of the stimulation. It is possible that this selectivity relies on the direct 
role of SMAD proteins in regulating the transcription of these genes (McKarns et 
al., 2004; Thomas and Massagué, 2005) whereas other markers, such as CD25 
and CD71 might be suppressed through indirect mechanisms. I tested whether 
the lack of IL-2 was one of those indirect mechanisms that was further depleting 
activation in OVA-T4-stimulated CD8+ T cells. IL-2 replenishment has been 
shown to revert TGFb-mediated suppression of T cell proliferation (Brownlie et 




recovered in IL-2 replete conditions (Thomas and Massagué, 2005), further 
reinforcing the hypothesis that only some effects are directly mediated by TGFb 
signalling. My data corroborates that the addition of IL-2 does not prevent TGFb-
mediated repression of GrB or CD25 expression. This data  indicates, therefore, 
that IL-2 depletion is not responsible for the TGFb-mediated inhibition of CD25, 
but whether other mechanisms might be involved is still unknown.  
So far, I have discussed and concluded that TGFb particularly represses CD8+ T 
cell responses against low affinity peptides in vitro. But, what are the likely 
consequences in vivo? Many reports that identified a TGFb-mediated decrease 
in anti-tumour CD8+ T cell responses utilised transplanted tumour models 
(Gorelik and Flavell, 2001; Thomas and Massagué, 2005) or models of 
spontaneous cancer (Donkor et al., 2011) that determine responses to well-
characterised peptides with high T cell reactivity. Nonetheless, any study has 
directly compared responses to strong vs weak agonists in the context of TGFb-
mediated inhibition and, therefore, there is still a lack of evidence regarding to the 
existence of different magnitudes of T cell suppression by TGFb in vivo. Future 
experiments could include, for example, the assessment of T cell responses 
against OVA-N4 vs OVA-T4-expressing tumours in vivo in the presence or 
absence of a TGFb neutralising agent (e.g. a TGFbR blocker). Albeit not directly 
testing T cell responses to different affinity peptides, Brownlie et al. (2017) 
showed that Ptpn22-/- T cells, which exhibit an improved recognition of weak 
agonists and increased TCR-signalling strength, counteracted TGFb inhibition 
during early stages of T cell activation in vitro resulting in enhanced tumour 
rejection upon ACT in vivo. This findings suggest that my in vitro observations 




respond even more poorly to low affinity peptides in the presence of TGFb leading 
to very deficient, or even null, T cell responses. 
Why is the previous statement particularly relevant in the field of cancer 
immunotherapy? If TGFb represses T cell function more significantly against 
weak peptides, it is likely that TGFb inhibits anti-tumour responses to low affinity 
TAAs to a greater extent than to high affinity neoantigens. Under this premise, it 
is reasonable to think that anti-TGFb therapies would be particularly beneficial 
against aberrantly expressed self-TAAs. A current weakness of ICB therapies is 
that successful outcomes are low unless tumours are highly immunogenic 
(known as ‘hot’ tumours), a feature usually observed when tumour specific 
antigens (TSAs, neoantigens) are expressed (Lechner et al., 2013). Thus, it has 
been proposed that TGFb neutralisation could potentially enhance anti-tumour 
responses against TAAs, transforming ‘cold’ tumours into ‘hot’ tumours and, ergo, 
promoting better anti-tumour responses when combined with ICB therapies. 
Accordingly, many investigations have demonstrated that the combination of ICB 
and anti-TGFb therapies significantly reduces tumour burden when compared to 
ICB treatment alone (Terabe et al., 2017; Mariathasan et al., 2018; Tauriello et 
al., 2018; Lan et al., 2018; Ravi et al., 2018).  
A key and novel contribution of this chapter is the characterisation of the 
transcriptomic profile of activated CD8+ T cells in the presence or absence of 
TGFb. Thomas and Massagué (2005) previously performed a gene micro array 
comparing the transcriptome of TGFb treated and untreated CD8+ T cells. 
However, the identified transcripts were restricted to a defined gene library and, 
therefore, the analysis was somewhat limited, with only 104 identified genes with 




understanding on how TGFb reshapes the transcriptome of CD8+ T cells (1553 
genes FC > 2). This has allowed me to perform KEGG analysis to distinguish key 
pathways affected by TGFb. In addition to the well-stablished repression of the 
cytotoxic program (Gzmb, Prf1, Fasl) (Thomas and Massagué, 2005), I have 
identified substantial changes in the translational machinery and, particularly, in 
metabolic pathways. Thus, I have found additional possible mechanisms by 
which TGFb might be interfering with the activation of CD8+ T lymphocytes, a key 
finding to better understand the intricacies of TGFb activity. The impact of TGFb 
on the metabolic reprogramming of CD8+ T cells will be further explored in 
Chapter 5. 
Defining the transcriptome of TGFb-treated T cells is a powerful strategy to 
understand global changes in gene expression, but it is important to considerate 
that transcript levels not always correlate with protein levels (Plotkin, 2010; Vogel 
and Marcotte, 2012). Hence, the interpretation of the RNA-seq data should be 
taken with caution and, although is valuable to guide us and predict changes, 
those should always be confirmed at the protein level. Furthermore, the RNA-seq 
data has the limitation of not including an unstimulated negative control (T=0h). 
In this chapter and the following, I have focused on the validation genes of interest 
for this thesis (e.g., activation markers, effector molecules, cytokines or metabolic 
proteins), which were mostly downregulated, but the RNA-seq data revealed that 
a significant cluster of genes is also substantially upregulated. Nonetheless, due 
to the lack of T=0h negative control, whether TGFb induces the expression of 
these genes or whether it prevents its downregulation upon TCR-stimulation is 




unstimulated negative control is required to better understand the mechanisms 
of action of TGFb. 
CD8+ T cells can respond to TGFb stimulation engaging an inhibitory (Treg) or an 
IL-17 or IL-9-producing phenotype (known as Tc17 and Tc9 cells, respectively) 
(St. Paul and Ohashi, 2020). Thus, we could argue that the scarcity of a cytotoxic 
phenotype is due to an alternative T cell differentiation. However, there is no 
strong evidence indicating that this could be the case in my TGFb-treated T cells. 
For example, in the context of Tregs, the RNA-seq data shows that there is no 
Foxp3 or Il10 expression. Similarly, there is no pattern suggesting a Tc9 
phenotype. Although some Tc17 classic genes are moderately upregulated by 
TGFb, such as Il17f or Rorc, these are expressed at very low levels, particularly 
when compared to classic Tc1 genes (e.g. Ifng, Tnf or Tbx21). Furthermore, it is 
important to note that these alternative phenotypes are acquired in combination 
of TGFb with other cytokines (St. Paul and Ohashi, 2020). Considering that those 
were missing in the in vitro conditions utilised here, it is unlikely that a 
Treg/Tc9/Tc17 phenotype would be optimally induced by TGFb alone. 
Nonetheless, we cannot exclude that this could occur in vivo and, therefore, it 
should be taken into consideration in future studies.  
An important discrepancy observed in the RNA-seq data when compared to 
previous investigations, is the lack of Ifng repression. It is well-stablished that Ifng 
is a direct target of SMADs (Thomas and Massagué, 2005) so it is surprising that 
I do not observe any significant changes upon TGFb treatment. However, Ifng  
levels are very low within the first 24h upon TCR-stimulation, particularly with low 
affinity stimulations and, therefore, it is more likely for changes to be more 




produced. Alternatively, it is important to note that SMADs often regulate 
transcription in association with another co-factors, a feature that allows TGFb to 
respond differently depending on the cell type and context (Massagué, 2012; 
David and Massagué, 2018; Batlle and Massagué, 2019). For example, it has 
been described that Ifng is repressed by a complex formed by SMAD2/3/4 and 
AFT1, whilst Gzmb regulation requires an additional CREB binding (Thomas and 
Massagué, 2005). It is therefore possible that the in vitro approach utilised here 
is missing a signal, perhaps CD28, relevant for the specific inhibition of Ifng. Albeit 
the absence of transcriptional repression, I have shown that IFNg levels are 
diminished after 48h of T cell activation suggesting that (1) transcriptional 
changes appear at later-timepoints or (2) TGFb also regulates IFNg expression 
post-transcriptionally.  
Finally, the study of the effect of TGFb on fully differentiated CTLs has shed light 
into some surprising findings. Although TGFb repressed IFNg production by 
CTLs, I have found that the presence of TGFb did not dampen their killing 
capacity. However, we have to be cautious with the interpretation of these results. 
CTLs generated in vitro contain pre-formed cytotoxic granules that could be 
secreted at the moment of encountering the target cells, regardless of the 
presence of TGFb. Thus, although I can confirm that TGFb does not prevent the 
immediate killing of target cells, it is likely that a delayed inhibitory effect, when 
effector molecules require to be re-synthesised, could occur. An alternative 
explanation to my results is that the deficient cytotoxic capacity observed in in 
vivo studies (Gorelik and Flavell, 2001; Thomas and Massagué, 2005; Donkor et 
al., 2011) is (1) only present when experiencing TGFb signalling during early 




cytotoxicity but rather by a loss of cytokine secretion or through its influence in 
other immune cells (Fridlender et al., 2009; Flavell et al., 2010; Tu et al., 2014). 
My results confirming SMAD2 phosphorylation and IFNg repression in CTLs 
exclude the loss of responsiveness to TGFb as a possible explanation. 
In summary, I have clearly established that TGFb directly interferes with the 
activation of CD8+ T lymphocytes, particularly against weak agonists. 
Furthermore, the characterisation of the transcriptome upon TGFb-treatment has 
revealed some possible underlying mechanisms. In the next chapter, I investigate 

















Chapter 5 The influence of TGFb on CD8+ T cell 
metabolic reprogramming  
5.1 Introduction 
In the previous chapter, I described the suppressive consequences of TGFb on 
the functionality of naïve and effector CD8+ T cells after TCR stimulation. 
Furthermore, the RNA-seq analysis provided new insight into the mechanisms of 
action of TGFb in CD8+ T lymphocytes. Amongst the major hallmarks of those 
CD8+ T cells primed in the presence of TGFb I found: (1) the repression of 
translation, (2) the inhibition of the cytotoxic program and, particularly, (3) the 
alteration of metabolism. 
Our current knowledge on TGFb and its modulation of immune cell metabolism 
is limited. Studies in NK cells have reported that TGFb inhibits their response to 
IL-15 through repression of mTOR activity and bioenergetic metabolism (Viel et 
al., 2016). Moreover, Zaiatz-Bittencourt et al. (2018) later described also in NK 
cells that TGFb prevents IL-2-induced metabolic reprogramming by suppressing 
OXPHOS, glycolytic capacity and upregulation of the transferrin receptor CD71. 
Dimeloe et al. (2019) defined that, in CD4+ T cells,  Smad proteins are able to 
directly interact with the mitochondria leading to a reduced respiratory capacity 
and IFNg secretion. However, how TGFb shapes CD8+ T cell metabolism is less 
well described. In this chapter, in order to further understand how TGFb induces 
CD8+ T cell dysfunction, I aimed to investigate the influence of TGFb on the 







5.2.1 TGFb inhibits T cell activation by repressing the Myc-induced 
transcriptional program 
Chromatin immunoprecipitation (ChIP) Enrichment Analysis (ChEA) is a gene-
set database that compiles the targets of 199 transcription factors based on ChIP-
X data (Lachmann et al., 2010). I utilised this tool to identify key transcriptional 
programs that could be modulated by TGFb. ChEA analysis of the genes 
downregulated by TGFb (FC > 1.5, adjusted p-value < 0.05) identified a 
significant overlap with the Myc-induced transcriptional program (Table 5.1). This 
finding suggested, therefore, that much of the TGFb-mediated T cell dysfunction 
might be caused by the repression of Myc expression.  
Index ChEA identifier p-value 
1 MYC 18555785 ChIP-Seq MESCs Mouse 7.262x10-51 
2 MYC 19030024 ChIP-ChIP MESCs Mouse 8.264x10-49 
3 MYC 18358816 ChIP-ChIP MESCs Mouse 1.937x10-46 
4 EKLF 21900194 ChIP-Seq ERYTHROCYTE Mouse 1.863x10-39 
5 MYC 19079543 ChIP-ChIP MESCs Mouse 4.787x10-17 
Table 5.1: ChEA analysis of downregulated genes by TGFb. 
 
In fact, as mentioned in the previous chapter, TGFb strongly inhibited Myc 
expression based on my RNA-seq data (FC = 2.77; Fig. 5.1A). This was also 
observed at the protein level. I stimulated OT-I T cells with OVA-p for 48h and 
observed that, as assessed by flow cytometry, Myc expression was significantly 
reduced in the presence of TGFb, irrespective of the strength of the TCR-
stimulation (Fig. 5.1B). 
As Myc stabilisation is highly dependent on IL-2 levels (Preston et al., 2015) I 




important role in Myc decline. Thus, OT-I cells were stimulated with OVA-p ± 
TGFb in the presence of exogenous IL-2 (1ng/ml). Data indicated that IL-2 
replenishment had no effect on the levels of Myc expression in T cells stimulated 
with OVA-N4 and TGFb, whereas it was slightly but not significantly increased in 
OVA-T4 stimulated T cells (Fig. 5.1C). To further reinforce these results, I delayed 
treating OT-I cells with TGFb until after 24h from TCR-priming, i.e., after the IL-2 
secretion peak. Again, I saw that, even when added at 24h, TGFb still suppressed 
Myc expression although in a lesser extent as compared to TGFb-treated T cells 
from timepoint 0h (Fig. 5.1D). Altogether, this data implied that TGFb dampened 
Myc expression and its subsequent transcriptional program through IL-2 






Figure 5.1: TGFb represses Myc expression in activated CD8+ T cells. 
OT-I T lymphocytes were stimulated in vitro for 24h (A) or 48h (B, C, D) with OVA-
p (10-8M) ± TGFb. Unstimulated T cells (No TCR) were cultured in the presence 
of IL-7 and used as negative controls. Where indicated, hIL-2 (1ng/ml) was 
added. Myc mRNA (A) or protein (B, C, D) levels were acquired by RNA-seq or 
FACS analysis, respectively. In (A), dots represent biological replicates. In (B, C, 
D), dots represent technical triplicates. Data is from one of at least two repeated 
experiments. NS – Not significant; * - P<0.05; ** - P<0.005; **** - P<0.0001, as 
determined by one-way ANOVA with Tukey’s multiple comparisons test. 
 
5.2.2 TGFb suppresses the glycolytic metabolism of activated CD8+ 
T cells 
The engagement of aerobic glycolysis is one of the key events of the TCR-
induced metabolic reprogramming. Glycolysis is mainly regulated in early 
activated T cells by upregulation of Myc and HIF-1a, both of which are 
suppressed by TGFb (Fig. 5.1 and 4.12). Thus, I hypothesised that T cells would 
inefficiently promote glycolysis after TCR-stimulation in the presence of TGFb. 
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First, I used the RNA-seq data to look into the mRNA levels of the glycolytic 
enzymes, as well as glucose and lactate transporters. There was a modest 
decrease in mRNA expression of almost all glycolytic enzymes, except Hk1 and 
Aldoc, which in fact displayed a mild but significant upregulation, and Ldhb (Fig. 
5.2). Gapdh was strongly repressed in 3 out of 4 biological replicates but the lack 
of consistency concluded in non-significant changes (Fig. 5.2). 
Figure 5.2: TGFb downregulates the expression of glycolysis associated 
genes. 
(A) Schematic representation of aerobic glycolysis. (B) mRNA expression of 
glycolytic enzymes upon 24h of TCR-stimulation with OVA-T4 (10-8M) ± TGFb, 
as assessed by RNA-seq (n=4). Values represent log2(FC). Non-differentially 
expressed genes are indicated with (*).  
 
The glucose transporters GLUT1 and GLUT3, encoded by Slc2a1 and Slc2a3 
respectively, were significantly downregulated (Fig. 5.2B and 5.3A). I confirmed 



























stimulation (Fig. 5.3B). These phenotypes  were associated with decreased 
uptake of the glucose analogue 2-NBDG (Fig. 5.3C).  
TGFb also prevented the upregulation of Ldha, the enzyme that ultimately 
converts pyruvate into lactate (Fig. 5.2 and 5.3D). To determine the magnitude of 
the consequences of Ldha downregulation, together with the decreased glucose 
uptake and expression of other glycolytic enzymes, I tested the glycolytic capacity 
of T cells based on their ability to modify the extracellular pH. Using the Seahorse 
XFe96 Analyser I saw that T lymphocytes stimulated in the presence of TGFb 
had an attenuated ECAR increase in response to glucose administration (Fig. 
5.3E). This phenomenon was observed in both OVA-N4 and OVA-T4 stimulated 
T cells, indicating that TGFb intervenes with glycolysis regardless of the strength 
of the initial TCR-stimulation (Fig. 5.3E). Importantly, a decrease was also 
observed in the expression of the lactate transporter Slc16a1 (Fig. 5.2B) which 
functions as a rate limiting step for the glycolytic flux due to the negative feedback 





Figure 5.3: TGFb treated T lymphocytes display an impaired glycolytic 
capacity. 
OT-I T lymphocytes were stimulated in vitro for 24h (A, D) or 48h (B, C, E) with 
OVA-p (10-8M) ± TGFb. Unstimulated T cells (No TCR) were cultured in the 
presence of IL-7 and used as negative controls. (A, D) Slc2a1 and Ldha 
expression was assessed by RNA-seq. (B) GLUT1 protein levels were assessed 
by intracellular staining followed by FACS analysis. (C) 2-NBDG uptake was 
assessed by FACS analysis upon incubation. (D) ECAR values were acquired 
using the Seahorse XFe96 analyser. Bar graph (right), represents ECAR values 
after glucose injection. In (A, D), dots represent biological replicates. In (B, E), 
dots represent technical triplicates. Data is from one of at least three repeated 
experiments. * - P<0.05; *** - P<0.0005; **** - P<0.0001, as determined by one-
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5.2.3 TGFb alters amino acid metabolism of activated CD8+ T 
lymphocytes 
Myc-induced metabolic reprogramming has been strongly associated with its 
ability to induce AA uptake, particularly via upregulation of LAT1 expression (i.e. 
Slc7a5) (Wang, R. et al., 2011; Marchingo et al., 2020). Thus, my next step 
consisted of testing the effects of TGFb on AA transport.  Using my RNA-seq 
data, I looked into the expression of genes encoding for some of the main AA 
transporters in T cells including ASCT2 (Slc1a5), the sodium-independent 
cationic AA transporters (CAT)1 and 3 (Slc7a1 and Slc7a3), CD98 (Slc3a2), 
LAT1 (Slc7a5), y+LAT2 (Slc7a6) and the sodium-coupled AA transporters 
(SNAT)1 and 2 (Slc38a1 and Slc38a2). All of them, except Slc38a2, were 
substantially downregulated (Fig. 5.4B). In Fig. 5.4A, a schematic representation 
of some key T cell AA transporters and their substrates, as reviewed by Wang, 
W. and Zou (2020), is shown. 
In order to link the transcriptional changes to functional outcomes, I focussed on 
the activity of Slc7a5, of which expression was reduced almost by half (Fig. 5.4C). 
First, I measured the protein levels of CD98, which binds to Slc7a5 to form LAT1 
as well as to Slc7a6 to form y+LAT2 (Fig. 5.4A). Consistent with mRNA levels, 
CD98 was diminished by TGFb (Fig. 5.4D). Furthermore, I directly assessed the 
functionality of the Slc7a5/CD98 heterodimer based on the uptake of kynurenine, 
a tryptophan metabolite with self-fluorescent properties that enters the cell using 
this specific transporter (Sinclair et al., 2018) (Fig. 5.4A). As expected, kynurenine 
uptake and, therefore, Slc7a5-mediated AA uptake, was significantly suppressed 




Figure 5.4: TGFb disrupts upregulation of amino acid transporters and 
uptake of AAs into activated CD8+ T cells. 
(A) Schematic representation of main amino acid transporters and their functions 
in activated T lymphocytes. (B, C, D, E) OT-I T lymphocytes were stimulated in 
vitro for 24h (B, C) or 48h (D, E) with OVA-p (10-8M) ± TGFb. Unstimulated T cells 
(No TCR) were cultured in the presence of IL-7 and used as negative controls. 
mRNA levels (B, C) are from RNA-seq data (n=4). In (B), values represent 
log2(FC) and non-differentially expressed genes are indicated with (*). In (D), 
CD98 expression was assessed by FACS analysis. In (E), kynurenine uptake 
was assessed by FACS analysis upon incubation. Values in histogram represent 
geometric MFI. Dots represent biological (C) or technical (D) replicates. In (D, E), 
data is from one of at least three repeated experiments. ** - P<0.005, as 
determined by one-way ANOVA with Tukey’s multiple comparisons test. 
 
I next focused on the study of glutamine (Gln), the most consumed AA in 
activated T cells. In T cells, Gln uptake is mostly mediated by ASCT2, whilst TCR-














































































protein level by TGFb, although only significantly when primed with OVA-T4 (Fig. 
5.5B). Then, I further explored how TGFb affected the expression of enzymes 
involved in the multiple pathways by which Gln is utilised upon TCR-stimulation. 
RNA-seq data showed that enzymes involved in the conversion of Gln into 
intermediaries of the hexosamine pathway (Gfpt1) were not affected, whilst those 
associated with nucleotide synthesis (Pfas, Ppat, Cad) were significantly 
downregulated by TGFb (Fig. 5.5C). Furthermore, the synthesis of Asn mediated 
by ASNS, key to act as an exchange factor for the uptake of essential AAs (EAAs) 
in transformed cells (Krall et al., 2016) and potentially in T lymphocytes (Hope et 
al., 2020), was severely impaired (Fig. 5.5C). These EAAs exchanged for Asn 
support mTOR activation and prevent the expression of activation transcription 
factor 4 (ATF4), an stress-induced transcription factor regulated by nutrient 
deprivation (Yang et al., 2018). However, Atf4 was not induced, but instead 
repressed, in the presence of TGFb. Importantly, the expression of 
glutaminolysis-associated genes (Gls1, Gls2, Got1, Got2), the pathway that fuels 
the TCA cycle in the absence of glycolysis-derived pyruvate, was also diminished 
in TGFb-treated T cells (Fig. 5.5C). Glutamine-derived glutamate also acts as a 
substrate for glutathione (GSH) synthesis, but no alterations were shown in the 
enzymes that mediate this process (Fig. 5.5C). Altogether, this findings suggest 







Figure 5.5: TGFb impairs glutamine metabolism upon TCR-stimulation. 
(A) Schematic representation of glutamine fates in activated T lymphocytes. (B, 
C). OT-I T lymphocytes were stimulated in vitro for 24h (B, C) or 48h (D, E) with 
OVA-p (10-8M) ± TGFb. Unstimulated T cells (No TCR) were cultured in the 
presence of IL-7 and used as negative controls. In (B), ASCT2 expression was 
determined by FACS analysis. In (C), mRNA levels are from RNA-seq data (n=4). 
Values represent log2(FC) and non-differentially expressed genes are indicated 
with (*). Dots represent technical replicates. Data is from one of three repeated 
experiments. NS – Not significant; ** - P<0.005, as determined by one-way 
ANOVA with Tukey’s multiple comparisons test. 
 
5.2.4 TGFb restricts protein synthesis during CD8+ T cell activation 
Amino acid uptake is crucial to permit the high rates of protein synthesis required 
during T cell activation. The previous findings (Fig. 5.4 and 5.5), added to the fact 
that some of the most affected pathways by TGFb were associated with ribosome 
biogenesis and RNA transport (see Section 4.2.5), led to the hypothesis that 
TGFb could interfere with T cell activation through translational repression. Thus, 
I tested the ability of T cells to synthesise new proteins in the presence or absence 
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stimulation with OVA-N4, TGFb did not limit protein synthesis (Fig. 5.6). 
Nonetheless, OPP-incorporation in T cells stimulated with OVA-T4 was 
suppressed, suggesting that TGFb impedes T cell activation against weak 
agonists, at least in part, by limiting the translational program (Fig. 5.6). 
Figure 5.6: TGFb inhibits protein synthesis in CD8+ T cells. 
OT-I T lymphocytes were stimulated in vitro with OVA-p (10-8M) ± TGFb. 
Cycloheximide (CHX) was used as negative control. After 48h of TCR-
stimulation, protein synthesis was assessed by OPP incorporation, determined 
by FACS analysis. Dots represent technical replicates. Data is from one of three 
repeated experiments. NS – Not significant; * - P<0.05, as determined by one-
way ANOVA with Tukey’s multiple comparisons test. 
 
5.2.5 TGFb does not affect mTORC1 activity in CD8+ T lymphocytes 
Another key function of AAs is to maintain mTORC1 activity (Kelly and Pearce, 
2020; Wang, W. and Zou, 2020). Furthermore, recent investigations have 
reported that mTORC1 also senses the glycolytic metabolite DHAP to be active 
(Orozco et al., 2020). Also, previous research has stablished that TGFb 
suppresses mTOR activation in NK cells (Viel et al., 2016). Hence, I wondered 
whether defective AA and glucose uptake caused upon TGFb exposure (Fig. 
5.3C and 5.4E) would lead to a diminished mTORC1 activity. To address this 
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activity based on the phosphorylation of one of its substrates, the ribosomal 
protein S6. After 24h, I unexpectedly observed that in either OVA-N4 or OVA-T4-
stimulated T cells TGFb did not restrict S6 phosphorylation (Fig. 5.7A) indicating, 
therefore, that TGFb does not affect mTORC1 activity, at least, within the first 
24h of T cell activation. Consistently, the expression of Mtor, Rptor, Mlst8, Akt1s1 
and Deptor, components of the mTORC1 complex, was not altered by TGFb (Fig. 
5.7B). 
 
Figure 5.7: mTORC1 activity is not altered by TGFb in CD8+ T cells. 
OT-I T lymphocytes were stimulated in vitro with OVA-p (10-8M) ± TGFb for 24h. 
Unstimulated T cells (No TCR) were cultured in the presence of IL-7 and used as 
negative controls. After 24h of TCR-stimulation, phosphorylation of ribosomal 
protein S6 at sites Ser240/244 was quantified by intracellular staining and FACS 
analysis.  In (B), mRNA expression was assessed by RNA-seq (n=4). Values 
represent log2(FC) and non-differentially expressed genes are indicated with (*). 
Dots represent technical replicates. Data is from one of three repeated 
experiments. NS – Not significant, as determined by one-way ANOVA with 
Tukey’s multiple comparisons test.  
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5.2.6 TGFb-treated CD8+ T cells remodel mitochondrial metabolism 
So far, I investigated how TGFb affects the Myc/HIF1a-driven metabolism of 
glucose and AAs in activated CD8+ T cells but, how was TGFb modulating 
mitochondrial metabolism?  
T lymphocytes promote mitochondrial biogenesis within the first 24h of TCR-
stimulation in order to support the increased mitochondrial activity (Ron-Harel et 
al., 2016). Thus, I first analysed the expression of a panel of TFs that have been 
associated with the regulation of mitochondrial biogenesis including Tfam, 
Ppargc1, Pprc1, Nrip1, Gabpb1, Nrf1 and Esrra (ERRa). I saw that two of them, 
Tfam and Pprc1, which encode for MTFA and the PGC-1-related co-activator 
respectively, were significantly downregulated by TGFb. This data suggested, as 
previously reported in other immune cells (Zaiatz-Bittencourt et al., 2018; Dimeloe 
et al., 2019), that TGFb could suppress CD8+ T cell function through modulation 








Figure 5.8: The expression of mitochondrial biogenesis related genes 
varies upon TGFb treatment. 
OT-I T lymphocytes were stimulated in vitro for 24h with OVA-p (10-8M) ± TGFb. 
mRNA expression was assessed by RNA-seq (n=4).  
 
The effect of TGFb on the mitochondria has been generally associated with an 
OXPHOS deficiency (Zaiatz-Bittencourt et al., 2018; Dimeloe et al., 2019). Taking 
this into account, I focused on the study of this particular mitochondrial function. 
To study the consequences of TGFb treatment on OXPHOS activity I first looked 
at the expression of genes encoding for TCA cycle related enzymes, key to 
provide a high amount of the NADH and FADH2 utilised by the ETC to synthesise 
ATP (Fig. 5.9). As shown in Fig. 5.10, TGFb generally reduces their expression. 
However, the inhibition was rather mild with only Pck2, an enzyme that converts 
oxaloacetate into PEP and, therefore, not directly a TCA cycle enzyme, showing 
a FC > 2. Similarly, the expression of the ETC complex subunits were slightly 




































































































































































































example, mt-Co1, mt-Co2 and mt-Co3, which encode for the subunits of the 
cytochrome C oxidase (complex IV) were not repressed but rather increased in 
the presence of TGFb (Fig. 5.10).  











Figure 5.10: TGFb mildly affects TCA cycle and ETC associated gene 
expression.  
OT-I T lymphocytes were stimulated in vitro for 24h with OVA-p (10-8M) ± TGFb. 
mRNA expression was assessed by RNA-seq (n=4). Values represent log2(FC) 
and non-differentially expressed genes are indicated with (*). 
 
Next, I investigated how the transcriptional repression of the TCA cycle and ETC, 
added to Tfam and Pprc1 inhibition, translated to mitochondrial performance. 
Some key readouts of active ETC/OXPHOS include (1) ATP production mediated 
by the ATP synthase and (2) oxygen consumption mediated by the complex IV 
(Fig. 5.9). I hypothesised that, considering the transcriptomic data and the 
repression of mitochondrial metabolism in previous reports (Zaiatz-Bittencourt et 
al., 2018; Dimeloe et al., 2019), the oxygen consumption rate (OCR) and ATP 
synthesis would decline upon TGFb treatment. However, I unexpectedly 
observed that TGFb did not impair either ATP synthesis nor basal oxygen 
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consumption after 48h of TCR-stimulation, as assessed by a luminescent-based 
assay or using the Seahorse XFe96 analyser, respectively (Fig. 5.11A and B).  
Figure 5.11: TGFb does not alter ETC and OXPHOS activity of CD8+ T cells. 
OT-I T lymphocytes were stimulated in vitro for 48h with OVA-p (10-8M) ± TGFb. 
Unstimulated T cells (No TCR) were cultured in the presence of IL-7 and used as 
negative controls. (A) Basal oxygen consumption rates (OCR) were determined 
using the Seahorse XFe96 analyser. (B) ATP levels were quantified using a 
luminescence-based assay. Dots represent biological (A) or technical (B) 
replicates. In (A), data is pooled from two independent experiments and in (B) 
data is from one of four repeated experiments. NS – Not significant, as 
determined by one-way ANOVA with Tukey’s multiple comparisons test. 
 
5.2.7 TGFb alters lipid metabolism of activated CD8+ T lymphocytes 
I have previously shown that TGFb inhibited glucose and AA uptake (Fig. 5.3C 
and 5.4E). However, ATP production was not significantly affected by TGFb and 
I wondered whether TGFb-treated cells could use fatty acids as an alternative 
source to fuel energy production. Using the dye Bodipy-C16, I determined that 
fatty acid uptake  was also diminished in TGFb-treated T lymphocytes when 
stimulated with OVA-T4 during 48h, whilst no differences were observed in OVA-
N4-stimulated T cells (Fig. 5.12A). To further study how fatty acids were utilised, 
I looked into the RNA-seq data to analyse the expression of enzymes that 
mediate b-oxidation (Acadm, Echs1, Hadh, Acaa2) but no significant changes 






















































Acsbg1 were significantly upregulated by TGFb (Fig. 5.12B). Cpt1 mediates fatty 
acid translocation into the mitochondria, whereas the LCFA-CoA ligase ACBG1 
activates LCFAs by binding them to Acyl-CoA which leads to the initiation of b-
oxidation or the synthesis of more complex lipids. Whether Cpt1 and Acsbg1 
upregulation results in a more efficient utilisation of LCFAs in T cells needs to be 
further explored.  
 
Figure 5.12: TGFb modifies lipid metabolism in CD8+ T lymphocytes. 
OT-I T lymphocytes were stimulated in vitro for 24h (B) or 48h (A) with OVA-p 
(10-8M) ± TGFb. Unstimulated T cells (No TCR) were cultured in the presence of 
IL-7 and used as negative controls. (A) Fatty acid uptake was assessed using 
Bodipy-C16 followed by FACS staining. (B) mRNA expression was assessed by 
RNA-seq (n=4). Values represent log2(FC) and non-differentially expressed 
genes are indicated with (*). In (A), dots represent technical replicates. Data is 
from one of three repeated experiments. NS – Not significant; ** - P<0.005, as 










































In Chapter 4, I described that the metabolic transcriptome was severely affected 
by TGFb during early stages of T cell activation. Here, I have shown that those 
transcriptomic modifications ultimately translate into a deficient TCR-induced 
metabolic reprogramming that leads to poor T cell activation.  
First, the performed ChEA analysis unravelled that the Myc-driven transcriptional 
program, essential to initiate the metabolic reprogramming of T lymphocytes 
(Wang, R. et al., 2011; Marchingo et al., 2020), was one of the most altered by 
TGFb. These findings suggested, therefore, that Myc could be a central target of 
TGFb signalling to lead the suppression of T cell responses. In transformed cells, 
Myc repression has actually been described as a key event during the TGFb 
cytostatic response (Zhang, Y. et al., 2017). In fact, it is well established that 
Smad3 works in conjunction with E2F4/5 and p107 to directly bind the Myc 
promoter (Chen, C.R. et al., 2002). In regards to T lymphocytes, Thomas and 
Massagué (2005) have previously shown that, consistent with my results, Myc 
expression is downregulated by TGFb. However, the exact mechanisms and 
whether or not SMADs directly target Myc also in T lymphocytes remains to be 
elucidated.  
As discussed in the previous chapter, I believe that those markers repressed by 
TGFb irrespective of the strength of the TCR-stimulation are more likely to be 
direct SMAD targets, whilst those suppressed only against weak agonists are 
probably mediated by indirect mechanisms. Here, I have shown that Myc is 
inhibited in both OVA-N4 and OVA-T4 stimulated T cells suggesting therefore 
that Myc might be a SMAD target. However, it is important to consider that Myc 




earlier (Fig. 4.3), TGFb strongly inhibits IL-2 production also in both OVA-N4 and 
OVA-T4 stimulated T cells. Although I have shown that Myc repression also 
occurs regardless of IL-2 abundance, IL-2 replenishment had a modest effect on 
TGFb-mediated inhibition of Myc (Fig. 5.1D). These findings suggest that, despite 
not being the unique mechanism by which TGFb inhibits Myc, the lack of IL-2 
supposes an additional obstacle to its upregulation and, therefore, whether the 
effects observed in Myc expression in both OVA-N4 and OVA-T4 stimulations are 
due to SMAD-direct or other indirect mechanisms is still uncertain.  
The relatively modest inhibition of Myc expression as compared to granzyme B, 
a well-defined SMAD target gene, and the implications of other signals (e.g. IL-
2) in Myc expression suggest that other mechanisms besides the canonical 
TGFbR-SMAD pathway might be involved in its regulation. For example, 
investigations by Gu et al. (2015) have reported that Smad4 plays an essential 
TGFbR-independent role in the induction of T cell proliferation, a phenomenon 
that, interestingly, is mediated by Myc. In this study, they show that Smad4-
deficient T cells fail to optimally express Myc after activation, ultimately leading 
to defective proliferation. Thus, it is reasonable to speculate that the recruitment 
of Smad4 upon triggering of TGFb receptor signalling prevents Smad4-mediated 
regulation of Myc expression. Altogether, these findings indicate that much is to 
be discovered about the specific mechanisms by which TGFb controls Myc 
expression. Better understanding of these mechanisms may help to identify 
potential targets to revert the TGFb-mediated T cell suppression during anti-
tumour responses.  
Consistent with reduced Myc expression, Myc-driven T cell metabolic 




functional level, as shown by altered glucose and AA metabolism (Fig. 5.2-5). In 
the context of glucose metabolism, TGFb-treated T cells had reduced 2-NBDG 
uptake and glycolysis, an effect that was observed in both OVA-N4 and OVA-T4 
stimulated T cells (Fig. 5.3). This data coincides with the effects of TGFb on NK 
cells and CD4+ T cells (Viel et al., 2016; Zaiatz-Bittencourt et al., 2018; Dimeloe 
et al., 2019), although in these studies the glycolytic deficiency has not directly 
been associated with Myc repression.  
With regards to AA metabolism, a relevant finding in this chapter is the severe 
diminishment in the Slc7a5-mediated AA uptake, as assessed utilising the 
tryptophan metabolite kynurenine (Fig. 5.4). In T lymphocytes, Slc7a5 deficiency 
results in a metabolic catastrophe that leads to a complete impairment of 
activation (Sinclair et al., 2013). Furthermore, the effects observed in Slc7a5-null 
and Myc-null T cells upon TCR-stimulation highly overlap suggesting, therefore, 
that a great extent of the Myc-induced metabolic reprogramming is caused by the 
lack of Slc7a5 expression (Marchingo et al., 2020). My results indicate that 
Slc7a5 expression and subsequent AA uptake is highly compromised by TGFb, 
further reinforcing that the loss of Myc expression is a central event during the 
TGFb-mediated suppression of T cell responses.  
The engagement of glycolysis and the uptake of AAs during T cell activation is 
essential to sustain the elevated rates of protein synthesis required for growth 
and proliferation (MacIver et al., 2013; Buck et al., 2015; Buck et al., 2017; Geltink 
et al., 2018). Consistently with my previous results, I have further shown that 
protein synthesis is dampened by TGFb. Moreover, in Chapter 4 I also identified 




TGFb, implying that protein synthesis might not only be affected by the lack of 
substrates but also by the lack of translational machinery.  
An unexpected result observed in this chapter is the absence of altered mTOR 
activity. Considering that mTOR activation can be regulated by IL-2 and the 
abundance of AAs and glycolytic intermediates (Chapman and Chi, 2015; Orozco 
et al., 2020; Kelly and Pearce, 2020), seems surprising that the levels of pS6 are 
comparable in TGFb treated and untreated T cells. Furthermore, mTOR has been 
recognised as a key target of TGFb signalling in NK cells, where TGFb and 
rapamycin treatment share a very similar effect in NK function and metabolism 
(Viel et al., 2016). mTOR inactivation has also been shown in human CD4+ 
effector memory T cells (Dimeloe et al., 2019). On the contrary, Zaiatz-Bittencourt 
et al. (2018) demonstrated in human NK cells that mTOR inhibition is not the main 
mechanisms by which TGFb suppressed NK metabolism. In fact, they also 
showed that mTOR activity was not affected within the first 18h upon cytokine-
stimulation, but rather only during extended time periods (i.e. 5 days). Thus, I 
speculate that a similar scenario could occur in CD8+ T cells: whilst mTOR activity 
is unaltered within the first 24h, the lack of IL-2, glucose and AAs might provide 
a delayed mTOR inactivation that I have not observed in my assay. These results 
suggest that the metabolic deficiencies in T cells treated with TGFb are likely to 
be independent of mTOR activity, further validating the hypothesis of Myc 
repression being the major cause of the T cell metabolic paralysis.  
My findings have shown that CD8+ T cell mitochondrial metabolism was not 
impaired by TGFb. This data contradicts the consensus in previous studies that 
corroborates a TGFb-mediated inhibition of OXPHOS in other immune cells 




in CD4+ T cells, the loss of OXPHOS activity is directly mediated by the 
translocation of SMADs to the mitochondria (Dimeloe et al., 2019). However, we 
have to take into account the complexities of TGFb activity and compare my data 
with other studies with caution. Specifically, the reported findings by Dimeloe et 
al. (2019) do not directly study how TGFb impairs the metabolism of T cells during 
priming, but rather, they investigate the metabolism of activated effector memory 
CD4+ T cells. Considering that, in CD8+ T cells, Myc expression is transient and 
it is down-regulated after differentiation (Chou et al., 2014), it is possible that the 
effects of TGFb on metabolism will differ depending on the stage of the T cell 
response. In terms of the Myc-induced metabolic reprogramming during T cell 
priming, Myc upregulates aerobic glycolysis and glutaminolyisis whilst 
downregulating b-oxidation (Wang, R. et al., 2011). Thus, it is reasonable to think 
that, in my assays, TGFb-treated T cells may display higher rates of lipid oxidation 
as compared to controls, compensating for the lack of glucose and AAs and being 
sufficient to fuel mitochondrial metabolism. To test this hypothesis it will be of 
interest to perform a Seahorse Mito Fuel Flex Test, a metabolic assay that 
measures the capacity of cells to oxidise the three main mitochondrial fuels, i.e., 
glucose, glutamine and LCFAs. If confirmed, albeit being explanatory of my data, 
whether this mechanism will be sufficient to temporarily support T lymphocytes 
and overcome the TGFb-induced Myc repression is still unknown.  
An important aspect that I have not explored here is how TGFb-treatment affected 
other metabolic pathways beyond glycolysis and OXPHOS. In the previous 
chapter, KEGG pathway analysis of all DEGs showed that one-carbon 
metabolism is one of the most affected pathways by TGFb. Furthermore, when 




with a FC > 2, those involved in the metabolism of serine, glycine or methionine 
were the most downregulated. These genes include Cbs, Cth, Shmt1, Psat1, 
Mthfd2 or Phgdh and belong to the so-called SGOC metabolism, which has been 
proven as one of the key fates of glucose in vivo during the TCR-induced 
metabolic reprogramming and its engagement its essential to promote T cell 
differentiation and proliferation (Ma et al., 2017a; Ma et al., 2019). The 
upregulation of the proteins encoded by these genes upon TCR-priming is 
completely dampened in Myc KO T cells (http://www.immpres.co.uk), suggesting 
that Myc is an important regulator of SGOC metabolism. Further exploring the 
impact of TGFb on SGOC metabolism will be of high interest to better 
comprehend the mechanisms by which the loss of Myc expression inhibits CD8+ 
T cell activation. 
Altogether, the findings in this chapter robustly confirm a TGFb-mediated 
suppression of T cell metabolism. Mechanistically, TGFb represses the 
expression of the key metabolic transcription factor Myc, resulting in an 
inadequate metabolic reprogramming during TCR-priming characterised by a 
poor engagement of aerobic glycolysis, Slc7a5-mediated AA transport and 
protein synthesis that ultimately leads to a deficient activation of CD8+ T cells. 
These results provide valuable new understanding on the mechanisms that 
regulate TGFb-mediated suppression and shed light into the attenuation of the T 
cell metabolic loss of motion as a potential target for TGFb resistance and 







Chapter 6 The role of asparagine in T cell 
function 
6.1 Introduction 
Another key environmental determinant of T cell activation, in addition to signals 
1, 2 and 3 and the cytokine milieu, is the availability of nutrients. Particularly, 
amino acids are highly demanded by activated T lymphocytes to sustain growth, 
proliferation and differentiation (Sinclair et al., 2013; Kelly and Pearce, 2020). The 
non-essential AA asparagine (Asn) can be intracellularly synthesised via 
asparagine synthetase (ASNS), an enzyme that catalyses the conversion of 
glutamine (Gln) and aspartate (Asp) into Asn and glutamate (Glu) (Lomelino et 
al., 2017). The role of Asn metabolism in cancer has been extensively studied, 
where it has been defined as a potential target due to its role in tumour growth 
and metastasis (Zhang, Ji et al., 2014; Krall et al., 2016; Knott et al., 2018). In 
fact, high ASNS expression is associated with poor prognosis in several cancer 
types (Lomelino et al., 2017; Chiu et al., 2020). Furthermore, asparaginases 
(ASNases), which break down Asn into Asp, have been widely used in the clinic 
as a chemotherapeutic adjuvant for the treatment of acute lymphoblastic 
leukaemia (ALL) (Lomelino et al., 2017; Chiu et al., 2020). A hallmark of ALL 
blasts is that they rely on an extracellular source of Asn due to the lack of ASNS 
expression. The action of ASNases deprives the cells of an extracellular source 
of Asn leading to a severe lack of Asn that results in cell death (Chiu et al., 2020).  
The role of Asn and ASNS in immune responses remains largely unknown. 
Torres et al. (2016) described that treating naïve T cells with Salmonella-derived 
ASNases suppresses exit from quiescence upon TCR-priming implying that T 




glutaminase activity (Lomelino et al., 2017; Zhu, W. et al., 2019) and, therefore, 
whether the effects are caused by the extracellular deprivation of Asn or Gln is 
uncertain. Moreover, it is not well described whether ASNS is expressed in T 
lymphocytes and, if so, at which stage of activation this occurs. Thus, the 
implications of Asn-deprivation in the development of T cell responses is still 
unclear. In this chapter, I aim to: 
1. Define the levels of ASNS expression in CD8+ T lymphocytes. 
2. Assess the requirements for extracellular Asn in CD8+ T cell survival and 
growth. 
3. Assess the requirements for extracellular Asn in CD8+ T cell activation, 
proliferation and acquisition of effector functions. 
4. Determine the impact of Asn-deprivation on the TCR-induced metabolic 
reprogramming of CD8+ T cells. 
5. Investigate the demands for extracellular Asn in CTL cytokine secretion. 













6.2.1 ASNS expression is upregulated after TCR-stimulation 
First of all, our group (Robert J. Salmond and Lynette P. Steele, University of 
Leeds) investigated ASNS expression in T cell subsets and showed that ASNS 
was not present either in thymocytes nor naïve T cells. However, ASNS 
expression was highly increased after 24h of TCR-stimulation in an mTOR-
dependent manner (Fig. 6.1) (Hope et al., 2020).  
 
Figure 6.1: Naïve CD8+ T lymphocytes do not express ASNS but it is highly 
upregulated upon TCR-stimulation. 
On the left, western blots show ASNS protein levels in lysates from OT-I 
thymocytes, naïve T cells or T cells activated in nutrient-replete conditions with 
OVA-peptide ± rapamycin (Rap) ±  Myc inhibitor (Myci) for the indicated time-
points. b-actin serves as a control for protein loading. On the right, bar graph 
representation of ASNS expression (ASNS/b-actin). Data is representative of two 
independent experiments. 
 
These findings led to the hypothesis that, whereas Asn availability would 
significantly limit early T cell activation, the Asn requirements would diminish as 
long as ASNS was upregulated. Hence, I designed a time-course experiment to 
explore the effects of Asn-deprivation during both ASNS-low (24h) and ASNS-
high (48h, 72h) stages. To do so, naïve OT-I T cells were stimulated in vitro with 




approach allowed us to (1) comprehend the importance of ASNS contribution to 
the Asn pool, (2) differentiate the effects of the deprivation of both AAs (as 
assessed in previous publications that used ASNases) vs Asn alone and (3) test 
the interplay between Gln and Asn to promote survival, a phenomenon already 
observed in transformed cells (Zhang, Ji et al., 2014). After appropriate 
stimulation, the repercussion of Asn-depletion on T cell survival, growth, 
activation, proliferation and metabolism was assessed. 
6.2.2 Asn availability determines survival and growth of CD8+ T 
lymphocytes upon TCR-stimulation. 
Amino acid deprivation induces a stress response mediated by GCN2 and ATF4 
that leads to apoptosis when AA availability is not restored (Balasubramanian et 
al., 2013; Yang et al., 2018). Thus, I first tested how Asn deprivation affected the 
survival of CD8+ T lymphocytes.  
After 24h of culture, as assessed using the viability dye LD Aqua, only 50% of the 
T cells stimulated in the absence of Asn were alive (Fig. 6.2). Similarly, TCR 
stimulation in the absence of Gln highly induced T cell death, whilst the combined 
absence of both AAs had detrimental effects and T cell viability was reduced by 
90% (Fig. 6.2). After 72h, >80% of the T cells stimulated without Gln were dead. 
However, no significant differences were observed between those T cells 
cultured in replete media conditions and those lacking Asn, suggesting that the 
latter were able to overcome the initial stress response seen at earlier timepoints 





Figure 6.2: Asn-deprivation induces cell death of CD8+ T lymphocytes 
during early stages of activation. 
OT-I T cells were stimulated in DMEM ± Asn ± Gln with OVA-peptide for 24 (left), 
48 (middle) or 72 (right) hours. Cell viability is represented as assessed by FACS 
and LD Aqua staining. Data is from one of three repeated experiments. Dots 
represent technical triplicates. NS – Not significant; **** - P<0.0001, as 
determined by one-way ANOVA with Tukey’s multiple comparisons test. 
 
Next, I examined the blasting capacity of T cells. As determined by flow cytometry 
and analysis of FSC-A/SSC-A plots, the majority of viable T cells (70-80%) had 
blasted after 24h of TCR-stimulation when both AAs were present whereas only 
a small proportion (20-30%) grew in Asn-deprived conditions (Fig. 6.3A and B). 
At 48h, around 70-80% of the live cells in the ‘No Asn’ conditions displayed a 
blast phenotype which was observed in all T cells after 72h (Fig. 6.3A and B). 
Without Gln, despite a proportion of the cells (40%) being able to survive within 
the first 48h, T cell growth was totally impaired at all timepoints (Fig. 6.3B). As 
AAs are building blocks for protein synthesis (Kelly and Pearce, 2020), I 
questioned how the lack of extracellular Asn affected this process. As measured 
by OPP incorporation, protein synthesis was severely disrupted after 24h of 






















































































differences were seen when comparing ‘No Asn’ and ‘No Gln’ conditions. 
However,  a small proportion of T cells under Asn-depleted conditions showed 
higher rates (similar to control cells) of newly synthesised proteins, a 
characteristic that was not observed without Gln (Fig. 6.4). This intermediate 
phenotype is comparable to previous results indicating that T cells stimulated in 
an Asn-deprived environment are unable to optimally initiate blastogenesis due 
to an incapacity to engage protein synthesis.  
 
Figure 6.3: Asn-deprivation disrupts blastogenesis within the first stages 
of CD8+ T cell activation. 
OT-I T cells were stimulated in DMEM ± Asn ± Gln with OVA-peptide for the 
indicated time-points. (A) Blasting population is gated as determined by cell size. 
(B) Bar chart represents summarised data of the proportion of T cells that have 
undergone blastogenesis at the indicated conditions and time-points. Data is from 
one of three repeated experiments. Error bars represent SD (N=3). NS – Not 






































Figure 6.4: The lack of extracellular Asn limits de novo protein synthesis in 
early activated CD8+ T lymphocytes. 
OT-I T cells were stimulated in DMEM ± Asn ± Gln with OVA-peptide for 24 hours. 
Protein synthesis capacity is represented as assessed by OPP incorporation and 
subsequent detection using Click-iTÔ reagents. Cycloheximide (CHX), a protein 
synthesis inhibitor, was utilised as negative control. Data is from one of three 
repeated experiments. Dots represent technical triplicates. NS – Not significant; 
** - P<0.005, as determined by one-way ANOVA with Tukey’s multiple 
comparisons test. 
 
6.2.3 CD8+ T cells are poorly activated in the absence of Asn 
To better understand how the lack of extracellular Asn affected antigen-induced 
responses I investigated the activation state of T lymphocytes. After 24-72h of 
TCR-stimulation, the expression of the activation markers CD25, CD69 and CD71 
was assessed. Upon 24h of antigen encounter, CD25 and CD71 upregulation 
was severely impaired in Asn-free conditions when compared to control but, 
interestingly, no effect was observed in CD69 expression despite the lack of Asn 
and/or Gln (Fig. 6.5A). Whereas most of the cells were CD25+CD71+ in AA replete 
media conditions at this time-point, only ~30% expressed both markers when Asn 
was absent (Fig. 6.5B). Nonetheless, at 72h, T cells lacking extracellular Asn 
were able to acquire a fully activated state comparable to those T cells grown 
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with both Gln and Asn (Fig. 6.5A and B). Without Gln, no upregulation of CD25 
was seen at any stage (Fig. 6.5A and B). However, a reduced but consistent level 
of CD71 expression was observed at 24h in all T cells stimulated in the absence 
of Gln (Fig. 6.5C).  
 
Figure 6.5: The lack of Asn compromises early T cell activation. 
OT-I T cells were stimulated in DMEM ± Asn ± Gln with OVA-peptide for the 
indicated time-points. (A) Summarised data representing CD25+, CD69+ and 
CD71hi T lymphocytes at the indicated time-points and condition, as assessed by 
FACS analysis in live gated cells. (B) Proportion of T cells expressing the 
activation markers CD25 and CD71. (C)  Histogram shows cell surface 
expression of CD71 after 24h of TCR-stimulation. Data is from one of three 
repeated experiments. Error bars represent SD. NS – Not significant; **** - 
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Similar phenotypes were observed when I assessed the levels of the transcription 
factors Eomes and Tbet (Fig. 6.6): whereas the absence of Gln completely 
suppressed their upregulation at all timepoints, Asn-depletion was suppressive 
only at early stages but T cells recovered upon longer antigen-stimulation. 
Consistently, the lack of Asn significantly reduced the proportion of GrB+ T cells 
within the first 48h, an effect that withdrew at 72h (Fig. 6.7). GrB levels were not 
tested at 24h due to its low or null expression at early time-points. It is important 
to highlight that, at 24h (or 48h for GrB), although a proportion of T cells 
upregulated the different markers in the absence of Asn, their expression levels 
tend to be lower than those seen in complete conditions when analysed at a 







Figure 6.6: Asn-depletion delays the upregulation of Tbet and Eomes. 
OT-I T cells were stimulated in DMEM ± Asn ± Gln with OVA-peptide for the 
indicated time-points. (A) Histogram shows intracellular expression of Tbet and 
Eomes after 24h of TCR-stimulation. (B) Summarised data representing Tbet+ 
and Eomes+  T lymphocytes at the indicated time-points and condition, as 
assessed by FACS analysis in live gated cells. Data is from one of three repeated 
experiments. Error bars represent SD. NS – Not significant; **** - P<0.0001, as 
determined by two-way ANOVA with multiple comparisons. 
 
























































Figure 6.7: The absence of extracellular Asn restricts granzyme B 
expression. 
OT-I T cells were stimulated in DMEM ± Asn ± Gln with OVA-peptide for 48 or 72 
hours, as indicated. Representative histograms of GrB expression (left) and the 
proportion of GrB+ T cells (middle) were determined by FACS analysis. 
Intracellular levels of GrB were quantified as assessed by mean fluorescence 
intensity (MFI). Data is from one of three repeated experiments. Dots represent 
technical triplicates. NS – Not significant; ** - P<0.005, as determined by one-
way ANOVA with Tukey’s multiple comparisons test. 
 
Additionally, I showed, as measured by dilution of the CTV dye, that TCR-induced 
T cell proliferation was completely blocked in the absence of extracellular Gln but 
not without Asn, where >70% of T lymphocytes were able to initiate cell division 
after 72h of stimulation (Fig. 6.8A and B). Nonetheless, T lymphocytes cultured 
in Asn-deprived conditions displayed a reduced division index (~1 vs ~1.5 in 
control T cells) (Fig. 6.8C). Whereas the majority of the cells had undergone 2 or 
3 divisions in control conditions only 30-40% of T cells were at this stage in the 
72h 
48h 
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absence of Asn (Fig. 6.8D) indicating a slower rate or delayed initiation of 
proliferation.  
Figure 6.8: Antigen-induced CD8+ T cell proliferation is impaired by the 
absence of extracellular Asn. 
OT-I T cells were stimulated in DMEM ± Asn ± Gln with OVA-peptide for 72 hours. 
Proliferative capacity was assessed by Cell Trace Violet (CTV) labelling of naïve 
T cells. Data is from one of three repeated experiments. Dots represent technical 
triplicates. NS – Not significant; **** - P<0.0001, as determined by one-way 
ANOVA with Tukey’s multiple comparisons test. 
 
Altogether, my findings indicate that Asn-deprivation compromises proliferation 
as well as the upregulation of activation markers, transcription factors and effector 
proteins during early stages upon TCR-stimulation. Nonetheless, and 
consistently with previous results (see Section 6.2.2), lymphocytes are able to 














































































overcome these effects and ultimately acquire a fully activated state comparable 
to control cells.  
6.2.4 CD8+ T lymphocytes are unable to optimally engage antigen-
induced metabolic reprogramming in the absence of 
extracellular asparagine 
To further comprehend the mechanisms underlying defective early activation in 
the absence of extracellular Asn, I investigated the implications of Asn-
deprivation on TCR-induced metabolic reprogramming. When measured at 24h 
of  activation, TCR-induced expression of nutrient transporters was decreased in 
the absence of Asn and, consequently, nutrient uptake was substantially 
reduced. Specifically, only 50% of T cells upregulated GLUT1 whilst almost 80% 
expressed the glucose transporter in control conditions (Fig. 6.9A). These results 
were mirrored in the reduced ability of T cells to take up the fluorescent glucose 
analogue 2-NBDG in conditions lacking Asn (Fig. 6.10A). Similarly, the 
upregulation of the scavenger receptor CD36 and amino acid transporter CD98 
was inhibited (Fig. 6.9B and C). Consequently, the uptake of AAs mediated by 
Slc7a5 and free fatty acids was severely impaired, as determined by the import 
of kynurenine and Bodipy-C16, respectively (Fig. 6.10B and C). The lack of 
extracellular Gln completely prevented GLUT1, CD98 and CD36 upregulation, 
leading to a failure to uptake nutrients (Fig. 6.9 and 6.10). To be noted, Gln-
depletion suppressed CD98 expression more profoundly than Asn-deprivation 
did, an effect that was not reflected in the kynurenine assay, which revealed no 




Figure 6.9: The lack of extracellular Asn limits the upregulation of the 
nutrient transporters GLUT1, CD98 and CD36 after TCR-stimulation. 
OT-I T cells were stimulated in DMEM ± Asn ± Gln with OVA-peptide. After 24h, 
GLUT1, CD98 and CD36 was determined by FACS analysis using conjugated 
antibodies. Data is from one of three repeated experiments. Dots represent 
technical triplicates. NS – Not significant; **** - P<0.0001; ** - P<0.005; * - P<0.05, 
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Figure 6.10: CD8+ T lymphocytes display reduced nutrient uptake when 
stimulated in the absence of extracellular Asn. 
OT-I T cells were stimulated in DMEM ± Asn ± Gln with OVA-peptide. After 24h, 
T cells were cultured with 2-NBDG, Bodipy-C16 or kynurenine to evaluate 
glucose (A), free FA (B) and Slc7a5-mediated AA uptake (C), respectively, by 
FACS analysis. Data is from one of three repeated experiments. Dots represent 
technical triplicates. NS – Not significant; **** - P<0.0001; *** - P<0.0005; * - 










































































































Next, I analysed OCR and ECAR values in T cells stimulated ± Asn to define their 
metabolic activity. Results indicated that T cells maintained in the absence of Asn 
were inefficient in engaging glycolysis and OXPHOS as indicated by reduced 
acidification and oxygen consumption, respectively (Fig. 6.11A). Lymphocytes 
stimulated without Asn displayed a quiescent phenotype when compared to 
control cells which exhibited an energetic phenotype characterised by elevated 
ECAR and OCR values (Fig. 6.11B). Consistent with these data, their ability to 
synthesise ATP was severely compromised, to the same extent as in Gln-







Figure 6.11: CD8+ T lymphocytes are unable to increase their metabolic 
activity after TCR-stimulation in Asn-deprived conditions. 
OT-I T cells were stimulated in DMEM ± Asn ± Gln with OVA-peptide for 24h.    
(A, B) ECAR and OCR were determined utilising Seahorse XFe96 metabolic 
analyser. (C) ATP synthesis capacity was tested using a luminescence-based 
assay. Data is from one of two (A, B) or three (C) repeated experiments. In (A, 
C), dots represent technical replicates. In (B), dots represent mean values. Error 
bars indicate SD. NS – Not significant; **** - P<0.0001, as determined by two-
tailed Student’s t-test or one-way ANOVA with Tukey’s multiple comparisons test, 
as appropriate. 
 
I wondered whether upon prolonged responses, consistent with previous results 
(see Section 6.2.2 and 6.2.3), T cells were ultimately capable of undergoing 
efficient metabolic reprogramming. As expected, T lymphocytes stimulated with 
OVA-peptide for 72h in the absence of Asn displayed a metabolic profile 
comparable to control cells. No differences were observed with respect to 2NBDG 
and Bodipy-C16 uptake or ATP production between those T cells activated in 
nutrient-replete and Asn-deprived conditions (Fig. 6.12) confirming that, upon 































































































prolonged stimulation, lymphocytes are able to complete the metabolic 
reprogramming regardless of extracellular Asn levels. 
Figure 6.12: CD8+ T lymphocytes are able to undergo the TCR-induced 
metabolic reprogramming at later stages regardless of extracellular Asn 
levels. 
OT-I T cells were stimulated in DMEM ± Asn with OVA-peptide for 72h. Then, 2-
NBDG uptake (left), Bodipy-C16 uptake (middle) and ATP production (right) was 
assessed. Data is from one of at least two repeated experiments. Dots represent 
technical replicates. Error bars indicate SD. NS – Not significant, as determined 
using Mann-Whitney’s test. 
 
6.2.5 ASNS upregulation is required, and sufficient, to sustain CD8+ 
T cell responses in the absence of extracellular Asn 
Altogether, these findings indicated that extracellular Asn was required by naïve 
CD8+ T lymphocytes within the first stages of activation. The lack of extracellular 
Asn restricted de novo protein synthesis resulting in high rates of cell death added 
to an incapacity to successfully engage the metabolic reprogramming that 
sustains blastogenesis, activation and proliferation. However, no phenotypic 
differences were observed at later time-points when comparing Asn-deprived and 
control conditions suggesting that CD8+ T cells lose its requirement for Asn upon 






























































CD8+ T cells sharply increase ASNS expression after 24h of TCR-stimulation 
(Fig. 6.1) (Hope et al., 2020). Thus, our group reasoned that the mechanism by 
which T cells were able to overcome the inefficient initial response was due to an 
emergent ASNS-derived source of Asn. To verify this interpretation, we used a 
genetically-modified AsnsTm1a mouse model. This strain contains an hypomorphic 
Asns allele that reduces >90% or ~60% of ASNS protein levels in homozygous 
and heterozygous mice, respectively (Fig. 6.13A). As expected, AsnsTm1a/Tm1a  
CD8+ T lymphocytes stimulated in Asn-free media were incapable to induce 
blastogenesis after 24h of stimulation (Fig. 6.13B). On the other hand, and 
consistent with previous results (Fig. 6.3), a proportion of AsnsWT/WT T cells was 
able to initiate blastogenesis in spite of Asn-deprivation (Fig. 6.13B). These 
results point out at ASNS expression as the fundamental event that allows T cell 
activation in the absence of Asn indicating that ASNS upregulation is sufficient to 
sustain CD8+ T cell responses (Hope et al., 2020). All the data included in Fig. 
6.14 was generated by other members in our laboratory (Robert J. Salmond and 





Figure 6.13: AsnsTm1a/Tm1a  CD8+ T lymphocytes are unable to undergo 
blastogenesis in the absence of extracellular Asn. 
(A) Immunoblot analysis of ASNS levels in AsnsWT/WT, AsnsWT/Tm1a  and 
AsnsTm1a/Tm1a activated T cells ± rapamycin (Rap). (B) AsnsWT/WT  and 
AsnsTm1a/Tm1a  CD8+ T cells were MACS-sorted and stimulated in vitro with aCD3 
and aCD28. After 24h of stimulation in DMEM ± Asn ± Gln, blasts were detected 
by FACS analysis with FSC/SSC plots.  
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6.2.6 The potency of TCR ligands determines survival and T cell 
activation in Asn-depleted environments 
As mentioned above, the progression of antigen-induced responses in the 
absence of extracellular Asn is dependent on ASNS upregulation (Hope et al., 
2020). So far, all experiments were performed using the high affinity OVA-peptide 
N4 for TCR-stimulation. However, the response rate of CD8+ T cells depends on 
ligand potency (Richard et al., 2018). Hence, I hypothesised that under 
suboptimal TCR-stimulation scenarios fewer T cells would be able to trigger 
ASNS upregulation and, therefore, to survive and differentiate in Asn-depleted 
conditions. To address this question I stimulated OT-I T cells with the lower 
affinity OVA-peptide T4 and saw that, when Asn was absent, <20% of the cells 
survived vs 40% in OVA-N4-stimulated T lymphocytes (Fig. 6.14A). Moreover, 
their activation state was clearly compromised as the lack of Asn reduced the 
proportion of CD25+CD71+ T cells from a 45% to a 15% in OVA-N4 vs OVA-T4 
stimulated cells (Fig. 6.14B). Although cell survival was not affected, CD25 and 
CD71 expression was proportionally impaired in nutrient-replete conditions when 
decreasing ligand potency (Fig. 6.14B). Thus, my data suggest that antigen 





Figure 6.14: CD8+ T cell responses in Asn-deprived environments are 
limited by peptide affinity. 
OT-I T cells were stimulated in DMEM ± Asn ± Gln with OVA-N4 or the lower 
affinity peptide OVA-T4. After 24h, cell viability (A) and cell surface expression of 
the activation markers CD25 and CD71 (B) were assessed by FACS analysis. 
Error bars represent SD. NS – Not significant; **** - P<0.0001; ** - P<0.005, as 
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6.2.7 Lack of extracellular asparagine suppresses early T cell 
activation independently of the loss of IL-2 secretion  
Previous results in our group revealed that the lack of extracellular Asn severely 
suppresses IL-2 production within the first 24h (Hope et al., 2020). IL-2 signalling 
is associated to a complex transduction network that induces protein synthesis 
and an effector-like transcriptional program (Ross and Cantrell, 2018; Rollings et 
al., 2018). Hence, I questioned if the effects seen under Asn-deprivation 
circumstances could be partially caused by the loss of autocrine IL-2 signalling. 
OT-I T lymphocytes were stimulated as described above + IL-2 supplementation 
from timepoint 0h. My data established that IL-2 replenishment did not sustain 
survival when Asn and/or Gln were absent (Fig. 6.15A). Equally, the levels of GrB 
or the activation markers CD25 and CD71 were not rescued by IL-2 (Fig. 6.15, B 
and C) indicating that the impact of Asn-depletion on these parameters is 




Figure 6.15: IL-2 replenishment does not rescue CD8+ T cell function in the 
absence of extracellular Asn. 
OT-I T cells were stimulated in DMEM ± Asn ± Gln with OVA-N4 ± hIL-2 (1ng/ml). 
After 24h, cell viability (A) and expression of GrB (B) and the activation markers 
CD25 and CD71 (C) were assessed by FACS analysis. Data is from one of three 
repeated experiments. Error bars represent SD (N=3). NS – Not significant, as 
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6.2.8 CTLs are not asparagine auxotrophs 
ASNS upregulation was key to promote CD8+ T cell differentiation in the absence 
of extracellular Asn (Hope et al., 2020) but whether or not its expression was 
enough to sustain the function of fully differentiated CTLs was unclear. To 
address this question I generated OT-I CTLs in vitro in IMDM (nutrient-rich 
conditions) and re-stimulated them after 6 days in Asn-free media. To be noted, 
CTLs were transferred on day 5 to media lacking Asn to ensure depletion of 
intracellular Asn levels at the moment of re-stimulation. After 24h, CTLs 
maintained in replete and Asn-deprived conditions displayed the same levels of 
IFNg and IL-2 secretion (Fig. 6.16) suggesting that ASNS upregulation is 
sufficient to sustain CTL function regardless of extracellular Asn availability. 
Thus, CD8+ T lymphocytes were not Asn auxotrophs. 
Figure 6.16: CTLs do not require extracellular Asn to sustain IFNg and IL-2  
secretion. 
CTLs were generated in vitro during 5d in IMDM, then transferred DMEM ± Asn 
for 24h. On day 6, CTLs were re-stimulated with OVA-peptide for 24h and levels 
of IFNg and IL-2 in supernatants were determined by ELISA. Data is from one of 
at least two repeated experiments. Dots represent technical replicates. NS – Not 

























































6.2.9 ASNS-deficiency does not affect IgM and IgG secretion by 
plasma cells after in vivo immunisation 
To further understand the role of Asn synthesis during immune responses I 
explored the phenotype of AsnsTm1a mice beyond the development of effector T 
lymphocytes. In order to do it, and in vivo immunisation with the hapten 4-
Hydroxy-3-nitrophenyilacetyl (NP) conjugated to OVA, which acted as a carrier 
protein, was performed.  NP-OVA immunisation provides T-cell dependent 
formation of germinal centres and class-switched, affinity matured NP-specific 
antibodies. AsnsWT/WT  AsnsWT/Tm1a  and AsnsTm1a/Tm1a were injected with NP-OVA 
emulsified in alum, a common vaccine adjuvant, on day 0 and boosted on day 35 
to induce primary and memory responses, respectively. After 13 and 43 days, 
blood samples were collected to quantify hapten-specific IgM and IgG levels in 
serum. IgM and IgG antibodies were detected on day 13 but, surprisingly, all mice 
displayed comparable levels regardless of their genotype (Fig. 6.17). 
Consistently, IgM and IgG secretion did not seem to be altered by the lack of 
ASNS when analysed on day 43 (Fig. 6.17). Thus, these results suggest that the  
amounts of Asn in SLOs and the BM are sufficient to sustain antibody secretion 
in spite of ASNS-deficiency.  
To be noted, all in vivo work (i.e. NP-OVA injections and collection of blood 





Figure 6.17: Secretion of IgM and IgG upon NP-OVA immunisation is not 
affected in ASNS-deficient mice. 
AsnsWT/WT (n=3), AsnsWT/Tm1a (n=12) and AsnsTm1a/Tm1a (n=4) littermate mice were 
injected i.p. with NP-OVA in alum on day 0 and 35. Mice were bled on day 13 and 
43. Serum IgM (left) and IgG (right) levels on day 13 (top) or 43 (bottom) were 
quantified using NP-specific ELISAs and EC50 values calculated by non-linear 
regression analysis. Dots represent biological replicates. NS – Not significant; * - 






























































































































































Antigen-induced T cell responses are driven by a metabolic reprogramming that 
sustains growth, clonal expansion and differentiation. One of the major events 
that occurs upon TCR-stimulation is an increase in nutrient uptake, including AAs. 
In this chapter, I have unravelled the importance of Asn uptake in the acquisition 
of a fully differentiated T cell effector phenotype. I have shown that Asn availability 
is required within the first stages of activation but, upon ASNS upregulation, CD8+ 
T lymphocytes are able to respond independently of extracellular Asn levels.  
Previous investigations reported that Asn deprivation generated by bacterial 
ASNases, which also have glutaminase activity, inhibits T cell activation (Kullas 
et al., 2012; Torres et al., 2016). My results endorse these studies and utilises a 
methodology that excludes ASNase-induced Gln-depletion as a possible 
suppressive mechanism in this scenario. Furthermore, my approach provides 
insight on the interplay between Gln and Asn to foster CD8+ T cell responses. 
Studies performed in transformed cells have stablished that Asn plays an 
important role promoting survival when Gln is absent (Zhang, Ji et al., 2014). My 
data shows that, within the first 24h upon TCR-stimulation, the lack of both AAs 
is detrimental whilst Asn supplementation partially protects from the Gln-
depletion induced cell death and vice versa, supporting this hypothesis also in T 
lymphocytes. Further, Gln enrichment is indispensable to initiate T cell activation 
in the absence of Asn indicating that Asn production via ASNS might be an 
important Gln contribution during T cell responses in addition to protein synthesis, 
anaplerosis or maintenance of redox balance (Kelly and Pearce, 2020).  
Unlike previous reports, my data elucidates the importance of Asn availability 
beyond early T cell activation. I have shown that, as the antigen-induced T cell 




extracellular Asn. Indeed, T cells successfully differentiate into CTLs even when 
Asn is absent (Hope et al., 2020). In this context, I have provided evidence to 
confirm that ASNS upregulation is sufficient to maintain T cell activation, 
differentiation and effector functions. Although this suggests that extracellular 
Asn is not essential in CD8+ T cell responses, it is important to consider that the 
lack of Asn might limit the magnitude of the response. The majority of viable T 
cells upon 24h of TCR-stimulation without Asn represent a non-blasting 
population that disappears at later timepoints. The lack of phenotypic differences 
observed after 72h between T cells cultured in nutrient-complete and Asn-
deprived conditions could be interpreted in two ways: (1) the non-blasting 
population is initially negative for ASNS, which is subsequently upregulated 
leading to a delayed blastogenesis, or (2) the non-blasting population is incapable 
to promote ASNS expression and eventually prompts cell death. The latter would 
imply an early all-or-none response where only the small blasting population 
observed at 24h in Asn-deprived conditions (~30%) would ultimately become 
CTLs. Considering that 50% of the cells have undergone apoptosis at this 
timepoint, just ~15% of the whole initial population would be able to actually 
respond, indicating that the lack of extracellular Asn diminishes the probability of 
a T cell to get activated. To elucidate the fate of the non-blasting population it will 
be of interest to sort these cells and further study their potential phenotype, i.e., 
whether they undergo differentiation, cell death or both. It is important to highlight 
that these hypotheses are under the assumption that non-blasting cells do not 
express ASNS. I believe that the lack of blastogenesis is associated to a protein 
synthesis deficit that can only be rescued when ASNS is upregulated. The 
rationale behind this interpretation relies on our experiments performed with 




prevents the formation of the blasting population in Asn-free media. However, 
investigating ASNS levels in non-blasting vs blasting cells upon sorting is still 
required for confirmation. 
The impairment of T cell activation by Asn-depletion and its implications in vivo 
are unclear. It is well stablished that the magnitude of primary T cell responses is 
dictated by the amount and duration of antigen presentation by APCs within 
secondary lymphoid organs. Moreover, it has been suggested that the size of the 
naïve T cell population that responds to antigen is also an important factor 
(Jenkins and Moon, 2012). Hence, as fewer T cells respond under Asn-deprived 
conditions, it is possible that the absence of Asn represents a further limiting 
factor of T cell responses. Also, we have to contemplate that in vivo environments 
are less favourable than my reductionist in vitro conditions, which can entail an 
additional obstacle for successful T cell responses when Asn is absent. In fact, 
my results showed that T cell activation is even more suppressed in Asn-free 
media when stimulated with the lower-affinity peptide OVA-T4. Thus, Asn 
availability might represent an extra piece into the complex inner workings that 
determines the extent of CD8+ T cell responses.  
Nonetheless, it is undescribed at the moment physiological situations in which 
the Asn levels drop within secondary lymphoid organs. Only the action of 
ASNases, produced either by bacterial pathogens or following parenteral 
administration, reduce the concentration of Asn in blood (Bunpo et al., 2008; 
Kullas et al., 2012; Knott et al., 2018). Both scenarios have been associated with 
dysfunctional immune responses (Kafkewitz and Bendich, 1983; Kullas et al., 
2012; Hijiya and van der Sluis, 2016; Song et al., 2017). However, no evidence 
directly links immunosuppression with the inhibition of T cell activation within 




as the development of precursors in the bone marrow, could be altered by 
ASNases (Friedman, 1971; Bunpo et al., 2008; Hijiya and van der Sluis, 2016). 
Furthermore, it is likely that the intrinsic glutaminase activity of ASNases 
significantly contributes to its deleterious effects (Durden and Distasio, 1981; 
Kafkewitz and Bendich, 1983; Bunpo et al., 2008; Nguyen et al., 2018) and, 
therefore, whether Asn-depletion induces immunosuppression is still under 
debate. The development of glutaminase-free ASNases will elucidate the impact 
of Asn restriction in immune responses. 
Cancer cells reprogram their metabolism to maintain aberrant proliferation 
(Pavlova and Thompson, 2016). Due to elevated metabolic activity, many cancer 
cells are auxotrophs for nutrients that are often otherwise non-essential and, 
therefore, the modification of nutrient availability has been proposed as a 
promising target for cancer therapy (Lukey et al., 2017; Kanarek et al., 2020). A 
key inconvenience of this approach is the side effects that nutrient deprivation 
might cause in healthy cells and, particularly, to the anti-tumour immune response 
(Chang et al., 2015; Kedia-Mehta and Finlay, 2019). Targeting Asn levels has not 
only been of interest in ALL or other ASNS-low tumours (Chiu et al., 2020). 
Several studies strongly sustain that asparagine synthesis is a key feature of 
aggressive tumours. ASNS expression is regulated by two of the most common 
mutated genes in cancer: p53 and KRAS (Gwinn et al., 2018; Deng et al., 2020). 
The former directly suppresses ASNS expression entering a reciprocal regulatory 
loop where p53 activation is sustained by a mechanism involving LKB1/AMPK. 
p53-null cells display increased ASNS expression and Asn synthesis which 
importantly contributes to proliferation while protecting from senescence (Deng 
et al., 2020). The latter induces ATF4 expression via Akt which directly 




proliferation (Gwinn et al., 2018). Furthermore, Asn availability has been 
described as a crucial driver of EMT transition in breast cancer models (Knott et 
al., 2018). Altogether, these findings indicate that ASNS expression and 
subsequent Asn synthesis importantly contribute to tumour growth and 
metastasis. ASNS upregulation provides to tumour cells a key mechanism of 
metabolic adaptation to a nutrient-depleted environments derived by the lack of 
vascularisation (DeBerardinis et al., 2008; Zhang, Ji et al., 2014; Nakamura et 
al., 2018; Pathria et al., 2019). Thus, interfering with Asn synthesis, either by the 
utilisation of ASNases or seeking for ASNS inhibitors (Zhu, W. et al., 2019), might 
yield to a promising therapeutic strategy in cancer. Importantly, host cells for 
some viruses or bacteria rely on Asn metabolism and, therefore, the application 
of ASNases has also been proposed in these contexts (Ren et al., 2018; Lee et 
al., 2019). My results indicate that neither approaches are likely to disrupt the 
function of CTLs within the TME/site of infection, thereby combating tumour 
cells/pathogens without negatively affecting CD8+ T cell responses. Furthermore, 
as a result of the interplay between Asn and Gln in tumour progression (Zhang, 
Ji et al., 2014), recent reports have pointed out their dual depletion as one of the 
strategies with better prospects (Kanarek et al., 2020). Nonetheless, my findings 
indicate that restricting both AAs might be catastrophic for T cell responses as 
the lack of Asn and Gln totally dampens T cell activation and differentiation. Thus, 
further investigations are required in order to determine whether depletion of Asn 
and Gln or Asn alone is more beneficial when taking into account the implications 
for both tumour growth and anti-tumour immune responses.  
Understanding the mechanisms by which ASNS is regulated in T lymphocytes 
will provide insight into novel ways of manipulating T cell responses. Our findings 




consistently with previous reports (Howden et al., 2019), that its expression is 
highly sensitive to rapamycin. ASNS regulation has been mainly attributed to 
ATF4 but this has been mostly studied in the context of stress responses. In CD4+ 
T lymphocytes, the increase in Asns mRNA levels upon 24h of TCR-binding 
disappears when knocking down Atf4 even in non-stress conditions suggesting 
that ASNS regulation, at least during early stages of T cell activation, is 
exclusively under the control of ATF4 (Yang et al., 2018). In transformed cells, 
ATF4 regulation has been associated to Akt (Gwinn et al., 2018) and the 
mTORC1 substrate 4E-BP (Park et al., 2017). I speculate that, in CD8+ T cells, a 
similar mechanism involving PI3K/Akt/mTOR activation might be sufficient to 
upregulate ASNS in an ATF4-dependent fashion upon TCR-stimulation. On the 
other hand, ATF4 is scarcely expressed in activated CD8+ T cells suggesting that 
other mechanisms might be implicated. ASNS upregulation is altered in activated 
T cells lacking Myc (Marchingo et al., 2020) or upon treatment with Myc inhibitors 
(see Fig. 6.1). These findings point out at Myc as a possible transcription factor 
associated to ASNS expression after TCR-stimulation. However, Myc-deficiency 
also dampens the upregulation of AA transporters (Marchingo et al., 2020), a 
phenomenon that could severely impact mTORC1 activity and, therefore, 
whether Myc regulates ASNS directly or indirectly is still unclear.  
I have demonstrated that Asn availability is crucial to initiate protein synthesis but 
whether it has ancillary functions is unknown. Other investigations performed in 
transformed cells have identified a role for Asn as signalling molecule where 
directly binds LKB1 to modulate AMPK activity (Deng et al., 2020). Furthermore, 
a report by Krall et al. (2016) revealed that Asn controls mTOR activation acting 
as an exchange factor for other AAs such as leucine or Gln. Our data shows that 




suggesting that Asn might have a comparable function also in T lymphocytes. 
However, T cells stimulated in the absence of Asn display a decreased 
expression of nutrient transporters and, therefore, whether the loss of mTOR 
activation is associated with a deficient AA-exchange or to a general disruption 
of AA and glucose uptake is inconclusive. Under the assumption that Asn fine-
tunes mTOR activity and considering that memory T cell differentiation is 
favoured when mTOR is attenuated (Nabe et al., 2018; Hope and Salmond, 
2019), it will be of interest to study how the restriction of extracellular Asn or the 
limitation of Asn biosynthesis (e.g. AsnsTm1a/WT T cells) influences memory 
formation and the acquisition of long-term responses. In fact, CTLs grown in the 
presence of IL-15, key driver of memory phenotypes, display reduced ASNS 
expression (http://www.immpres.co.uk) further reinforcing a link between ASNS, 
mTOR and memory. 
Another important question is whether ASNS upregulation supports T cell 
function exclusively through Asn synthesis. A number of metabolic enzymes have 
been associated with signalling roles above and beyond their metabolic functions, 
that are key to control T cell activation and effector function (Shyer et al., 2020). 
No reports have related ASNS with extra purposes other than Asn synthesis. 
However, it is important to consider that the levels of other AAs, such as Glu and 
Asp, are affected by the ASNS-mediated reaction. Nonetheless, our results 
clearly sustain that Asn replenishment is sufficient to recover CD8+ T cell function 
in the AsnsTm1a/Tm1a model denoting that ASNS is not the only and major source 
of those AAs and that its contributions to T cell function are mainly a side effect 
to the ASNS-reaction. 
Lastly, I have also explored how the lack of ASNS and/or Asn availability 




does not affect antibody secretion upon in vivo immunisation. Plasma cells 
strongly upregulate ASNS expression in normal conditions suggesting that Asn 
requirements for protein synthesis are elevated (http://www.immgen.org). 
However, the findings described here indicate that exogenous Asn levels are 
plenty to sustain B cell function in vivo. An alternative hypothesis is that even 
<10% of ASNS expression in AsnsTm1a/Tm1a mice is able to synthesise enough 
Asn to maintain B cell function. The lack of a suitable ASNS inhibitor or a genetic 
model that completely abrogates Asns expression limits our further study and 
understanding regarding the significance of ASNS contribution to the total Asn 
pool. Furthermore, some preliminary analysis (data not shown) suggest that Th1 
cells, which do not upregulate as high amounts of ASNS when compared to CTLs 
(http://www.immpres.co.uk), are more sensitive to extracellular depletion of Asn. 
Nevertheless, at the moment, only AsnsTm1a/WT or AsnsTm1a/Tm1a T cells have been 
used to assess the impact of Asn-deprivation in Th1 lymphocytes. Whether 
complete ASNS upregulation in AsnsWT/WT Th1s is sufficient to counterbalance 
the lack of an extracellular Asn source is unknown. 
Altogether, these results indicate that the relevance of Asn supplementation is 
cell specific, seemingly to be dependent on the capacity of the cell to upregulate 
ASNS expression. The development of cell-type-specific ASNS KOs will allow the 
further study of the role of Asn and ASNS in T lymphocytes and other immune 
cell subsets in vivo and, ultimately, will provide valuable insight on our current 






Chapter 7 Discussion 
7.1 Concluding remarks 
The aim of this PhD project was to better understand how environmental cues 
shape CD8+ T cell function and metabolism. So, what can we conclude from this 
research?  
First, I have shown that signals 1, 2 and 3 contribute to the full activation of T 
lymphocytes through the regulation of distinct functions and metabolic pathways. 
Thus, I have reinforced the idea that, whilst signal 1 is required to trigger an 
antigen specific response, signals 2 and 3 also cooperate to promote T cell 
expansion and differentiation. Metabolically, this seems to be reflected in the 
magnitude or the type of metabolism that is engaged (e.g. glycolytic vs 
mitochondrial in IL-12- or IFNa-treated T cells, respectively), further emphasising 
that T cell activity and metabolism are tightly linked (Fig. 7.1A). Second, I have 
demonstrated that the action of the anti-inflammatory cytokine TGFb represses 
CD8+ T cell activation through transcriptional regulation of metabolic pathways. 
Specifically, I have shown that TGFb significantly inhibits Myc expression and its 
induced metabolic reprogramming. Consequently, TGFb-treated T cells present 
an unsuccessful engagement of glycolysis added to a deficient Slc7a5-mediated 
amino acid uptake that results in a poor translational activity that ultimately leads 
to the inhibition of T cell activation (Fig. 7.1B). Lastly, I have proven that CD8+ T 
lymphocytes require extracellular Asn within the first stages upon TCR-





Figure 7.1: Graphical summary of the findings of this thesis.  
Here, some of the major findings described in this thesis are shown. In (A), 
the influence of signals 1, 2 and 3 (Chapter 3). In (B), the impact of the anti-
inflammatory cytokine TGFb (Chapters 4 and 5). In (C), the effect of Asn-






7.2 ‘Alright, so what is next?’ 
While doing my PhD, I used to frequently meet with my main supervisor, Dr. 
Salmond, to show him my latest results. After discussing my data, he would 
always conclude the meeting with a brief silence followed by an ‘alright, so what 
is next?’, and I cannot finish this thesis without asking myself again this same 
question.  
The findings exposed here have shed light into novel mechanisms that improve 
our understanding on the regulation of CD8+ T cell function, which is key to 
comprehend immune associated diseases and find strategies to combat them. 
Only focusing on the elements investigated within this thesis, we can find several 
prospective questions that serve as an example of the value of this research and 
how could be exploited. For example: as T cell adaptation to Asn-deprivation is 
reduced against weak peptides, would T cells with an enhanced TCR signalling 
strength (e.g. Ptpn22-/- T cells) provide better responses in this type of 
environment? As TGFb represses Asns expression, would CTLs be sensitive to 
the lack of extracellular Asn in the presence of TGFb (e.g. in the TME)? As TGFb 
is more suppressive against low affinity peptides, would the manipulation of the 
TCR signalling offer a suitable approach to counteract the TGFb-mediated T cell 
suppression? 
In spite of the contributions of this research, it is important to take into account 
that I have primarily focused on the study of CD8+ T cells in the context of T cell 
priming. However, CD8+ T cells navigate through multiple stages (e.g. naïve vs 
effector vs memory) and locations (e.g. SLOs vs sites of infection or TME) that 
might change the responsiveness to the certain signals. Moreover, we should 




that the studied signals could interfere with other cells in vivo, ultimately affecting 
to the final response of CD8+ T cells. So, how would these signals affect other T 
cell subsets or immune cells? Are these findings comparable in other cell types? 
Would these effects on other cell types consequently modify CD8+ T cell 
responses? Investigating how these environmental cues act on other immune 
cells and/or contexts comprise some of the loose ends that need to be tied in the 
near future in order gain a systemic perspective of their impact on the regulation 
of immune responses. 
Continuing with the previous point, I should highlight that the findings described 
here are almost exclusively based on reductionist in vitro strategies. Following 
the rationale of this thesis, T cell responses are determined by the sum of 
integrated inputs, suggesting, therefore, that the influence of the studied signals 
might vary to some extent in an in vivo scenario. Furthermore, a recent report by 
Ma et al. (2019) found that the metabolic profile of CD8+ T cells activated in vivo 
is slightly different to what has been previously established in vitro: whereas T 
cells activated in vitro shift from OXPHOS towards glycolysis, in vivo activated T 
cells are highly dependent on oxidative metabolism and SGOC metabolism. 
These statements highlight the importance of validating our findings in vivo in 
future research. The utilisation of recently developed technologies oriented to the 
study of the metabolic state of immune cells in vivo will provide further, more 
accurate and more detailed comprehension on the metabolic behaviour of T cells 
under the influence of the studied signals (Artyomov and Van den Bossche, 
2020). These include, among others, the use of stable isotopes to track nutrient 
consumption and the engagement of metabolic pathways (Ma et al., 2019) or the 
performance of ‘omic analysis of immune cells sorted ex vivo including 




seq), both in a population and single-cell level (Artyomov and Van den Bossche, 
2020; Hartmann et al., 2020; Argüello et al., 2020). Furthermore, we should also 
contemplate that our in vitro approaches and metabolic assays have been 
somewhat limited and some might present some weak spots. For example, 
Sinclair et al. (2020) recently reported that the utilisation of 2NBDG as a readout 
of glucose uptake is not a reliable tool in murine T cells indicating that the 
experiments carried out here using this fluorescent glucose analogue should be 
interpreted with caution.  
In conclusion, the field of immunometabolism has evolved tremendously during 
the last decade. The realisation that immune regulation and metabolism are 
inextricably tied has given rise to a wave of studies exploring the metabolism of 
immune cells in health and disease which has led to the identification of new 
regulatory mechanisms and therapeutic targets. In fact, some metabolic-targeted 
drugs (e.g. dimethyl fumarate or methotrexate) are already in the market for the 
treatment of some autoimmune diseases, indicating the bench-to-bedside 
potential of this area of study. Moreover, although in this thesis I have focused on 
the research of metabolism in the context of immunity, emerging investigations 
situate metabolism at the spotlight as a hub connecting multiple disciplines 
including cancer, cellular development or aging. All seems to point at metabolism 
as the path to follow to build a solid strategy to modulate cell function to our liking. 
Further research on both cell-intrinsic and systemic metabolism and its 
connection to cell function (or dysfunction) will provide invaluable new knowledge 
on our understanding of the regulation of cellular processes in health and 
disease. I believe that the findings presented here will contribute and become the 
basis of future research focused on the translation of this knowledge to the 
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